

DEPARTMENT OF DEFENSE / NIH NATIONAL CANCER INSTITUTE
CANCER DEMONSTRATION PROJECT

ANALYSIS PLAN: STUDY TO MEASURE THE COST OF
CHAMPUS-ELIGIBLE PARTICIPANTS IN SOUTHWEST ONCOLOGY GROUP
NCI COOPERATIVE PROGRAM
CANCER CLINICAL TRIALS 1988-1996

TECHNICAL REPORT NO. 1


SCOTT A. OPTENBERG, DrPH, GM-15
SANDRA L. SCHNEIDER, DrPH
Center for Healthcare Education and Studies

ARNOLD POTOSKY, PhD
MARY MCCABE, RN
National Cancer Institute

19971230 122

DTIC QUALITY INSPECTED 2

RP 98-002
DECEMBER 1997



UNITED STATES ARMY
MEDICAL DEPARTMENT CENTER AND SCHOOL
FORT SAM HOUSTON, TEXAS 78234-6100

DEPARTMENT OF DEFENSE / NIH NATIONAL CANCER INSTITUTE
CANCER DEMONSTRATION PROJECT

**ANALYSIS PLAN: STUDY TO MEASURE THE COST OF
CHAMPUS-ELIGIBLE PARTICIPANTS IN SOUTHWEST ONCOLOGY GROUP
NCI COOPERATIVE PROGRAM
CANCER CLINICAL TRIALS 1988-1996**

TECHNICAL REPORT NO. 1

SCOTT A. OPTENBERG, DrPH, GM-15
Chief, Analysis Branch

SANDRA L. SCHNEIDER, DrPH
Study Director

Analysis Branch
Center for Healthcare Education and Studies
Academy of Health Sciences

ARNOLD POTOSKY, PhD
Division of Cancer Prevention and Control

MARY MCCABE, RN
Office of Clinical Prevention and Control

National Cancer Institute
Bethesda, Maryland

RP 98-002
DECEMBER 1, 1997

UNITED STATES ARMY
MEDICAL DEPARTMENT CENTER AND SCHOOL
FORT SAM HOUSTON, TEXAS 78234-6100

NOTICE

The findings in this report are
not to be construed as an official
Department of the Defense position
unless so designated by other
authorized documents.

* * * * *

Address of author's organization:

Center for Healthcare Education and Studies (CHES)
ATTN: MCCS-HRN
AMEDDC&S
1608 Stanley Road, Building 2268
Fort Sam Houston, Texas 78234-6125

* * * * *

Reports may be purchased directly from the following:

Defense Technical Information Center (DTIC)
ATTN: DTIC-DDR
Cameron Station
Alexandria, VA 22304-6145

Telephones: DSN 284-7633, 4, or 5
Commercial (703) 274-7633, 4, or 5

U.S. Department of Commerce
National Technical Information Service (NTIS)
5285 Port Royal Road
Springfield, VA 22161

Telephone: Commercial (703) 487-4600

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

1a. REPORT SECURITY CLASSIFICATION Unclassified			1b. RESTRICTIVE MARKINGS	
2a. SECURITY CLASSIFICATION AUTHORITY			3. DISTRIBUTION / AVAILABILITY OF REPORT Distribution Unlimited; Public Use Authorized.	
2b. DECLASSIFICATION / DOWNGRADING SCHEDULE				
4. PERFORMING ORGANIZATION REPORT NUMBER(S) RP 98-002			5. MONITORING ORGANIZATION REPORT NUMBER(S)	
6a. NAME OF PERFORMING ORGANIZATION Center for Healthcare Education and Studies (CHES)		6b. OFFICE SYMBOL (If applicable) MCCS-HRN		7a. NAME OF MONITORING ORGANIZATION U. S. Army Medical Department Center and School
6c. ADDRESS (City, State, and ZIP Code) Bldg 2268, 1608 Stanley Road Fort Sam Houston, TX 78234-6125			7b. ADDRESS (City, State, and ZIP Code) Fort Sam Houston, TX 78234-6100	
8a. NAME OF FUNDING / SPONSORING ORGANIZATION U. S. Army Medical Department Center and School		8b. OFFICE SYMBOL (If applicable)		9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER
8c. ADDRESS (City, State, and ZIP Code) Fort Sam Houston, TX 78234-6100			10. SOURCE OF FUNDING NUMBERS	
			PROGRAM ELEMENT NO.	PROJECT NO.
			TASK NO.	WORK UNIT ACCESSION NO.
11. TITLE (Include Security Classification) (U) Analysis Plan: Study to Measure the Cost of CHAMPUS-Eligible Participants in Southwest Oncology Group NCI Cooperative Program Cancer Clinical Trials 1988-1996: Technical Report No. 1				
12. PERSONAL AUTHOR(S) Scott A. Optenberg, DrPh; Sandra L. Schneider, DrPh; Arnold Potosky, PhD; Mary McCabe, RN				
13a. TYPE OF REPORT Interim		13b. TIME COVERED FROM Oct88 to Sep96		14. DATE OF REPORT (Year, Month, Day) 1997 Dec 1
15. PAGE COUNT 80				
16. SUPPLEMENTARY NOTATION				
17. COSATI CODES			18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)	
FIELD	GROUP	SUB-GROUP	CHAMPUS, National Cancer Institute, Southwest Oncology, clinical trials, cancer, cost analysis	
19. ABSTRACT (Continue on reverse if necessary and identify by block number) The National Cancer Institute's Division of Cancer Treatment, Diagnosis, and Centers (DCTDC) has initiated effort to expand clinical trial participation by proposing coverage agreement of NCI clinical trial participants with various third party payers. An agreement was signed with the Department of Defense (DOD) to allow patients who are beneficiaries of TRICARE/CHAMPUS to participate in, and be reimbursed for, NCI-sponsored clinical cancer treatment trials. This study is a cancer demonstration project pilot study to evaluate the potential cost impact of the NCI/DOD agreement. The initial study phase identified CHAMPUS eligible beneficiaries (CEBs) diagnosed with cancer and enrolled in NCI clinical trials (1988-1996). CEBs treated for cancer of the breast, prostate, colon, lung, leukemia, and lymphoma in phase 2 and 3 adjuvant, advanced/ recurrent disease trials were identified. The second phase of this study will be to determine the cost of the clinical trials by using TRICARE/CHAMPUS claims data from resource utilization of inpatient and outpatient (ambulatory) professional services and institutional costs. CEB enrolled in clinical trials will be compared to a non-trial group disease and clinical matched CEB cancer cases.				
20. DISTRIBUTION / AVAILABILITY OF ABSTRACT <input type="checkbox"/> UNCLASSIFIED/UNLIMITED <input checked="" type="checkbox"/> SAME AS RPT. <input type="checkbox"/> DTIC USERS			21. ABSTRACT SECURITY CLASSIFICATION Unclassified	
22a. NAME OF RESPONSIBLE INDIVIDUAL Dr. Scott A. Optenberg			22b. TELEPHONE (Include Area Code) (210) 221-9333	22c. OFFICE SYMBOL MCCS-HRN

TABLE OF CONTENTS

SECTION	PAGE
DISCLAIMER.....	ii
REPORT DOCUMENTATION PAGE (DD FORM 1473).....	iii
TABLE OF CONTENTS.....	v
LIST OF TABLES.....	vi
LIST OF FIGURES.....	vii
EXECUTIVE SUMMARY.....	1
METHODS.....	2
•Study Population.....	2
•Identification of NCI Clinical Trials.....	2
•CHAMPUS Eligible Beneficiaries Cancer Classification.....	2
•CHAMPUS Eligible Beneficiaries Case and Cost Analysis Files.....	3
RESULTS.....	3
•Study Population.....	3
•Demographics of Study Population.....	3
•CHAMPUS Eligible Beneficiaries Cancer Classification.....	4
•Cancer Site Distribution of CHAMPUS Eligible Clinical Trials Participants.....	4
•CHAMPUS Clinical Trials Participants.....	5
•Clinical Trials Selected for NCI Cooperative Program.....	6
RESEARCH PHASE.....	6-7
NCI COOPERATIVE PROGRAM STUDY GROUP.....	28-29
REFERENCES.....	30
DISTRIBUTION LIST.....	31

APPENDIX

ICD9CM Cancer Diagnosis For Department of Defense CHAMPUS Patients Enrolled and Treated in NCI Sponsored Clinical Trials.

- Percent Frequency and Prevalence of Site Specific Cancer For In-Patient Professional Services..... A1-A18
- Percent Frequency and Prevalence of Site Specific Cancer For Out-Patient Professional Services..... A19-A36

LIST OF TABLES

TABLE	PAGE
1 Demographics of Study Population By Gender and Age	8
2 Cancer Diagnosis ICD9CM 140-149 (Neoplasm Lip, Oral Cavity, Pharynx)	8
3 Cancer Diagnosis ICD9CM 150-159 (Neoplasm Digestive Organs and Peritoneum)	8
4 Cancer Diagnosis ICD9CM 160-165 (Neoplasm Respiratory and Intrathoracic Organs)	9
5 Cancer Diagnosis ICD9CM 170-176 (Neoplasm Bone, Connective Tissue, Skin, Breast)	9
6 Cancer Diagnosis ICD9CM 179-189 (Neoplasm Genitourinary Organs)	9
7 Cancer Diagnosis ICD9CM 190-199 (Neoplasm of Other and Unspecified Sites)	10
8 Cancer Diagnosis ICD9CM 200-208 (Neoplasm Lymphatic and Hematopoietic Tissue)	10
9 Cancer Diagnosis ICD9CM 210-229 (Benign Neoplasm)	10
10 Cancer Diagnosis ICD9CM 230-234 (Neoplasm Carcinoma In Situ)	11
11 Cancer Diagnosis ICD9CM 235-238 (Neoplasm of Uncertain Behavior)	11
12 Cancer Diagnosis ICD9CM 239 (Neoplasm of Unspecified Nature)	12
13 CHAMPUS Eligible Beneficiaries - NCI Cancer Prevention Clinical Trials	13
14 CHAMPUS Eligible Beneficiaries - NCI Developmental Biology Clinical Trials	13
15 CHAMPUS Eligible Beneficiaries - NCI Brain Clinical Trials	13
16 CHAMPUS Eligible Beneficiaries - NCI Breast Clinical Trials	14
17 CHAMPUS Eligible Beneficiaries - NCI Gastrointestinal Clinical Trials	15
18 CHAMPUS Eligible Beneficiaries - NCI Genitourinary System Clinical Trials	16
19 CHAMPUS Eligible Beneficiaries - NCI Gynecological Clinical Trials	17
20 CHAMPUS Eligible Beneficiaries - NCI Head and Neck Clinical Trials	17
21 CHAMPUS Eligible Beneficiaries - NCI Leukemia Clinical Trials	18
22 CHAMPUS Eligible Beneficiaries - NCI Lung Clinical Trials	19
23 CHAMPUS Eligible Beneficiaries - NCI Lymphoma Clinical Trials	20
24 CHAMPUS Eligible Beneficiaries - NCI Melanoma Clinical Trials	20
25 CHAMPUS Eligible Beneficiaries - NCI Myeloma Clinical Trials	21
26 CHAMPUS Eligible Beneficiaries - NCI Sarcoma Clinical Trials	21
27 NCI Clinical Trials SWOG /DEERS Matched Cases By Breast Tumor	22
28 NCI Clinical Trials SWOG /DEERS Matched Cases By Prostate Tumor	23
29 NCI Clinical Trials SWOG /DEERS Matched Cases By Leukemia Tumor	24
30 NCI Clinical Trials SWOG /DEERS Matched Cases By Lymphoma Tumor	25
31 NCI Clinical Trials SWOG /DEERS Matched Cases By Colon/Rectal Tumor	26
32 NCI Clinical Trials SWOG /DEERS Matched Cases By Lung Tumor	27

LIST OF FIGURES

FIGURE	PAGE
1 Schema: Selection of CHAMPUS Eligible Participants in NCI Clinical Trials.....	8
2 CHAMPUS Eligible Participants in NCI Clinical Trials.....	13

Analysis Plan: Study To Measure The Cost of CHAMPUS-Eligible Participants in Southwest Oncology Group NCI Cooperative Program Cancer Clinical Trials 1988-1996

EXECUTIVE SUMMARY

Cancer is projected to be the number one cause of death, within the next decade, in the United States. A national effort is under way, to not only understand the cause and prevention of cancer, but to identify the costs associated with treatment, control and prevention of cancer (1). The National Cancer Institutes (NCI) Division of Cancer Treatment, Diagnosis, and Centers (DCTDC) has initiated efforts to expand clinical trial participation by proposing coverage agreements for NCI clinical trials participants with various third party payers. As part of a cancer demonstration project, the Department of Defense (DOD) and NCI have an agreement to evaluate the cost to treat CHAMPUS eligible beneficiaries (CEBs), diagnosed and enrolled, in NCI sponsored Southwest Oncology Group (SWOG) clinical trials from 1988-1996.

The data files from the Defense Enrollment Eligibility Reporting System (DEERS), were used to identify CEBs, enrolled in SWOG clinical trials. During 1988-1996, 69,435 cancer patients were enrolled in 423 NCI sponsored clinical trials. Of this group, 5,234 CEBs received treatment in 170 of the clinical trials. The distribution of CEBs participating in clinical trials, by specific cancer sites, was 59.1% chemoprevention trials; 10.1% breast; 7.9% genitourinary (GU); 6.6% gastrointestinal (GI); 3.5% lymphoma; 3.1% lung; 2.4% leukemia; 1.9% gynecological (GYN); 1.3% melanoma; 0.8% brain; 0.6% head and neck, and sarcoma; and 0.2% developmental biology clinical trials. Major organ site studies in which CEBs were treated included: 29 breast, 21 prostate, 30 lung, 25 colon, 19 leukemia and 46 lymphoma (lymphoma, melanoma, multiple myeloma, sarcoma) clinical trials. The study population demographics included 1178 (22.1%) females and 4056 (77.49%) males. The International Classification of Diseases ICD9CM neoplasm codes (140-239) were used to identify site specific cancer sites. CHAMPUS claims data were selected for ICD9CM neoplasm codes 140-239. Claims data were used to determine frequency and prevalence of organ specific cancer in the CHAMPUS population.

The analysis portion of this research study will determine the cost of phase 2 and 3 clinical trials that provided treatment, intervention and evaluation of adjuvant, advanced or recurrent disease. The cost of cancer treatment for CEBs enrolled in clinical trials, compared to CEBs with cancer not enrolled in clinical trials, will be determined using CHAMPUS professional services records as a detailed account of inpatient, outpatient, and institutional cancer treatment services. The evaluation of costs and benefits associated with the efficacy of cancer treatment must be understood as part of the risks and interventions associated with cancer, and the clinical management of cancer. This study contributes directly to NCI's overall goal to expand participation of cancer patients in clinical research studies. Information from this pilot study also will give NCI guidelines to negotiate coverage agreements with other health care payers for cancer clinical trials.

METHODS

Study Population

The study population for the cancer demonstration project was CHAMPUS eligible beneficiaries (CEBs) who met diagnostic protocol eligibility criteria to participate in the National Institutes of Health, National Cancer Institute (NCI) cancer treatment clinical trials for the years 1988-1996. CEBs were selected from the Army, Air Force, Navy, and Coast Guard branches of the Department of Defense (DOD) services. CEBs were identified by the Defense Enrollment Eligibility Reporting System (DEERS). DEERS is a computer-based system that establishes and reports the eligibility status of DOD beneficiaries for various services, to include care at medical treatment facilities (MTF).

Identification of NCI Clinical Trials

CEBs enrolled and treated in NCI clinical trials were identified by linking the DEERS data files with the Southwest Oncology Group (SWOG) 1988-1996 cancer trials database. The SWOG and DEERS data files were linked by name, age, date of birth (DOB), race, sponsor social security number (SSN), and dependent social security number (DSSN). The DEERS/SWOG data sets were matched by the following criteria: SSN eligible and non-eligible; DSSN eligible active duty, eligible retired, non-eligible active duty, non-eligible retired; dependents by name and DOB for eligible active duty, eligible retired, non-eligible active duty, and non-eligible retired. Patient discrepancies, duplications, and matches, within the DEERS and SWOG databases, were verified. To quality control the study population data variables, only exact CEBs and SWOG matches were used.

CHAMPUS Eligible Beneficiaries Cancer Classification

The International Classification of Diseases ICD 9 CM Neoplasm, Codes 140-239, was used to identify site specific cancer in the study population. The CHAMPUS claims data was used to identify beneficiaries with ICD9CM cancer codes 140-239 during the years 1988-1996. For simplicity in reporting, the ICD9CM cancer codes were group by major cancer organ sites: 140-149 (neoplasm lip, oral cavity, pharynx); 150-159 (neoplasm digestive organs and peritoneum); 160-165 neoplasm respiratory and intrathoracic organs); 170-176 (neoplasm bone, connective tissue, skin, breast); 179-189 (neoplasm genitourinary organs); 190-199 (neoplasm of other and unspecified sites); 200-208 (neoplasm lymphatic and hematopoietic tissue); 210-229 (benign neoplasm); 230-234 (neoplasm carcinoma in situ); 235-238 (neoplasm of uncertain behavior); and 239 (neoplasm of unspecified nature).

Percent (%) frequency of cancer diagnosis was determined as the number of specified ICD9CM cancer cases divided by the total number of all cancer cases in the time period selected. The formula used to calculate % frequency was: $\% \text{ Frequency} = \text{Total Number ICD9CM Cancer Cases} \div \text{Total Number of Cancer Cases}$. Cancer prevalence was determined as the total number of specified ICD9CM cancer cases divided by the population of professional services users at risk for cancer during a time point, as determined by fiscal year (FY). The formula used to calculate cancer prevalence was: $\text{Prevalence} = \text{Total Number of ICD9CM Cancer Cases} \div \text{Total Population of FY CHAMPUS Beneficiaries}$. The total number, or population, of CHAMPUS beneficiaries, for each year, was used as the denominator to determine cancer prevalence for inpatient and outpatient professional services. The denominators for in-patient institutional

professional services were: 300815 (FY88), 279,493 (FY89), 268,455 (FY90), 261205 (FY91), 246,607 (FY92), 218,056 (FY93), 200,160 (FY94), 195,248 (FY95), 173,265 (FY96). The denominators for out-patient (ambulatory) professional services were: 1,726,444 (FY88), 1,989,7784 (FY89), 2,303,450 (FY90), 2,319,445 (FY91), 2,182,878 (FY92), 2,110,066 (FY93), 2,0087,951 (FY94), 2,032,367 (FY95), 1,979,137 (FY96). The number of TRICARE/CHAMPUS user beneficiaries (DOD and non-DOD combined) by in-patient or out-patient category of care, for each fiscal year, was obtained from the DOD Information Systems Division, Statistics Branch (2,3).

CHAMPUS Eligible Beneficiaries Case and Cost Analysis Files

The CHAMPUS eligible beneficiaries data files, from the TRICARE/CHAMPUS Healthcare Program Information System for fiscal years 1988-1996, were used to prepare case file and cost analysis files. The original files consisted of 974 tapes by fiscal years (FY88-96) and branch of service, to include: Army, Air Force, Navy, and Coast Guard. Coast Guard data were available for FY90, FY91, FY93, and FY95. The case files were constructed as one record per person, and contained a summary of main patient-level variables for sociodemographic, socioeconomic, and clinical study variables. The cost analysis files contained all claims data information from CHAMPUS and non-CHAMPUS providers for Inpatient and Outpatient professional services, and institutional expenditures from resource utilization.

RESULTS

Study Population

The study population was derived from 14,557,571 patients identified in the 1988-1996 DEERS data base (**Figure 1**). The DEERS data base was merged with the SWOG data base, which contained 69,435 patients enrolled and treated in 423 trials during the years 1988-1996. This SWOG/DEERS selection identified 5,234 CEBs who were enrolled and treated for cancer in 279 clinical trials. The CEBs accounted for 7.5% of all patients enrolled and treated in NCI sponsored clinical trials during the years 1988-1996. From the CEBs enrolled and treated in clinical trials, a study population was selected based on the major cancer organ site clinical trials. The initial case group consisted of 4,653 (89%) patients enrolled and treated in 170 (61%) of the clinical SWOG clinical trials. These patients were enrolled in 29 breast, 21 prostate, 30 lung, 25 colon, 19 leukemia, and 46 lymphoma clinical trials.

Demographics of Study Population

CEBs enrolled and treated in NCI clinical trials were identified by gender and age (**Table 1**). The 5,234 clinical trial participants consisted of 1178 (22.1%) females and 4056 (77.49%) males. The age distribution of participants was: 4 females (0.08%) and 4 males (0.08%) in <20 years of age; 72 (1.38%) females and 25 (0.86%) males in 20-29 years of age; 143 females (2.73%) and 66 (1.26%) males in 30-39 years of age; 237 (4.53%) females and 103 (1.97%) males in 40-49 years of age; 334 females (6.38%) females and 605 (11.56%) males in 50-59 years of age; 366 females (6.99%) and 2289 (43.73%) males in 60-69 years of age, and 22 (0.44%) females and 944 (18.04%) males in ≥70 years of age. Race was not available from the DEERS or SWOG data files. Race and other demographic variables will be determined from the DOD Automated Central Tumor Registry (ACTUR) in a later phase of the study.

CHAMPUS Eligible Beneficiaries (CEBs) Cancer Classification

ICD9CM neoplasm codes were used to classify the specific cancer sites in the study population (**Appendices A, B**). The major cancer organ sites were grouped by ICD9CM codes to include: 140-149 (neoplasm lip, oral cavity, pharynx); 150-159 (neoplasm digestive organs and peritoneum); 160-165 neoplasm respiratory and intrathoracic organs); 170-176 (neoplasm bone, connective tissue, skin, breast); 179-189 (neoplasm genitourinary organs); 190-199 (neoplasm of other and unspecified sites); 200-208 (neoplasm lymphatic and hematopoietic tissue); 210-229 (benign neoplasm); 230-234 (neoplasm carcinoma in situ); 235-238 (neoplasm of uncertain behavior); and 239 (neoplasm of unspecified nature). There were 186,734 CEBs identified, from CHAMPUS claims data, as having cancer for the years 1988-1996. These patients accounted for 1,119,156 claims, of which 342,395 were associated with Inpatient professional services, and 776,395 were associated with Outpatient (ambulatory) professional services. The percent (%) frequency and prevalence of cancer by ICD9CM neoplasm codes for CEBs is presented in **Tables 2-12**.

The percent frequency and prevalence of cancer was similar for the Inpatient and Outpatient (ambulatory) professional services. Inpatient professional services for neoplasm of bone, connective tissue, skin, and breast (170-176) were slightly higher than those observed for out-patient services. Outpatient professional services calculations for GI (150-159), and respiratory (160-165) were slightly higher than those observed for in-patient services. A linear use of ICD9CM 239 (neoplasm of unspecified nature), in both Inpatient and Outpatient professional services was observed over the nine year time period. By ICD9CM codes, the greatest frequency of cancer sites for in-patient professional services, years 1988-1996, was: 210-220 (benign neoplasm) > 170-176 (bone, skin, breast) > 190-176 (other and unspecified) > 179-189 (GU) > 160-165 (respiratory and intrathoracic) > 150-159 (GI) > 200-208 (lymphatic and hematopoietic) > 235-238 (uncertain) > 230-234 (in situ) > 140-149 (lip, oral cavity, pharynx). The greatest frequency of cancer sites for out-patient professional services, years 1988-1996, was: 210-220 (benign neoplasm) > 190-176 (other and unspecified) > 170-176 (bone, skin, breast) > 160-165 (respiratory and intrathoracic) > 179-189 (GU) > 150-159 (GI) > 200-208 (lymphatic and hematopoietic) > 235-238 (uncertain) > 230-234 (in situ) > 140-149 (lip, oral cavity, pharynx). The trends for cancer prevalence followed the trends in frequency. Prevalence was higher when calculated using Outpatient records for all ICD9CM groups for all years. Statistical modeling will be used in the analysis portion of the study to determine if statistical differences exist between Inpatient and Outpatient professional services utilization, in relationship to cancer diagnosis.

Cancer Site Distribution of CHAMPUS Eligible Clinical Trial Participants

The distribution of organ specific cancer site clinical trials within the CEBs from 1988-1996 was determined (**Figure 2**). The greatest percentage of CEBs were enrolled and treated in the chemoprevention/cancer cure (cc) trials (59.1%). Of this population, 0.04% participated in the compliance, breast self exam education trial, and 96% participated in the chemoprevention of prostate cancer with Finasteride (Proscar), phase III, inter-group study. The remaining cancer sites included: 10.1% breast; 7.9% genitourinary (GU); 6.6% gastrointestinal (GI); 3.5% lymphoma; 3.1% lung; 2.4% leukemia; 1.9% gynecological (GYN) and myeloma; 1.3% melanoma; 0.8% brain; 0.6% head and neck, sarcoma; and 0.2% developmental biology clinical trials.

CHAMPUS Clinical Trials Participants

CEBs enrolled and treated in the NCI clinical trials were identified by cancer study type, study identification number, and sponsored clinical trial phase. The total number of SWOG clinical trials participants 1988-1996 was 69,435 patients, distributed in 423 sponsored clinical trials. The DEERS database identified and matched 5,234 CEBs cancer patients, or 7.5% of the total clinical trials population, as enrolled and treated in 279 (66%) of the clinical trials. The clinical trials, categorized by administrative cancer sites, were characterized by NCI study identification code, trial phase, total N of trial, N of DEERS matched, and % enrollment of CEBs participating in each clinical trial (*Tables 13-26*). Following are summaries of Tables 13-26.

- *Table 13.* Cancer prevention trials included 20,157 participants, of whom 3091 (15.30%) were enrolled in DEERS. Five percent (5%) of the participants in the compliance breast self examination education trial were CEBs, and 16.76% of the prostate chemoprevention participants were CEBs.

- *Table 14.* Developmental biology trials included 118 participants, of which 8 (6.8%) were DEERS enrolled. These trials included four (4) trials of non-specified advanced cancers with various chemotherapeutics.

- *Table 15.* Brain trials included 1,048 participants, of which 42 (4%) were DEERS enrolled. These trials included both solid and CNS tumors.

- *Table 16.* Breast trials included 13,308 participants, of which 531 (4%) were DEERS enrolled.

- *Table 17.* Gastrointestinal (GI) trials included 7,366 participants, of which 346 (4.7%) were DEERS enrolled. These trials included gastric, colon, colorectal, esophageal, pancreas, and hepatic cancer sites.

- *Table 18.* Genitourinary (GU) trials included 6,282 participants, of which 415 (6.6%) were DEERS enrolled. These trials included prostate, bladder, penis, testis, and renal cancer sites.

- *Table 19.* Gynecological (GYN) trials included 2,031 participants, of which 99 (4.9%) were DEERS enrolled. These trials included ovarian, cervical, and peritoneal cancer sites.

- *Table 20.* Head and neck trials included 858 participants, of which 31 (3.6%) were DEERS enrolled. The head and neck trials included nasopharyngeal cancer sites.

- *Table 21.* Leukemia trials included 3400 participants, of which 127 (3.7%) were DEERS enrolled. These trials included ANL, ALL, AL, CML, CLL, AML, and B-CLL cancer sites.

- *Table 22.* Lung trials included 3,269 participants, of which 165 (5.1%) were DEERS enrolled. These trials included small cell and non-small cell cancer sites.

- *Table 23.* Lymphoma trials included 3,969 participants, of which 183 (4.6%) were DEERS enrolled. These trials included non-Hodgkin's and Hodgkin's lymphoma, and AIDS.

- *Table 24.* Melanoma trials included 1,689 participants, of which 66 (3.9%) were DEERS enrolled.

•*Table 25.* Multiple myeloma trials included 1,984 participants, of which 97 (4.9%) were DEERS enrolled.

•*Table 26.* Sarcoma trials included 333 participants, of which 819 (4%) were DEERS enrolled.

Clinical Trials Selected for NCI Cooperative Program

This study focused on the selection of clinical trials for the major cancer organ sites. Of the original 279 clinical trials, 170 were selected for the pilot study. The NCI clinical trials, for the SWOG/DEERS matched cases, were identified by cancer organ site study ID, phase, trial, and number of participants in the adjuvant, advanced/recurrent disease stage, or other category of the trial (Tables 27-32). There were 4,653 CEBs identified, as SWOG/DEERS matched cases, that received treatment in the 170 trials. These clinical trials included: 29 breast trials; 21 prostate trials; 19 leukemia trials; 46 lymphoma (lymphoma, melanoma, multiple myeloma, sarcoma) trials; 25 colon/rectal trials; and 30 lung trials. The clinical trials included participation by SWOG, Eastern Cooperative Oncology Groups (ECOG), North Central Cancer Treatment Group (NCCTG), Veterans Administration Prostate Intervention vs Observation Trials (VA PIVOT). Trials included the Cancer and Leukemia Group B (CALGVB) study, Quality of Life (QOL) study, and Prostate Cancer Prevention Trial (PCPT) study.

•*Table 27.* The 29 breast tumor trials included phase-3, phase-2, and cancer control studies. The number of patients in the various phase trials included: 400 adjuvant studies (399 phase-3 and 1 cancer control study); 37 advanced cancer studies (30 phase-3, and 7 phase-2); and 203 other studies (74 phase-3, 6 phase-2 and 123 in cancer control).

•*Table 28.* The 21 prostate tumor clinical trials included phase-3, phase-2, and cancer control studies. The number of patients in the various phase trials included: 63 adjuvant (55 phase-3 and 8 phase-2); 2969 advanced cancer (2968 cancer control and 1 phase-2); and 239 other studies (111 phase-3, 27 phase-2, and 101 cancer control).

•*Table 29.* The 19 leukemia clinical trials included phase-3, phase-2,3, phase-2, and phase-1 studies. There were 89 patients in the various leukemia trials: 72 phase-3, 15 phase-2, 1 phase-2,3, and 3 phase-1 studies.

•*Table 30.* The 46 lymphoma clinical trials included phase-3, phase-2, phase-1, and pilot studies. Three hundred (300) patients were in the various lymphoma studies: 215 phase-3, 73 phase-2, 1 phase-1, and 11 pilot studies.

•*Table 31.* The 25 colon/rectal tumor clinical trials included phase-3, phase-2, phase-1, pilot, and cancer control studies. The number of patients in the phase trials included: 194 adjuvant (192 phase-3, 1 phase-2, 1 pilot), 37 advanced cancer (20 phase-3, 16 phase-2, 3 phase-2,3), and 41 other cancer studies (4 phase-3, 26 pilot, 11 cancer control)

•*Table 32.* The 30 lung tumor clinical trials included phase-3 and phase-2 studies. The number of patients in the phase trials included: 16 adjuvant (3 phase-3, 13 phase-2), 41 advanced (22 phase-3, 19 phase-2), and 108 other studies (85 phase-3, 23 phase-2).

Phase 2 Research

Phase 2 of this pilot study will complete the cost analysis of the cancer clinical trials cooperative program. Patients identified in the phase 2 and 3 trials of adjuvant therapy or advanced/recurrent disease will be matched, according to clinical disease identifiers, with a comparison group of cancer patients in the CHAMPUS program, who were not enrolled in clinical trials. CHAMPUS claims data for professional inpatient and outpatient (ambulatory) services will be combined with institutional resource utilization data to compare the costs of trial and non-trial treatment for the major cancer organ sites.




Figure 1. Schema: Selection of analysis study group from CHAMPUS eligible beneficiaries (CEBs) identified in Defense Enrollment Eligibility Reporting System (DEERS) as enrolled and treated in Southwest Oncology Group (SWOG) cancer clinical trials sponsored by the National Cancer Institute.

Table 1: Demographics of Study Population By Gender and Age

Age	Females		Males		Total	
	N	%	N	%	N	%
<20	4	0.08	4	0.08	8	0.15
20-29	72	1.38	45	0.86	117	2.24
30-39	143	2.73	66	1.26	209	3.99
40-49	237	4.53	103	1.97	340	6.50
50-59	334	6.38	605	11.56	939	17.94
60-69	366	6.99	2289	43.73	2655	50.73
≥70	22	0.42	944	18.04	966	18.46
TOTAL	1178	22.51	4056	77.49	5234	100

Table 2: Cancer Diagnosis ICD9CM 140-149 (Neoplasm Lip, Oral Cavity, Pharynx)

Fiscal Year	In Patient Services		Out Patient Services	
	% Frequency	Prevalence	% Frequency	Prevalence
1988	1.93	0.07	1.74	0.20
1989	1.95	0.07	1.58	0.20
1990	2.02	0.07	1.76	0.23
1991	1.90	0.08	1.45	0.23
1992	1.90	0.08	1.50	0.24
1993	1.84	0.09	1.56	0.31
1994	1.84	0.08	1.42	0.29
1995	1.89	0.08	1.51	0.29
1996	1.76	0.08	1.46	0.30

Table 3: Cancer Diagnosis ICD9CM 150-159 (Neoplasm Digestive Organs and Peritoneum)

Fiscal Year	In Patient Services		Out Patient Services	
	% Frequency	Prevalence	% Frequency	Prevalence
1988	7.95	0.28	9.02	1.06
1989	7.97	0.28	9.42	1.17
1990	8.09	0.28	9.87	1.30
1991	8.02	0.33	9.83	1.56
1992	8.01	0.35	9.58	1.52
1993	8.07	0.37	9.44	1.80
1994	8.38	0.40	9.69	1.92
1995	8.48	0.37	10.28	1.95
1996	8.47	0.38	10.09	2.06

Table 4: Cancer Diagnosis ICD9CM 160-165 (Neoplasm Respiratory and Intrathoracic Organs)

In Patient Services			Out Patient Services	
Fiscal Year	% Frequency	Prevalence	% Frequency	Prevalence
1988	8.47	0.29	11.04	1.29
1989	8.56	0.30	11.72	1.46
1990	8.29	0.28	10.95	1.44
1991	8.20	0.34	10.79	1.71
1992	8.39	0.36	11.06	1.75
1993	8.22	0.38	10.49	2.08
1994	8.16	0.39	10.56	2.14
1995	8.07	0.36	10.44	1.98
1996	8.07	0.37	10.25	2.10

Table 5: Cancer Diagnosis ICD9CM 170-176 (Neoplasm Bone, Connective Tissue, Skin, Breast)

In Patient Services			Out Patient Services	
Fiscal Year	% Frequency	Prevalence	% Frequency	Prevalence
1988	15.72	0.55	12.02	1.41
1989	16.29	0.57	11.60	1.45
1990	16.28	0.56	11.58	1.53
1991	16.25	0.67	11.43	1.81
1992	16.90	0.73	11.13	1.77
1993	16.65	0.77	10.46	2.08
1994	17.28	0.83	10.56	2.14
1995	18.07	0.80	10.60	2.02
1996	18.64	0.89	10.37	2.12

Table 6: Cancer Diagnosis ICD9CM 179-189 (Neoplasm Genitourinary Organs)

In Patient Services			Out Patient Services	
Fiscal Year	% Frequency	Prevalence	% Frequency	Prevalence
1988	7.58	0.26	9.16	1.07
1989	8.16	0.28	9.85	1.23
1990	8.38	0.29	9.85	1.30
1991	8.58	0.36	9.77	1.55
1992	9.47	0.41	10.76	1.71
1993	9.97	0.46	10.97	2.18
1994	10.34	0.50	10.93	2.22
1995	11.03	0.49	11.47	2.18
1996	11.07	0.50	11.37	2.33

Table 7: Cancer Diagnosis ICD9CM 190-199 (Neoplasm of Other and Unspecified Sites)

In Patient Services			Out Patient Services	
Fiscal Year	% Frequency	Prevalence	% Frequency	Prevalence
1988	14.53	0.51	13.19	1.54
1989	13.86	0.48	13.43	1.68
1990	13.18	0.45	12.77	1.68
1991	12.45	0.52	12.66	2.00
1992	12.03	0.52	12.54	1.99
1993	11.48	0.53	11.87	2.36
1994	11.17	0.54	11.45	2.32
1995	11.20	0.49	11.59	2.20
1996	10.93	0.50	11.83	2.42

Table 8: Cancer Diagnosis ICD9CM 200-208 (Neoplasm Lymphatic and Hematopoietic Tissue)

In Patient Services			Out Patient Services	
Fiscal Year	% Frequency	Prevalence	% Frequency	Prevalence
1988	5.95	0.21	5.42	0.64
1989	5.94	0.21	5.51	0.69
1990	5.97	0.20	5.69	0.75
1991	6.58	0.27	6.10	0.97
1992	5.81	0.25	5.77	0.91
1993	8.04	0.37	6.92	1.37
1994	6.66	0.32	6.83	1.39
1995	6.55	0.29	6.64	1.26
1996	6.71	0.30	6.57	1.34

Table 9: Cancer Diagnosis ICD9CM 210-229 (Benign Neoplasm)

In Patient Services			Out Patient Services	
Fiscal Year	% Frequency	Prevalence	% Frequency	Prevalence
1988	19.15	0.67	22.00	2.57
1989	19.53	0.68	20.79	2.57
1990	20.08	0.69	21.51	2.83
1991	19.69	0.82	21.15	3.35
1992	19.62	0.86	21.66	3.43
1993	19.32	0.89	22.39	4.45
1994	19.37	0.94	22.65	4.60
1995	18.90	0.83	22.97	4.37
1996	19.15	0.87	23.93	4.89

Table 10: Cancer Diagnosis ICD9CM 230-234 (Neoplasm Carcinoma In Situ)

Fiscal Year	In Patient Services		Out Patient Services	
	% Frequency	Prevalence	% Frequency	Prevalence
1988	2.93	0.10	3.15	0.37
1989	3.45	0.12	3.50	0.44
1990	3.42	0.12	3.33	0.44
1991	3.78	0.16	3.56	0.56
1992	3.60	0.16	3.33	0.53
1993	3.35	0.15	3.35	0.67
1994	3.48	0.17	3.47	0.71
1995	3.22	0.14	3.04	0.58
1996	3.10	0.14	2.75	0.56

Table 11: Cancer Diagnosis ICD9CM 235-238 (Neoplasm of Uncertain Behavior)

Fiscal Year	In Patient Services		Out Patient Services	
	% Frequency	Prevalence	% Frequency	Prevalence
1988	2.94	0.10	2.56	0.30
1989	3.02	0.11	2.80	0.35
1990	3.32	0.11	3.05	0.40
1991	3.85	0.16	3.34	0.53
1992	4.25	0.18	3.76	0.60
1993	4.38	0.20	4.13	0.82
1994	4.78	0.23	3.99	0.81
1995	4.82	0.21	3.70	0.70
1996	5.04	0.23	4.47	0.91

Table 12: Cancer Diagnosis ICD9CM 239 (Neoplasm of Unspecified Nature)

Fiscal Year	In Patient Services		Out Patient Services	
	% Frequency	Prevalence	% Frequency	Prevalence
1988	12.80	0.45	10.64	1.24
1989	11.31	0.39	9.42	1.17
1990	10.92	0.38	9.65	1.27
1991	10.70	0.44	9.94	1.57
1992	9.73	0.42	8.91	1.41
1993	8.68	0.40	8.40	1.67
1994	8.56	0.41	8.44	1.71
1995	7.77	0.34	7.76	1.48
1996	6.71	0.30	6.90	1.41




Figure 2. Distribution of CHAMPUS eligible beneficiaries (CEBs) (N = 5,234) in NCI cancer clinical trials by cancer site.

Table 13: CHAMPUS Eligible Beneficiaries - NCI Cancer Prevention Clinical Trials

Study ID	Study Name	Phase	Trial N	DEERS Matched	% Enrolled
S8807	Compliance, BSE Education	cc	2451	123	5.02
S9217	Prostate Chemoprevention	cc	17706	2968	16.76
TOTAL			20157	3091	15.30

Table 14: CHAMPUS Eligible Beneficiaries - NCI Developmental Biology Clinical Trials

Study ID	Study Name	Phase	Trial N	DEERS Matched	% Enrolled
S8902	Multiple Advanced ADR+CBRA+/-GM-CSF	I	21	1	4.76
S8940	Multiple Advanced IL-1/VP-16/CBRA	I	64	5	7.81
S9026	IL-3, VP-16, CBDCA	I	32	1	3.13
S9112	Multiple Advanced Chemo+GM-CS+IL-2	I	1	1	100.00
TOTAL			118	8	6.80

Table 15: CHAMPUS Eligible Beneficiaries - NCI Brain Clinical Trials

Study ID	Study Name	Phase	Trial N	DEERS Matched	% Enrolled
S8737	Glioma, AZQ vs BCNU	III	246	7	2.85
S8829	CNS, Amonafide	II	29	1	3.45
S8834	CNS Tumors, Fazarabine	II	27	1	3.70
S9005	Meningioma, RU-486 vs Placebo	III	184	3	1.63
S9016	Brain, RT+CDDP/BCNU	II	74	6	8.11
S9021	Brain Met, Post-OP RT vs Obs	III	54	1	1.85
S9110	Brain, Adv, STG III-IV, PH II	II	48	4	8.33
S9149	REC AA/GBM, HU+ARC+CDDP	II	57	2	3.51
S9310	CNS Lymphoms, Comb Modlity	II	31	1	3.23
S9340	Astro, RT+PCV+BUDR, RTOG	III	50	3	6.00
S9402	Oligodendro, Chemo +RT, RTOG	III	22	1	4.55
S9436	REC Glioma, Taxol PHI-II, NABTC	I-II	57	2	3.51
S9462	Solid Tumors, BCNU/TEM, NABTC	I	45	2	4.44
S9503	GBM/GS, BCNU+(H)RT+(P), NCCTG	III	124	8	6.45
TOTAL			1048	42	4.00

Table 16: CHAMPUS Eligible Beneficiaries - NCI Breast Clinical Trials

Study ID	Study Name	Phase	Trial N	DEERS Matched	% Enrolled
S7827	Stage II, Adjuvant	III	193	13	6.74
S8312	Adjuvant ER+, 2 nd Endocrine	III	141	5	3.55
S8313	Stage II, ER-, Comb Chemo	III	297	15	5.05
S8366	TI-3 NO-1. Cell Kinetics	III	370	4	1.08
S8568	Stage III or IV, Comb Mod	II	34	1	2.94
S8621	Advanced ER/PGR-, Post Phase	III	63	3	4.76
S8692	Advanced ER/PGR-, Pre Phase	III	138	1	0.72
S8697	Intergr, Advanced ER-	III	115	3	2.61
S8741	Advanced RTNF	II	22	2	9.09
S8748	Advanced Alternating Chemo	II	27	2	7.41
S8811	Advanced 5-FU+CF	II	58	1	1.72
S8814	N1 Post CAF/TAM	III	1558	54	3.47
S8851	Adjuvant N1, REC+, Pre Phase	III	507	29	5.72
S8897	Adjuvant N0, Chemo /TAM	III	4406	180	4.09
S8931	Adjuvant N1, REC-	III	213	9	4.23
S9061	Adjuvant Chemo + ABMI vs CAP	III	135	8	5.93
S9114	Adjuvant HD Chemo +ABMS	III	121	15	12.40
S9115	Adjuvant STAMPV V ABMS	III	41	4	9.76
S9215	Adjuvant N1, RC-, QOL	cc	24	1	4.17
S9248	Adjuvant PACLITAXEL	II	135	3	2.22
S9313	Adjuvant N0-N1 Hi-dose AC	III	3176	101	3.18
S9332	Adjuvant	III	176	5	2.84
S9347	Adjuvant N0, TAM+/-OVX	III	115	2	1.74
S9410	Adjuvant N1, ADR+, -TAXOL	III	804	38	4.73
S9412	Adjuvant Chemo ABMT	III	90	8	8.89
S9514	Adjuvant Elderly N1, TAM/4HPR	III	82	4	4.88
S9520	MET, DOX, TAXOL	II	92	5	5.43
S9623	Adjuvant A+T+C/C=Chemo+AHPCS	III	164	13	7.93
S9630	MA s OBS for Endometrial Pathology	III	8	1	12.50
S9632	Enhancing Well Being Breast Ca	Pilot	3	1	33.33
TOTAL			13308	531	4.00

Table 17: CHAMPUS Eligible Beneficiaries - NCI Gastrointestinal Clinical Trials

Study ID	Study Name	Phase	Trial	DEERS	%
			N	Matched	Enrolled
S7804	Gastric, Adjuvant FAM vs Control	III	50	2	4.00
S8572	Colon, Adjuvant 5-FU + RT	pilot	52	1	1.92
S8591	Colon, Adjuvant LEV vs LEV/5-FU	III	37	1	2.70
S8598	Esophageal, 5FU/CDDP/RT vs RT	III	55	1	1.82
S8611	Colorectal, Advanced TMTM vs 5-FU	II-III	70	1	1.43
S8626	Pancreas Advanced, Gamma IFN	II	32	1	3.13
28630	Colorectal Advanced Gamma IFN	II	42	2	4.76
S8721	Esophageal Advanced, TMTX	II	24	1	4.17
S8730	Esophageal, Amonafide	II	16	1	6.25
S8743	Colorectal Advanced RTNF	II	25	1	4.00
S8896	Rectal Adjuvant 5-FU+RT +/- MECCNU	III	165	6	3.64
S8899	Colon Adjuvant Chemo vs Obs	III	1530	91	5.95
S8905	Colorectal Advanced 5-FU Modulation	II-III	620	21	3.39
S8906	Hepatoma Advanced Merbarone	II	22	1	4.55
S8910	Gastric, Advanced 5-FU + CDDP	II	46	2	4.35
S8917	Colorectal Advanced 5-FU/CF/Roferona	II	54	8	14.81
S8933	Pancreas Advanced Piroxantrone	II	42	1	2.38
S8936	Gastric Advanced Piroxantrone	II	27	3	11.11
S8939	Colorectal Advanced Merbarone	II	8	1	12.50
S8990	Colorectal Hepatoma Mets Resection	III	40	1	2.50
S9008	Gastric Adjuvant, Chemoradiation	III	543	21	3.87
S9013	Esophageal Neoadjuvant CHEM/SRG vs SRG	III	95	9	9.47
S9040	Rectal Adjuvant Chemo + RT	III	443	20	4.51
S9041	Colorectal Chemoprevention	pilot	202	26	12.87
S9045	Colorectal QOL	cc	287	11	3.83
S9051	Colorectal Advanced, HEPCHEMO+5-FU/CF	II	33	1	3.03
S9060	Esophageal 5-FU/CDDP/RT	II	33	1	3.03
S9100	Pancreas Advanced 5-FU/CF/PALA	II	30	3	10.00
S9107	Colorectal Advanced 5-FU/CF/PALA	II	28	2	7.14
S9135	Pancreas Advanced 5-FU/CF/PALA	II	45	1	2.22
S9150	Gastric TOPOTECAN	II	20	1	5.00
S9151	Hepatoma TOPOTECAN	II	38	2	5.26
S9157	Hepatoma Trans-Retinoic Acid	II	30	1	3.33
S9241	Colorectal Advanced TOPOTECAN	II	50	1	2.00
S9250	Colon, Peri 5-FU Adjuvant 5-FU/LEV	III	108	13	12.04
S9303	Colon Adjuvant RT/5-FU/LEV	III	54	3	5.56
S9304	Colon Adjuvant 5-FU/RT/LV/LEV	III	1089	31	2.85
S9306	Rectal Adjuvant 5-FU/RT/LV/LEV	II	19	1	5.26
S9339	Esophageal TOPOTECAN	II	47	1	2.13
S9401	Colorectal Adjuvant 5-FU/LEV/LV	III	29	2	6.90
S9411	Colon LAP vs Open Colectomy	III	74	3	4.05
S9413	Pancreas Advanced ELFI	II	55	1	1.82
S9415	Colon Adjuvant 5-FU/LV/LEV	III	696	25	3.59
S9420	Colon Advanced 5-FU	III	361	19	5.26
TOTAL			7366	346	4.70

Table 18: CHAMPUS Eligible Beneficiaries - NCI Genitourinary System Clinical Trials

Study ID	Study Name	Phase	Trial N	DEERS Matched	% Enrolled
JPR3	Pros, Blockade vs Blockade/RT	III	9	1	11.11
S8507	Bladder, BCG vs BCG+Maintenance	III	298	5	1.68
S8520	Penis, Stage III-IV, CDDP, MTX & Bleo	II	42	2	4.76
S8708	Prostrate, Stage D, CHIP	II	46	1	2.17
S8710	Bladder, Advanced, Cystmy vs MVAC	III	306	11	3.56
S8711	Testis Reproduction	cc	207	11	5.31
S8719	Prostate, DIDDMNIN-B, IFF/MESNA	II	78	2	2.56
S8733	Bladder, RT+/-5-F	pilot	81	4	4.94
S8788	Testis, Advanced, High vs Standard CDDP	III	42	1	2.38
S8789	Germ CL, Advanced, VP16+(CDDPVSCBDCA)	III	106	6	5.66
S8792	Renal, Wellfron vs Observation	III	166	11	6.63
S8793	Prostate, D1, Hormonal vs Observation	III	73	6	8.22
S8794	Prostate, Path C, RT vs Observation	III	431	55	12.76
S8795	Bladder, Superficial, BCG vs MMC	III	469	16	3.41
S8802	Renal, Echinomycin	II	49	1	2.04
S8824	Renal RIL-2	II	47	1	2.13
S8894	Prostate, D2, Orch+FLUT/Placebo	III	1387	86	6.20
S8925	Adrenal, CDDP+VP16, Mitotane	II	47	3	6.38
S8929	Renal Cell, Merbarone	II	41	2	4.88
S8949	Renal Mer, INTRON-A +/-Nephrectomy	III	231	15	6.49
S8955	Prostate, HR, 5-FU+ROFERON-A	II	23	1	4.35
S8956	Bladder, CDDP+5-FU-I	II	38	1	2.63
S8994	Prostate, Stage C, QOL	cc	219	47	21.46
S8997	Testes, CDDP & VP-16+/-BLEO/IFF	III	94	2	2.13
S9012	Advanced Renal, Los Dose ALPHA-IFN	II	59	2	3.39
S9024	Prostate, Clin C, RT+5-FU	II	31	8	25.81
S9039	Prostate, Stage D2, QOL	cc	739	54	7.31
S9109	Prostate C, Zoladex/Flutamide	II	62	9	14.52
S9122	Renal, A-IFN W/5-FU	II	40	1	2.50
S9124	GC, REL/REF EDATREXATE	II	25	2	8.00
S9130	Bladder, Smoking Cessation	cc	25	2	8.00
S9140	Bladder, CIS, BROPIRIMINE+BCG	II	49	1	2.04
S9142	Bladder, Gallium Nitrate	II	46	4	8.70
S9230	Renal, IL-4	II	58	2	3.45
S9235	Prostate, CASODEX	II	53	1	1.89
S9312	Bladder, CDDP+5FU+XRT	II	54	3	5.56
S9338	Renal, 5-FU+INTRONA+IL-2	II	38	1	2.63
S9343	Prostate, SUMARIN	II	62	4	6.45
S9346	Prostate, Intermittent Androgen Deprivation	III	145	3	2.07
S9407	Prostate, Hormone, EMCYT & VP-16	II	55	4	7.27
S9426	Prostate, FLUTAMIDE Withdrawal	II	70	2	2.86
S9450	Prostatectomy vs Observation	III	14	5	35.71
S9452	Prostate, SURAMIN	III	10	1	10.00
S9457	Bladder, TAXOL & CBDCA	II	53	1	1.89
S9460	Chemoprevention of 4-HPR in TCC	cc	16	1	6.25
S9510	Prostate, TOPOTECAN	II	23	7	30.43
S9615	Prostate, Neoadjuvant Therapy	III	22	6	27.27
TOTAL			6282	415	6.60

Table 19: CHAMPUS Eligible Beneficiaries - NCI Gynecological Clinical Trials

Study ID	Study Name	Phase	Trial N	DEERS Matched	% Enrolled
S8412	Ovarian Stage III-IV	III	166	3	1.81
S8501	Ovarian OPT Stage III, IP vs CDDP	III	571	33	5.78
S8695	Cervical Stage 11B—IVA, Chem/RT	III	37	2	5.41
S8717	Ovarian Advanced Stage III-IV	II	38	1	2.63
S8745	Cervical Folic Acid	cc	135	10	7.41
S8790	Ovarian Stage III CR, IFN vs Obs	III	61	1	1.64
S8797	Cervical Stage IA2-IIA, Chem/RT	III	268	13	4.85
S8835	Ovarian <1cm Resistant IP	II	83	1	1.20
S8914	Ovarian Advanced, Chemo+GMM-CSF	III	109	3	2.75
S9106	Ovarian Advanced, Chemo+ABMT	II	62	11	17.74
S9132	Cervical Stage III-IV, IFN+C/TRA	II	62	1	1.59
S9227	Ovarian OPT, Stage III	III	70	1	1.43
S9238	Ovarian, Plat Resistant, Stage III	III	40	2	5.00
S9249	Ovarian, SUBOPT, Chemo PACL	III	57	4	7.02
S9324	Ovarian, REL, Navelbione	II	92	7	7.61
S9326	Ovarian CLINCR, AALTRET	II	112	2	1.79
S9618	Peritoneal Advanced, ABDCA/PACLITAXEL	II	18	1	5.56
S9619	Ovarian, OPTSTIII IP/IV CDDP/PACL	II	49	3	6.12
TOTAL			2031	99	4.90

Table 20: CHAMPUS Eligible Beneficiaries - NCI Head and Neck Clinical Trials

Study ID	Study Name	Phase	Trial N	DEERS Matched	% Enrolled
S8590	HN Adjuvant CDDP/5-FU+XRT vs XRT	III	72	2	2.78
S8810	HN Local Advanced CDDP+5-FU	II	110	1	0.91
S8852	Hn Local Advanced ACC FR RT+CDDP	II	48	1	2.08
S8892	Nasopharyngeal, CDDP+RT vs RT	III	193	8	4.15
S8895	HN Cricopharyngeal Myotomy	III	21	3	14.29
S8957	HN Resection, RT+CDDP/5-FU+CDDP	II	72	4	5.56
S9046	HN Recurrent, 10-EDAM	II	52	4	7.69
S9059	HN RT vs RT+CDDP vs RT+CDDP+5-FU	III	122	2	1.64
S9062	HN Recurrent 5-FU+CDDP+AIFN	II	52	1	1.92
S9201	HN Laryngeal Preservation	III	53	3	5.66
S9446	HN State I-III, 13-CRA Chemoprevention	III	36	1	2.78
S9519	HN REC/MET SCC, TOMIDEX	II	27	1	3.70
TOTAL			858	31	3.60

Table 21: CHAMPUS Eligible Beneficiaries - NCI Leukemia Clinical Trials

Study ID	Study Name	Phase	Trial N	DEERS Matched	% Enrolled
S8326	ANL, CGL Relapse Induction	III	373	9	2.41
S8417	ALL Post Remission Therapy	III	288	99	3.13
S8600	ANL, ARA-C+DNR	III	728	20	2.75
S8612	AL HighRisk, CML ASS/BLAST, BMT	III	120	3	2.50
S8691	HCL, Untreated DCF vs A-IFN	III	301	6	1.99
S8735	CML Untreated IFN	I-II	20	1	5.00
S8833	CLL, REL/REF, CLB+FLAMP	I	21	1	4.76
S9030	ALL, REL/REFR, HIDAC+DHAD	II	33	4	12.12
S9031	AML, DNM, ARA-C+GCSF/Placebo	III	234	9	3.85
S9034	ANL, Post Remission Therapy	III	293	14	4.78
S9108	B-CLL, FLAMP vs CHLOR vs FLAMP+CHLOR	III	158	9	5.70
S9120	MDS,GGCSF, T-RA	I	7	1	14.29
S9126	AML, ARA-C/DNR+/-Cyclosporin	III	213	12	5.63
S9129	APL, TRA vs RA-C/DNR	III	92	3	3.26
S9300	CML, AATRA?IFN and ATRA/HU	II	93	4	4.30
S9333	AML, DHAD/VP-16 vs ARA-C/DNR	III	233	14	6.01
S9400	ALL,Chemo+/-PIXY321, BMT	II	75	2	2.67
S9500	AML, Intensive ARA-C+DNR	II	104	5	4.81
S9617	AML, PSC833 PTS>55	I	14	1	7.14
TOTAL			3400	127	3.70

Table 22: CHAMPUS Eligible Beneficiaries - NCI Lung Clinical Trials

Study ID	Study Name	Phase	Trial N	DEERS Matched	% Enrolled
S8609	SCL, Ext VM-26	II	45	2	4.44
S8625	NSCL,EXT CDDP+CONS	II	81	1	1.23
S8738	NSCL, Adv, CDDP	III	356	6	1.69
S8805	NSCL, Neoadj CDDP/VP-16+RT	II	156	10	6.41
S8812	SCL, LTD, IND+/-GM-CSF, +/-IFN	III	304	13	4.28
S8836	NSCL, Local Advanced, RT/CDDP,CONS	II	65	2	3.08
S8850	NSCL Advanced, Novobiocin+CDDP	II	36	1	2.78
S8857	SCL, EXT, CDDP/VP-16/Cont CAV	II	67	7	10.45
S8991	SCL, LTD, RT/CHEMPO	III	50	3	6.00
S8992	NSCL, Local Advanced, RT vs RT/Chemo	III	28	1	3.57
S9019	NSCL, Stage IIIB, CDDP/VP-16+RT	III	145	12	8.28
S9038	NSCL, Advanced, Oral VP-16/Cytosan	II	66	3	4.55
S9127	NSCL, Advanced, CDDP/CBDCA/VP-16	II	83	4	4.82
S9148	SCL/NSCL, Advanced, CDDP/ARA-C/HU	II	58	3	5.17
S9158	Squamous, Trans-Ret A/A-IFN	II	18	1	5.56
S9207	NSCL, Advanced, 10-EDAM, CBDCA	II	24	3	12.50
S9216	SCL, Ext, CODE/RT vs CAV/EP	III	143	13	9.09
S9221	NSCL, Stage I, 13-CRA Chemoprevention	III	226	22	9.73
S9229	SCL, LTD, CDDP/VP, VCR, PCI	II	58	1	1.72
S9242	SCL, Ext, Taxotere	II	47	1	2.13
S9252	NSCL, State II-III A, Adjuvant	III	38	3	7.89
S9307	SCL, ET, Po VP-16/Cytosan/PCI	II	65	6	9.23
S9308	NSCL, Advanced, CDDP vs CDDP+VINLB	III	432	15	3.47
S9336	NSCL, Stage IIIA, Chemo/RT+/-Surgery	III	49	7	14.29
S9416	NSCL, PANCOAST, Chemo/RT/Surgery	II	61	1	1.64
S9424	NSCL, Advanced, HD Tamoxifen+CDDP	II	82	3	3.66
S9429	NSCL, Stage III, Poor Risk	II	63	3	4.76
S9504	NSCL, CDDP/VP-16/RT+Taxotere	II	41	2	4.88
S9509	NSCL, CDDP/VIN vs CBDCA/PAC	III	348	15	4.31
X1195	NSCLC, PACLITAXEL/CBDCA	II	34	1	2.94
TOTAL			3269	165	5.10

Table 23: CHAMPUS Eligible Beneficiaries -NCI Lymphoma Clinical Trials

Study ID	Study Name	Phase	Trial N	DEERS Matched	% Enrolled
S8309	NHL, Autologous BMT	II	17	2	11.76
S8406	Lymphoma, Malignant ESORUBICIN	II	24	2	8.33
S8516	NHL, Four Treatment Comparison	III	963	22	2.28
S8736	NHL, CHOP vs CHOP/RT	III	442	31	7.01
S8796	HD, Combo Chemo	III	158	5	3.16
S8809	NHL, Promace-MOPP	III	571	28	4.90
S8816	Lymphoma, MF, 13-CIS RA+Roferon-A	II	25	3	12.00
S8942	NHL, ABMT, Chemo or TBI Prep	II	104	5	4.81
S8952	HD, Combo Chemo	III	305	17	5.57
S8954	Lymphoblastic NHL, L-17M	II	37	1	2.70
S9011	HD, ABMT, Chemo o TBI Prep	II	81	6	7.41
S9125	NHL, CVAD. VERAPAMIL/QUININE	II	100	6	6.00
S9133	HD, I-IIA, SNRT vs AV+SNRT	III	263	16	6.08
S9208	Early Stage HD, QOL	CC	178	10	5.62
S9219	NHL or HD, Interleukin-4	II	29	1	3.45
S9240	NHLK< CVAD	II	112	4	3.57
S9246	NHL or HD, Relapses TAXOL	II	69	2	2.90
S9320	AIDS. Lymphoma, PROMACE-CYTABOM	II	35	2	5.71
S9349	NHL, CHOP vs PROMACE-CYTABOM	II	210	4	1.90
S9438	TBI, PBSCT, IL-2 vs Observation	III	154	13	8.44
S9501	NHL, FLUDARABINE/MITOXANTRONE	II	92	3	3.26
TOTAL			3969	183	4.60

Table 24: CHAMPUS Eligible Beneficiaries - NCI Melanoma Clinical Trials

Study ID	Study Name	Phase	Trial N	DEERS Matched	% Enrolled
S8393	Stage I, Surgery, INTGR	III	36	5	13.89
S8569	Interleukin	II	10	1	10.00
S8642	IFN-GAMMA vs Observation	III	284	7	2.46
S8723	AMONAFIDE	II	23	1	4.35
S8921	3 Phase Trials	II	96	1	1.04
S9035	Immunotherapy	III	689	32	4.64
S9111	T4 or N+, A-IFN 2	III	272	8	2.94
S9116	PIROXANTRONE	II	52	1	1.92
S9223	A-IFN+TRA	II	57	4	7.02
S9228	IL-4	II	236	1	2.78
S9348	BCNU/DTIC/CDDP/TAM	II	84	3	3.57
S9350	IFN/DTIC/CDDP/TAM	II	26	1	3.85
S9622	CI-980	II	24	1	4.17
TOTAL			1689	66	3.90

Table 25: CHAMPUS Eligible Beneficiaries - NCI Multiple Myeloma Clinical Trials

Study ID	Study Name	Phase	Trial N	DEERS Matched	% Enrolled
S8624	Combined Therapy	III	467	11	2.36
S8726	REF	II	17	1	5.88
S8744	REF	II	9	1	11.11
S8900	REF	II	127	2	1.57
S8944	REF	I-II	19	1	5.26
S8993	REF Stem Cell Support	II	72	6	8.33
S9003	Fludarabine	pilot	222	10	4.50
S9028	Combined Therapy	III	23	12	5.15
S9210	VAD-P/Q	III	259	15	5.79
S9237	REF TOTOTECAN	II	46	2	4.35
S9321	Standard vs High Dose	III	500	35	7.00
S9628	DEX+Interferon	pilot	13	1	7.69
TOTAL			1984	97	4.90

Table 26: CHAMPUS Eligible Beneficiaries - NCI Sarcoma Clinical Trials

Study ID	Study Name	Phase	Trial N	DEERS Matched	% Enrolled
S8616	ISS 4	III	434	10	2.30
S8693	Osteosarcoma ISS 3	III	6	1	16.67
S8922	ADR+DTIC+IFF+GM-CSF	I	17	1	5.88
S8930	PIROXANTRONE	II	25	2	9.00
S8943	MERBARONE	II	37	1	2.70
S9119	MAID	II	57	3	5.26
S9128	ADR+DTIC+IFFGMCSF	I	1	1	14.29
S9134	TAXOL+GCSF	II	51	2	3.92
S9139	ADR+CDDP+IFF	II	65	3	4.62
S9143	CDDP+ARA-C+HYDROX	II	43	3	6.98
S9147	DESMOID< TAM	II	14	1	7.14
S9341	IFF+MESMA+G-CSF	II	41	3	7.32
S9518	Soft Tissue, TOPOTECAN	II	22	2	9.09
TOTAL			333	33	4.00

Table 27: NCI Clinical Trials SWOG/DEERS Matched Cases By Breast Tumor

Breast Study ID	Phase	Trial	N	N	N
			Adjuvant	Advanced	Other
S7827	3		13		
S8312	3			5	
S8313	3	ECOG			15
S8366	3				4
S8568	2				1
S8621	3			3	
S8692	3			1	
S8697	3	ECOG		3	
S8741	2			2	
S8748	2			2	
S8807*	cc				123
S8811	2			1	
S8814	3				54
S8851	3	ECOG	29		
S8897	3		180		
S8931	3	ECOG	9		
S9061	3	ECOG	8		
S9114	3	CALGB	15		
S9115	3			4	
S9215	cc	QOL	1		
S9248	2			3	
S9313	3		101		
S9332	3	ECOG		5	
S9347	3	ECOG	2		
S9410	3	CALGB	38		
S9412	3	ECOG		8	
S9514	3		4		
S9520	2				5
S9623	3	QOL			1
N=29			400	37	203

*chemoprevention trials

Table 28: NCI Clinical Trials SWOG/DEERS Matched Cases By Prostate Tumor

Prostate Study ID	Phase	Trial	N	N	N
			Adjuvant	Advanced	Other
JPR3	3				1
S8708	2				1
S8719	2				2
S8793	3				6
S8794	3		55		
S8894	3				86
S8955	2				1
S8994	cc	QOL			47
S9024	2				8
S9039	cc	QOL			54
S9109	2				9
S9217*	cc	PCPT		2968	
S9235	2			1	
S9343	2		4		
S9346	3				3
S9407	2		4		
S9426	2				2
S9450	3	VA PIVOT			5
S9452	3				1
S9510	2				7
S9615	3				6
N=21			63	2969	239

*chemoprevention trials

Table 29: NCI Clinical Trials SWOG/DEERS Matched Cases By Leukemia Tumor

Leukemia			N	N	N
Study ID	Phase	Trial	Adjuvant	Advanced	Other
S8326	3	CALGB			9
S8417	3				9
S8600	3				20
S8612	3				3
S8691	3				6
S8735	2,3				1
S8833	1				1
S9030	2				4
S9031	3				9
S9034	3				14
S9108	3				9
S9120	1				1
S9126	3				12
S9129	3				3
S9300	2				4
S9333	3				14
S9400	2				2
S9500	2				5
S9617	1				1
N=19					

Table 30: NCI Clinical Trials SWOG/DEERS Matched Cases By Lymphoma Tumor

Lymphoma Study ID	Phase	Trial	N		N Other
			Adjuvant	Advanced	
S8309	2				2
S8406	2				2
S8516	3				22
S8616	3				10
S8624	3				11
S8693	3				1
S8726	2				1
S8736	3				31
S8744	2				1
S8796	3				5
S8809	3				28
S8816	2				3
S8900	2				2
S8922	1				1
S8930	2				2
S8942	2				5
S8943	2				1
S8944	2				1
S8952	3	CALGB			17
S8954	2				1
S8993	2				6
S9003	pilot				10
S9011	2				6
S9028	3				12
S9119	2				3
S9125	2				6
S9128	1				1
S9133	3				16
S9134	2				2
S9139	2				3
S9143	2				3
S9147	2				1
S9208	cc	QOL			10
S9210	3				15
S9219	2				1
S9237	2				2
S9240	2				4
S9246	2				2
S9320	2				2
S9321	3				35
S9341	2				2
S9349	2				4
S9438	3				13
S9501	2				3
S9518	2				2
S9628	pilot				1
N=46					216

Table 31: NCI Clinical Trials SWOG/DEERS Matched Cases By Colon/Rectal Tumor

Colon / Rectal Study ID	Phase	Trial	N	N	N
			Adjuvant	Advanced	Other
S8572	pilot		1		
S8591	3		1		
S8611	2,3				
S8630	2			2	
S8743	2			1	
S8896	3		6		
S8899	3		91		
S8905	2,3			2	
S8917	2			8	
S8939	2			1	
S8990	3				1
S9040	3	CALGB	20		
S9041*	pilot				26
S9045	cc	QOL			11
S9051	2			1	
S9107	2			2	
S9241	2			1	
S9250	3		13		
S9303	3		3		
S9304	3		31		
S9306	2		1		
S9401	3		2		
S9411	3	NCCTG			3
S9415	3		25		
S9420	3			19	
N=25			194	37	41

*chemoprevention trials

Table 32: NCI Clinical Trials SWOG/DEERS Matched Cases By Lung Tumor

Lung Study ID	Phase	Trial	N	N	N
			Adjuvant	Advanced	Other
S8609	2				2
S8625	2				1
S8738	3			6	
S8805	2		10		
S8812	3				13
S8836	2			2	
S8850	2			1	
S8857	2				7
S8991	3				3
S8992	3			1	
S9019	3				12
S9038	2			3	
S9127	2			4	
S9148	2			3	
S9158	2				1
S9207	2			3	
S9216	3				13
S9221*	3				22
S9229	2				1
S9242	2				1
S9252	3		3		
S9307	2				6
S9308	3			15	
S9336	3				7
S9416	2				1
S9424	2			3	
S9429	2				3
S9504	2		2		
S9509	3				15
X1195	2		1		
N=30			16	41	108

*chemoprevention trials

NCI Cooperative Program Study Group

Co - Principle Investigators

Scott A Optenberg, DrPH
Center for Healthcare Education and Studies
Army Medical Department Center and School
Fort San Houston, Texas

Sandra L. Schneider, DrPH
Center for Healthcare Education and Studies
Army Medical Department Center and School
Fort San Houston, Texas

Arnold Potosky, PhD
Division of Cancer Prevention and Control
National Cancer Institute
Bethesda, MD

Mary McCabe, RN
Office of Clinical Research Promotions
National Cancer Institute
Bethesda, MD

Systems and Technical Transfer Programmers

Steve Willhoite
Center for Healthcare Education and Studies
Army Medical Department Center and School
Fort San Houston, Texas

Don Saathoff
Center for Healthcare Education and Studies
Army Medical Department Center and School
Fort San Houston, Texas

Robert Serafin
Center for Healthcare Education and Studies
Army Medical Department Center and School
Fort San Houston, Texas

Steve Condit
Southwest Oncology Group
Statistical Center
Fred Hutchinson Research Center
Seattle Washington

Collaborators

Charles A. Coltman, Jr., MD
Southwest Oncology Group
Cancer Therapy and Research Center (CTRC)
San Antonio Texas

John Crowley, PhD
Southwest Oncology Group
Statistical Center
Fred Hutchinson Research Center
Seattle Washington

Rick Barnett, PhD
OCHAMPUS
Department of Defense
Statistics Branch
TRICARE Support Office (TSO)
Office of Civilian and Health and Medical Program of the Uniformed Services
Aurora, Colorado

Administration and Operations

Tony Guillen
Center for Healthcare Education and Studies
Army Medical Department Center and School
Fort San Houston, Texas

Marge Godfrey
Southwest Oncology Group
Cancer Therapy and Research Center (CTRC)
San Antonio Texas

REFERENCES

1. Kiberstis, P and Marx, J (eds). Frontiers in Cancer Research. Science 278:1035-1077, 1997.
2. Department of Defense. CHAMPUS Chartbook of Statistics: OCHAMPUS Guide 5400.2-CB. Civilian Health and Medical Program of the Uniformed Services. Information Systems Division Statistics Branch,. Office of Civilian Health and Medical Program of the Uniformed Services, Aurora, Co. December 1995
3. Department of Defense. CHAMPUS Chartbook of Statistics: TSO/OCHAMPUS Guide 5400.2-CB. Civilian Health and Medical Program of the Uniformed Services. Information Systems Division Statistics Branch,. Office of Civilian Health and Medical Program of the Uniformed Services, Aurora, Co. January 1997.

DISTRIBUTION LIST

HQDA, ATTN: DASG-ZA, Suite 672, 5109 Leesburg Pike, Falls Church, VA 22041-3258 (1)
HQDA, ATTN: DASG-ZB, Suite 672, 5109 Leesburg Pike, Falls Church, VA 22041-3258 (1)
HQDA, ATTN: DASG-HSZ, 5111 Leesburg Pike, Falls Church, VA 22041-3258 (1)
HQDA, ATTN: DASG-RMZ (COL Blum), Room 638, 5111 Leesburg Pike, Falls Church, VA 22041-3258 (3)
HQDA, ATTN: DASG-HS&AP, Room 611, Skyline 5, 5111 Leesburg, Pike, Falls Church, VA 22041-3258 (1)
Defense Technical Information Center, ATTN: Pat Mawby, (Acquisition), Suite 0944, 8725 John J. Kingman Rd, Fort Belvoir, VA 22060-6218 (2)
Commandant, Academy of Health Sciences, ATTN: MCCS-H, Suite 310, 2250 Stanley Rd, Fort Sam Houston, TX 78234-6100 (1)
HQDA, Armed Forces Medical Library, ATTN: DASG-AAFJML, Room 670, 5109 Leesburg Pike, Falls Church, VA 22041-3258 (1)
HQ MEDCOM, ATTN: MCCG, Suite 223, Bldg 2792, Worth Rd, Fort Sam Houston, TX 78234-6009 (1)
HQ MEDCOM, ATTN: MCCL-M (COL Ferguson), Bldg 2792, Worth Rd, Fort Sam Houston, TX 78234-6009 (3)
HQ MEDCOM, ATTN: MCRM (COL Clouse), Rm 203, Suite 9, Bldg 2792, Worth Rd, Fort Sam Houston, TX 78234-6009 (8)
Academy of Health Sciences, Stimson Library, ATTN: MCCS-HSL, Bldg 2840, Fort Sam Houston, TX 78234-6100 (1)
Brooke Army Medical Center, Medical Library, ATTN: MCHE-CSL, Bldg 3600, 3851 Roger Brooke Dr, Fort Sam Houston, TX 78234-6200 (1)
Defense Logistics Studies Information Exchange, U.S. Army Logistic Management College, ATTN: DLSIE-ATSZ-DL (Director), Bldg 12500, 2401 Quarters Rd, Fort Lee, VA 23801-1705 (1)
Robert Wittes, MD, Office of Clinical Research Promotions, National Cancer Institute, 31 Center Drive, MSC 2440, Bldg 31, Room 3A44, Bethesda, MD, 20892-2440 (2)
Mary McCabe, RN, Office of Clinical Research Promotions, National Cancer Institute, 31 Center Drive, MSC 2440, Bldg 31, Room 3A44, Bethesda, MD, 20892-2440 (5)
Faina Shtern, PhD, Office of Clinical Research Promotions, National Cancer Institute, 31 Center Drive, MSC 2440, Bldg 31, Room 3A44, Bethesda, MD, 20892-2440 (1)
Arnold Potosky, PhD, Division of Cancer Prevention and Control, National Cancer Institute, Executive Plaza North, Room 3313, Bethesda, MD 20892-7344 (3)
Martin Brown, PhD, Division of Cancer Prevention and Control, National Cancer Institute, Executive Plaza North, Room 3313, Bethesda, MD 20892-7344 (1)
Kim McGuigan, PhD, RAND Corporation, Research Director 1700 Main St, Santa Monica, Calif 90407-2138 (1)
Charles A. Coltman, Jr., MD, Southwest Oncology Group, Cancer Therapy and Research Center (CTRC), 8122 Data Point Dr., Suite 600, San Antonio Texas, 78229-3264 (3)
Robert Opsut, PhD, Program Review and Evaluations, OASD Health Affairs, Department of Defense, 5111 Leesburg Pike, Suite 810, Falls Church, VA 22041 (1)
Capt Deborah Kamin, NC, USN, Director Health Services Financing Policy, Pentagon, Room 1B657, Washington, DC 20301-1200 (1)

APPENDIX

ICD9CM Cancer Diagnosis For Department of Defense CHAMPUS Patients Enrolled and Treated in NCI Sponsored Clinical Trials

Percent Frequency and Prevalence of Site Specific Cancer For In-Patient Professional Services (FY88-96)

Percent Frequency and Prevalence of Site Specific Cancer For Out-Patient Professional Services (FY88-96)

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1988
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 300815

A1

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
1	MALIGNANT NEOPLASM LIP	140	19	0.05%	0.01%
2	MALIGNANT NEOPL TONGUE	141	148	0.42%	0.05%
3	MAL NEOPL MAJOR SG	142	54	0.15%	0.02%
4	MALIGNANT NEOPLASM GUM	143	15	0.04%	0.00%
5	MAL NEOPLASM FLOOR MOUTH	144	50	0.14%	0.02%
6	MAL NEOPL MOUTH NEC/NOS	145	85	0.24%	0.03%
7	MAL NEOPLASM OROPHARYNX	146	63	0.18%	0.02%
8	MAL NEOPLASM NASOPHARYNX	147	53	0.15%	0.02%
9	MAL NEOPL HYPOPHARYNX	148	39	0.11%	0.01%
10	OTH MAL NEOPL OROPHARYNX	149	87	0.25%	0.03%
11	MAL NEOPL ESOPHAGUS	150	233	0.66%	0.08%
12	MAL NEOPL STOMACH	151	259	0.74%	0.09%
13	MAL NEOPL SMALL BOWEL	152	40	0.11%	0.01%
14	MALIGNANT NEOPLASM COLON	153	929	2.64%	0.31%
15	MAL NEOPL RECTUM/ANUS	154	991	2.82%	0.33%
16	MALIGNANT NEOPLASM LIVER	155	261	0.74%	0.09%
17	MAL NEOPL GB/BD	156	56	0.16%	0.02%
18	MAL NEOPL PANCREAS	157	286	0.81%	0.10%
19	MAL NEOPLASM PERITONEUM	158	44	0.13%	0.01%
20	OTH DIGEST MAL NEOPL	159	77	0.22%	0.03%
21	MAL NEOPL NOSE/ME/SINUS	160	52	0.15%	0.02%
22	MAL NEOPL LARYNX	161	253	0.72%	0.08%
23	MAL NEOPL TRACHEA/LUNG	162	3450	9.80%	1.15%
24	MALIGNANT NEOPL PLEURA	163	32	0.09%	0.01%
25	MAL NEOPL THYMUS/MEDIAST	164	76	0.22%	0.03%
26	MAL NEOPL RESP NEC	165	21	0.06%	0.01%
27	MAL NEOPL BONE/CART	170	307	0.87%	0.10%
28	MAL NEOPL SOFT TISSUE	171	280	0.80%	0.09%
29	MALIGNANT MELANOMA SKIN	172	253	0.72%	0.08%
30	OTHER MAL NEOPL SKIN	173	336	0.95%	0.11%
31	MAL NEOPL FEMALE BREAST	174	3033	8.62%	1.01%
32	MAL NEOPL MALE BREAST	175	22	0.06%	0.01%
33	MAL NEOPL UTERUS NOS	179	176	0.50%	0.06%
34	MAL NEOPL CERVIX UTERI	180	511	1.45%	0.17%
35	MALIGNANT NEOPL PLACENTA	181	6	0.02%	0.00%
36	MAL NEOPL UTERUS BODY	182	352	1.00%	0.12%
37	MAL NEOPL UTERINE ADNEXA	183	602	1.71%	0.20%
38	MAL NEOPL FE GENIT NEC	184	68	0.19%	0.02%
39	MAL NEOPL PROSTATE	185	576	1.64%	0.19%
40	MAL NEOPL TESTIS	186	44	0.13%	0.01%
41	MAL NEOPL MALE GENIT NEC	187	16	0.05%	0.01%
42	MAL NEOPL BLADDER	188	469	1.33%	0.16%
43	MAL GU NEOPL NEC/NOS	189	405	1.15%	0.13%
44	MALIGNANT NEOPLASM EYE	190	63	0.18%	0.02%
45	MALIGNANT NEOPLASM BRAIN	191	952	2.71%	0.32%
46	MAL NEOPL NERVE NEC/NOS	192	102	0.29%	0.03%
47	MALIGNANT NEOPL THYROID	193	151	0.43%	0.05%
48	MAL NEOPL ENDOCRINE NEC	194	156	0.44%	0.05%
49	MAL NEOPL ILL-DEF SITES	195	491	1.40%	0.16%
50	SECONDARY MAL NEOPL LN	196	130	0.37%	0.04%
51	2ND MAL NEOPLASM GI/RESP	197	496	1.41%	0.16%
52	2ND MAL NEOPL OTH SITES	198	711	2.02%	0.24%
53	MALIGNANT NEOPLASM NOS	199	1391	3.95%	0.46%
54	LYMPHOSARC/RETICULOSARC	200	141	0.40%	0.05%
55	HODGKIN'S DISEASE	201	196	0.56%	0.07%
56	OTH MAL NEOPL LYMPH/HIST	202	544	1.55%	0.18%
57	MULTIPLE MYELOMA ET AL	203	160	0.45%	0.05%
58	LYMPHOID LEUKEMIA	204	275	0.78%	0.09%
59	MYELOID LEUKEMIA	205	203	0.58%	0.07%
60	MONOCYTIC LEUKEMIA	206	23	0.07%	0.01%
61	OTHER SPECIFIED LEUKEMIA	207	18	0.05%	0.01%
62	LEUKEMIA-UNSPECIF CELL	208	365	1.04%	0.12%
63	BEN NEOPL MOUTH/PHARYNX	210	137	0.39%	0.05%
64	OTH BENIGN NEOPLASM GI	211	825	2.34%	0.27%
65	BEN INTRATHOR NEOPLASM	212	182	0.52%	0.06%
66	BEN NEOPLASM BONE/CART	213	1297	3.69%	0.43%
67	LIPOMA	214	176	0.50%	0.06%
68	OTH BEN NEOPL SOFT TISS	215	229	0.65%	0.08%
69	BENIGN NEOPLASM OF SKIN	216	339	0.96%	0.11%
70	BENIGN NEOPLASM BREAST	217	174	0.49%	0.06%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1988
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (71)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 300815

A2

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
71	UTERINE LEIOMYOMA	218	2846	8.09%	0.95%
72	OTH BENIGN NEOPL UTERUS	219	138	0.39%	0.05%
73	BENIGN NEOPLASM OVARY	220	247	0.70%	0.08%
74	BEN NEOPL OTH FEM GENIT	221	71	0.20%	0.02%
75	BENIGN NEOPL MALE GENIT	222	49	0.14%	0.02%
76	BENIGN NEOPLASM URINARY	223	80	0.23%	0.03%
77	BENIGN NEOPLASM OF EYE	224	16	0.05%	0.01%
78	BENIGN NEOPL NERV SYST	225	338	0.96%	0.11%
79	BENIGN NEOPLASM THYROID	226	130	0.37%	0.04%
80	BEN NEOPL OTH ENDOCRINE	227	108	0.31%	0.04%
81	HEMANGIOMA/LYMPHANGIOMA	228	158	0.45%	0.05%
82	BENIGN NEOPLASM NEC/NOS	229	202	0.57%	0.07%
83	CA IN SITU DIGESTIVE ORG	230	195	0.55%	0.06%
84	CA IN SITU RESPIRATORY	231	217	0.62%	0.07%
85	CARCINOMA IN SITU SKIN	232	29	0.08%	0.01%
86	CA IN SITU BREAST/GU	233	582	1.65%	0.19%
87	CA IN SITU NEC/NOS	234	86	0.24%	0.03%
88	UNC BEHAV NEOPL GI/RESP	235	196	0.56%	0.07%
89	UNC BEHAV NEOPL GU	236	185	0.53%	0.06%
90	UNC NEOPL ENDOCR/NERV	237	194	0.55%	0.06%
91	UNC BEHAV NEOPL NEC/NOS	238	326	0.93%	0.11%
92	UNSPECIFIED NEOPLASM	239	3745	10.64%	1.24%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1989
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 279493

A3

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
1	MALIGNANT NEOPLASM LIP	140	18	0.05%	0.01%
2	MALIGNANT NEOPL TONGUE	141	145	0.42%	0.05%
3	MAL NEOPL MAJOR SG	142	43	0.12%	0.02%
4	MALIGNANT NEOPLASM GUM	143	12	0.03%	0.00%
5	MAL NEOPLASM FLOOR MOUTH	144	31	0.09%	0.01%
6	MAL NEOPL MOUTH NEC/NOS	145	74	0.21%	0.03%
7	MAL NEOPLASM OROPHARYNX	146	67	0.19%	0.02%
8	MAL NEOPLASM NASOPHARYNX	147	54	0.15%	0.02%
9	MAL NEOPL HYPOPHARYNX	148	32	0.09%	0.01%
10	OTH MAL NEOPL OROPHARYNX	149	75	0.22%	0.03%
11	MAL NEOPL ESOPHAGUS	150	253	0.73%	0.09%
12	MAL NEOPL STOMACH	151	263	0.75%	0.09%
13	MAL NEOPL SMALL BOWEL	152	46	0.13%	0.02%
14	MALIGNANT NEOPLASM COLON	153	1040	2.98%	0.37%
15	MAL NEOPL RECTUM/ANUS	154	923	2.65%	0.33%
16	MALIGNANT NEOPLASM LIVER	155	280	0.80%	0.10%
17	MAL NEOPL GB/BD	156	61	0.17%	0.02%
18	MAL NEOPL PANCREAS	157	319	0.91%	0.11%
19	MAL NEOPLASM PERITONEUM	158	48	0.14%	0.02%
20	OTH DIGEST MAL NEOPL	159	51	0.15%	0.02%
21	MAL NEOPL NOSE/ME/SINUS	160	51	0.15%	0.02%
22	MAL NEOPL LARYNX	161	297	0.85%	0.11%
23	MAL NEOPL TRACHEA/LUNG	162	3611	10.35%	1.29%
24	MALIGNANT NEOPL PLEURA	163	39	0.11%	0.01%
25	MAL NEOPL THYMUS/MEDIAST	164	67	0.19%	0.02%
26	MAL NEOPL RESP NEC	165	21	0.06%	0.01%
27	MAL NEOPL BONE/CART	170	298	0.85%	0.11%
28	MAL NEOPL SOFT TISSUE	171	254	0.73%	0.09%
29	MALIGNANT MELANOMA SKIN	172	249	0.71%	0.09%
30	OTHER MAL NEOPL SKIN	173	298	0.85%	0.11%
31	MAL NEOPL FEMALE BREAST	174	2931	8.40%	1.05%
32	MAL NEOPL MALE BREAST	175	17	0.05%	0.01%
33	MAL NEOPL UTERUS NOS	179	145	0.42%	0.05%
34	MAL NEOPL CERVIX UTERI	180	553	1.59%	0.20%
35	MALIGNANT NEOPL PLACENTA	181	5	0.01%	0.00%
36	MAL NEOPL UTERUS BODY	182	333	0.95%	0.12%
37	MAL NEOPL UTERINE ADNEXA	183	620	1.78%	0.22%
38	MAL NEOPL FE GENIT NEC	184	79	0.23%	0.03%
39	MAL NEOPL PROSTATE	185	618	1.77%	0.22%
40	MAL NEOPL TESTIS	186	62	0.18%	0.02%
41	MAL NEOPL MALE GENIT NEC	187	21	0.06%	0.01%
42	MAL NEOPL BLADDER	188	538	1.54%	0.19%
43	MAL GU NEOPL NEC/NOS	189	462	1.32%	0.17%
44	MALIGNANT NEOPLASM EYE	190	56	0.16%	0.02%
45	MALIGNANT NEOPLASM BRAIN	191	894	2.56%	0.32%
46	MAL NEOPL NERVE NEC/NOS	192	91	0.26%	0.03%
47	MALIGNANT NEOPL THYROID	193	135	0.39%	0.05%
48	MAL NEOPL ENDOCRINE NEC	194	139	0.40%	0.05%
49	MAL NEOPL ILL-DEF SITES	195	453	1.30%	0.16%
50	SECONDARY MAL NEOPL LN	196	160	0.46%	0.06%
51	2ND MAL NEOPLASM GI/RESP	197	575	1.65%	0.21%
52	2ND MAL NEOPL OTH SITES	198	847	2.43%	0.30%
53	MALIGNANT NEOPLASM NOS	199	1334	3.83%	0.48%
54	LYMPHOSARC/RETICULOSARC	200	120	0.34%	0.04%
55	HODGKIN'S DISEASE	201	196	0.56%	0.07%
56	OTH MAL NEOPL LYMPH/HIST	202	567	1.63%	0.20%
57	MULTIPLE MYELOMA ET AL	203	159	0.46%	0.06%
58	LYMPHOID LEUKEMIA	204	273	0.78%	0.10%
59	MYELOID LEUKEMIA	205	227	0.65%	0.08%
60	MONOCYTIC LEUKEMIA	206	23	0.07%	0.01%
61	OTHER SPECIFIED LEUKEMIA	207	36	0.10%	0.01%
62	LEUKEMIA-UNSPECIF CELL	208	322	0.92%	0.12%
63	BEN NEOPL MOUTH/PHARYNX	210	134	0.38%	0.05%
64	OTH BENIGN NEOPLASM GI	211	786	2.25%	0.28%
65	BEN INTRATHOR NEOPLASM	212	184	0.53%	0.07%
66	BEN NEOPLASM BONE/CART	213	718	2.06%	0.26%
67	LIPOMA	214	231	0.66%	0.08%
68	OTH BEN NEOPL SOFT TISS	215	250	0.72%	0.09%
69	BENIGN NEOPLASM OF SKIN	216	273	0.78%	0.10%
70	BENIGN NEOPLASM BREAST	217	188	0.54%	0.07%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1989
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 279493

A4

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
71	UTERINE LEIOMYOMA	218	2845	8.16%	1.02%
72	OTH BENIGN NEOPL UTERUS	219	142	0.41%	0.05%
73	BENIGN NEOPLASM OVARY	220	216	0.62%	0.08%
74	BEN NEOPL OTH FEM GENIT	221	74	0.21%	0.03%
75	BENIGN NEOPL MALE GENIT	222	57	0.16%	0.02%
76	BENIGN NEOPLASM URINARY	223	90	0.26%	0.03%
77	BENIGN NEOPLASM OF EYE	224	18	0.05%	0.01%
78	BENIGN NEOPL NERV SYST	225	334	0.96%	0.12%
79	BENIGN NEOPLASM THYROID	226	175	0.50%	0.06%
80	BEN NEOPL OTH ENDOCRINE	227	146	0.42%	0.05%
81	HEMANGIOMA/LYMPHANGIOMA	228	176	0.50%	0.06%
82	BENIGN NEOPLASM NEC/NOS	229	215	0.62%	0.08%
83	CA IN SITU DIGESTIVE ORG	230	219	0.63%	0.08%
84	CA IN SITU RESPIRATORY	231	215	0.62%	0.08%
85	CARCINOMA IN SITU SKIN	232	44	0.13%	0.02%
86	CA IN SITU BREAST/GU	233	631	1.81%	0.23%
87	CA IN SITU NEC/NOS	234	112	0.32%	0.04%
88	UNC BEHAV NEOPL GI/RESP	235	226	0.65%	0.08%
89	UNC BEHAV NEOPL GU	236	186	0.53%	0.07%
90	UNC NEOPL ENDOCR/NERV	237	218	0.63%	0.08%
91	UNC BEHAV NEOPL NEC/NOS	238	346	0.99%	0.12%
92	UNSPECIFIED NEOPLASM	239	3414	9.79%	1.22%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1990
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (71)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 268455

A5

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
1	MALIGNANT NEOPLASM LIP	140	15	0.04%	0.01%
2	MALIGNANT NEOPL TONGUE	141	146	0.41%	0.05%
3	MAL NEOPL MAJOR SG	142	59	0.17%	0.02%
4	MALIGNANT NEOPLASM GUM	143	11	0.03%	0.00%
5	MAL NEOPLASM FLOOR MOUTH	144	52	0.15%	0.02%
6	MAL NEOPL MOUTH NEC/NOS	145	102	0.29%	0.04%
7	MAL NEOPLASM OROPHARYNX	146	55	0.16%	0.02%
8	MAL NEOPLASM NASOPHARYNX	147	50	0.14%	0.02%
9	MAL NEOPL HYPOPHARYNX	148	55	0.16%	0.02%
10	OTH MAL NEOPL OROPHARYNX	149	76	0.21%	0.03%
11	MAL NEOPL ESOPHAGUS	150	287	0.81%	0.11%
12	MAL NEOPL STOMACH	151	294	0.83%	0.11%
13	MAL NEOPL SMALL BOWEL	152	68	0.19%	0.03%
14	MALIGNANT NEOPLASM COLON	153	1093	3.09%	0.41%
15	MAL NEOPL RECTUM/ANUS	154	935	2.64%	0.35%
16	MALIGNANT NEOPLASM LIVER	155	236	0.67%	0.09%
17	MAL NEOPL GB/BD	156	57	0.16%	0.02%
18	MAL NEOPL PANCREAS	157	379	1.07%	0.14%
19	MAL NEOPLASM PERITONEUM	158	65	0.18%	0.02%
20	OTH DIGEST MAL NEOPL	159	75	0.21%	0.03%
21	MAL NEOPL NOSE/ME/SINUS	160	42	0.12%	0.02%
22	MAL NEOPL LARYNX	161	261	0.74%	0.10%
23	MAL NEOPL TRACHEA/LUNG	162	3467	9.80%	1.29%
24	MALIGNANT NEOPL PLEURA	163	34	0.10%	0.01%
25	MAL NEOPL THYMUS/MEDIAST	164	54	0.15%	0.02%
26	MAL NEOPL RESP NEC	165	13	0.04%	0.00%
27	MAL NEOPL BONE/CART	170	321	0.91%	0.12%
28	MAL NEOPL SOFT TISSUE	171	257	0.73%	0.10%
29	MALIGNANT MELANOMA SKIN	172	232	0.66%	0.09%
30	OTHER MAL NEOPL SKIN	173	272	0.77%	0.10%
31	MAL NEOPL FEMALE BREAST	174	2999	8.48%	1.12%
32	MAL NEOPL MALE BREAST	175	15	0.04%	0.01%
33	MAL NEOPL UTERUS NOS	179	110	0.31%	0.04%
34	MAL NEOPL CERVIX UTERI	180	469	1.33%	0.17%
35	MALIGNANT NEOPL PLACENTA	181	5	0.01%	0.00%
36	MAL NEOPL UTERUS BODY	182	284	0.80%	0.11%
37	MAL NEOPL UTERINE ADNEXA	183	746	2.11%	0.28%
38	MAL NEOPL FE GENIT NEC	184	82	0.23%	0.03%
39	MAL NEOPL PROSTATE	185	652	1.84%	0.24%
40	MAL NEOPL TESTIS	186	58	0.16%	0.02%
41	MAL NEOPL MALE GENIT NEC	187	25	0.07%	0.01%
42	MAL NEOPL BLADDER	188	561	1.59%	0.21%
43	MAL GU NEOPL NEC/NOS	189	490	1.39%	0.18%
44	MALIGNANT NEOPLASM EYE	190	62	0.18%	0.02%
45	MALIGNANT NEOPLASM BRAIN	191	872	2.47%	0.32%
46	MAL NEOPL NERVE NEC/NOS	192	115	0.33%	0.04%
47	MALIGNANT NEOPL THYROID	193	170	0.48%	0.06%
48	MAL NEOPL ENDOCRINE NEC	194	153	0.43%	0.06%
49	MAL NEOPL ILL-DEF SITES	195	403	1.14%	0.15%
50	SECONDARY MAL NEOPL LN	196	147	0.42%	0.05%
51	2ND MAL NEOPLASM GI/RESP	197	602	1.70%	0.22%
52	2ND MAL NEOPL OTH SITES	198	936	2.65%	0.35%
53	MALIGNANT NEOPLASM NOS	199	1056	2.99%	0.39%
54	LYMPHOSARC/RETICULOSARC	200	157	0.44%	0.06%
55	HODGKIN'S DISEASE	201	180	0.51%	0.07%
56	OTH MAL NEOPL LYMPH/HIST	202	570	1.61%	0.21%
57	MULTIPLE MYELOMA ET AL	203	152	0.43%	0.06%
58	LYMPHOID LEUKEMIA	204	292	0.83%	0.11%
59	MYELOID LEUKEMIA	205	238	0.67%	0.09%
60	MONOCYTIC LEUKEMIA	206	30	0.08%	0.01%
61	OTHER SPECIFIED LEUKEMIA	207	24	0.07%	0.01%
62	LEUKEMIA-UNSPECIF CELL	208	369	1.04%	0.14%
63	BEN NEOPL MOUTH/PHARYNX	210	145	0.41%	0.05%
64	OTH BENIGN NEOPLASM GI	211	896	2.53%	0.33%
65	BEN INTRATHOR NEOPLASM	212	218	0.62%	0.08%
66	BEN NEOPLASM BONE/CART	213	420	1.19%	0.16%
67	LIPOMA	214	246	0.70%	0.09%
68	OTH BEN NEOPL SOFT TISS	215	221	0.62%	0.08%
69	BENIGN NEOPLASM OF SKIN	216	367	1.04%	0.14%
70	BENIGN NEOPLASM BREAST	217	156	0.44%	0.06%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1990
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 268455

A6

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
71	UTERINE LEIOMYOMA	218	3098	8.76%	1.15%
72	OTH BENIGN NEOPL UTERUS	219	211	0.60%	0.08%
73	BENIGN NEOPLASM OVARY	220	336	0.95%	0.13%
74	BEN NEOPL OTH FEM GENIT	221	121	0.34%	0.05%
75	BENIGN NEOPL MALE GENIT	222	67	0.19%	0.02%
76	BENIGN NEOPLASM URINARY	223	72	0.20%	0.03%
77	BENIGN NEOPLASM OF EYE	224	17	0.05%	0.01%
78	BENIGN NEOPL NERV SYST	225	336	0.95%	0.13%
79	BENIGN NEOPLASM THYROID	226	176	0.50%	0.07%
80	BEN NEOPL OTH ENDOCRINE	227	120	0.34%	0.04%
81	HEMANGIOMA/LYMPHANGIOMA	228	150	0.42%	0.06%
82	BENIGN NEOPLASM NEC/NOS	229	232	0.66%	0.09%
83	CA IN SITU DIGESTIVE ORG	230	227	0.64%	0.08%
84	CA IN SITU RESPIRATORY	231	214	0.61%	0.08%
85	CARCINOMA IN SITU SKIN	232	28	0.08%	0.01%
86	CA IN SITU BREAST/GU	233	605	1.71%	0.23%
87	CA IN SITU NEC/NOS	234	104	0.29%	0.04%
88	UNC BEHAV NEOPL GI/RESP	235	263	0.74%	0.10%
89	UNC BEHAV NEOPL GU	236	234	0.66%	0.09%
90	UNC NEOPL ENDOCR/NERV	237	225	0.64%	0.08%
91	UNC BEHAV NEOPL NEC/NOS	238	358	1.01%	0.13%
92	UNSPECIFIED NEOPLASM	239	3413	9.65%	1.27%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1991
FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (71)
IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
DENOMINATOR IS 261205

A7

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
1	MALIGNANT NEOPLASM LIP	140	17	0.04%	0.01%
2	MALIGNANT NEOPL TONGUE	141	147	0.36%	0.06%
3	MAL NEOPL MAJOR SG	142	54	0.13%	0.02%
4	MALIGNANT NEOPLASM GUM	143	17	0.04%	0.01%
5	MAL NEOPLASM FLOOR MOUTH	144	43	0.10%	0.02%
6	MAL NEOPL MOUTH NEC/NOS	145	85	0.21%	0.03%
7	MAL NEOPLASM OROPHARYNX	146	68	0.16%	0.03%
8	MAL NEOPLASM NASOPHARYNX	147	50	0.12%	0.02%
9	MAL NEOPL HYPOPHARYNX	148	44	0.11%	0.02%
10	OTH MAL NEOPL OROPHARYNX	149	73	0.18%	0.03%
11	MAL NEOPL ESOPHAGUS	150	321	0.78%	0.12%
12	MAL NEOPL STOMACH	151	300	0.73%	0.11%
13	MAL NEOPL SMALL BOWEL	152	55	0.13%	0.02%
14	MALIGNANT NEOPLASM COLON	153	1392	3.37%	0.53%
15	MAL NEOPL RECTUM/ANUS	154	1096	2.65%	0.42%
16	MALIGNANT NEOPLASM LIVER	155	281	0.68%	0.11%
17	MAL NEOPL GB/BD	156	81	0.20%	0.03%
18	MAL NEOPL PANCREAS	157	413	1.00%	0.16%
19	MAL NEOPLASM PERITONEUM	158	66	0.16%	0.03%
20	OTH DIGEST MAL NEOPL	159	58	0.14%	0.02%
21	MAL NEOPL NOSE/ME/SINUS	160	39	0.09%	0.01%
22	MAL NEOPL LARYNX	161	332	0.80%	0.13%
23	MAL NEOPL TRACHEA/LUNG	162	3989	9.65%	1.53%
24	MALIGNANT NEOPL PLEURA	163	40	0.10%	0.02%
25	MAL NEOPL THYMUS/MEDIAST	164	50	0.12%	0.02%
26	MAL NEOPL RESP NEC	165	12	0.03%	0.00%
27	MAL NEOPL BONE/CART	170	344	0.83%	0.13%
28	MAL NEOPL SOFT TISSUE	171	268	0.65%	0.10%
29	MALIGNANT MELANOMA SKIN	172	260	0.63%	0.10%
30	OTHER MAL NEOPL SKIN	173	369	0.89%	0.14%
31	MAL NEOPL FEMALE BREAST	174	3471	8.40%	1.33%
32	MAL NEOPL MALE BREAST	175	15	0.04%	0.01%
33	MAL NEOPL UTERUS NOS	179	127	0.31%	0.05%
34	MAL NEOPL CERVIX UTERI	180	519	1.26%	0.20%
35	MALIGNANT NEOPL PLACENTA	181	4	0.01%	0.00%
36	MAL NEOPL UTERUS BODY	182	320	0.77%	0.12%
37	MAL NEOPL UTERINE ADNEXA	183	735	1.78%	0.28%
38	MAL NEOPL FE GENIT NEC	184	86	0.21%	0.03%
39	MAL NEOPL PROSTATE	185	945	2.29%	0.36%
40	MAL NEOPL TESTIS	186	51	0.12%	0.02%
41	MAL NEOPL MALE GENIT NEC	187	18	0.04%	0.01%
42	MAL NEOPL BLADDER	188	703	1.70%	0.27%
43	MAL GU NEOPL NEC/NOS	189	530	1.28%	0.20%
44	MALIGNANT NEOPLASM EYE	190	68	0.16%	0.03%
45	MALIGNANT NEOPLASM BRAIN	191	1045	2.53%	0.40%
46	MAL NEOPL NERVE NEC/NOS	192	129	0.31%	0.05%
47	MALIGNANT NEOPL THYROID	193	197	0.48%	0.08%
48	MAL NEOPL ENDOCRINE NEC	194	166	0.40%	0.06%
49	MAL NEOPL ILL-DEF SITES	195	484	1.17%	0.19%
50	SECONDARY MAL NEOPL LN	196	202	0.49%	0.08%
51	2ND MAL NEOPLASM GI/RESP	197	783	1.89%	0.30%
52	2ND MAL NEOPL OTH SITES	198	1180	2.85%	0.45%
53	MALIGNANT NEOPLASM NOS	199	979	2.37%	0.37%
54	LYMPHOSARC/RETICULOSARC	200	174	0.42%	0.07%
55	HODGKIN'S DISEASE	201	277	0.67%	0.11%
56	OTH MAL NEOPL LYMPH/HIST	202	713	1.72%	0.27%
57	MULTIPLE MYELOMA ET AL	203	197	0.48%	0.08%
58	LYMPHOID LEUKEMIA	204	391	0.95%	0.15%
59	MYELOID LEUKEMIA	205	287	0.69%	0.11%
60	MONOCYTIC LEUKEMIA	206	34	0.08%	0.01%
61	OTHER SPECIFIED LEUKEMIA	207	23	0.06%	0.01%
62	LEUKEMIA-UNSPECIF CELL	208	425	1.03%	0.16%
63	BEN NEOPL MOUTH/PHARYNX	210	154	0.37%	0.06%
64	OTH BENIGN NEOPLASM GI	211	1143	2.76%	0.44%
65	BEN INTRATHOR NEOPLASM	212	281	0.68%	0.11%
66	BEN NEOPLASM BONE/CART	213	291	0.70%	0.11%
67	LIPOMA	214	221	0.53%	0.08%
68	OTH BEN NEOPL SOFT TISS	215	207	0.50%	0.08%
69	BENIGN NEOPLASM OF SKIN	216	424	1.03%	0.16%
70	BENIGN NEOPLASM BREAST	217	217	0.52%	0.08%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1991
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 261205

A8

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
71	UTERINE LEIOMYOMA	218	3719	9.00%	1.42%
72	OTH BENIGN NEOPL UTERUS	219	172	0.42%	0.07%
73	BENIGN NEOPLASM OVARY	220	389	0.94%	0.15%
74	BEN NEOPL OTH FEM GENIT	221	107	0.26%	0.04%
75	BENIGN NEOPL MALE GENIT	222	81	0.20%	0.03%
76	BENIGN NEOPLASM URINARY	223	74	0.18%	0.03%
77	BENIGN NEOPLASM OF EYE	224	26	0.06%	0.01%
78	BENIGN NEOPL NERV SYST	225	397	0.96%	0.15%
79	BENIGN NEOPLASM THYROID	226	182	0.44%	0.07%
80	BEN NEOPL OTH ENDOCRINE	227	193	0.47%	0.07%
81	HEMANGIOMA/LYMPHANGIOMA	228	207	0.50%	0.08%
82	BENIGN NEOPLASM NEC/NOS	229	259	0.63%	0.10%
83	CA IN SITU DIGESTIVE ORG	230	261	0.63%	0.10%
84	CA IN SITU RESPIRATORY	231	215	0.52%	0.08%
85	CARCINOMA IN SITU SKIN	232	56	0.14%	0.02%
86	CA IN SITU BREAST/GU	233	819	1.98%	0.31%
87	CA IN SITU NEC/NOS	234	119	0.29%	0.05%
88	UNC BEHAV NEOPL GI/RESP	235	349	0.84%	0.13%
89	UNC BEHAV NEOPL GU	236	302	0.73%	0.12%
90	UNC NEOPL ENDOCR/NERV	237	278	0.67%	0.11%
91	UNC BEHAV NEOPL NEC/NOS	238	450	1.09%	0.17%
92	UNSPECIFIED NEOPLASM	239	4108	9.94%	1.57%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1992
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (71)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 246607

A9

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
1	MALIGNANT NEOPLASM LIP	140	21	0.05%	0.01%
2	MALIGNANT NEOPL TONGUE	141	159	0.41%	0.06%
3	MAL NEOPL MAJOR SG	142	50	0.13%	0.02%
4	MALIGNANT NEOPLASM GUM	143	10	0.03%	0.00%
5	MAL NEOPLASM FLOOR MOUTH	144	49	0.13%	0.02%
6	MAL NEOPL MOUTH NEC/NOS	145	75	0.19%	0.03%
7	MAL NEOPLASM OROPHARYNX	146	71	0.18%	0.03%
8	MAL NEOPLASM NASOPHARYNX	147	45	0.12%	0.02%
9	MAL NEOPL HYPOPHARYNX	148	41	0.10%	0.02%
10	OTH MAL NEOPL OROPHARYNX	149	64	0.16%	0.03%
11	MAL NEOPL ESOPHAGUS	150	282	0.72%	0.11%
12	MAL NEOPL STOMACH	151	276	0.71%	0.11%
13	MAL NEOPL SMALL BOWEL	152	55	0.14%	0.02%
14	MALIGNANT NEOPLASM COLON	153	1291	3.30%	0.52%
15	MAL NEOPL RECTUM/ANUS	154	967	2.47%	0.39%
16	MALIGNANT NEOPLASM LIVER	155	283	0.72%	0.11%
17	MAL NEOPL GB/BD	156	81	0.21%	0.03%
18	MAL NEOPL PANCREAS	157	398	1.02%	0.16%
19	MAL NEOPLASM PERITONEUM	158	66	0.17%	0.03%
20	OTH DIGEST MAL NEOPL	159	46	0.12%	0.02%
21	MAL NEOPL NOSE/ME/SINUS	160	47	0.12%	0.02%
22	MAL NEOPL LARYNX	161	268	0.69%	0.11%
23	MAL NEOPL TRACHEA/LUNG	162	3890	9.95%	1.58%
24	MALIGNANT NEOPL PLEURA	163	47	0.12%	0.02%
25	MAL NEOPL THYMUS/MEDIAST	164	57	0.15%	0.02%
26	MAL NEOPL RESP NEC	165	15	0.04%	0.01%
27	MAL NEOPL BONE/CART	170	311	0.80%	0.13%
28	MAL NEOPL SOFT TISSUE	171	252	0.64%	0.10%
29	MALIGNANT MELANOMA SKIN	172	249	0.64%	0.10%
30	OTHER MAL NEOPL SKIN	173	335	0.86%	0.14%
31	MAL NEOPL FEMALE BREAST	174	3186	8.15%	1.29%
32	MAL NEOPL MALE BREAST	175	16	0.04%	0.01%
33	KAPOSI'S SARCOMA	176	4	0.01%	0.00%
34	MAL NEOPL UTERUS NOS	179	100	0.26%	0.04%
35	MAL NEOPL CERVIX UTERI	180	480	1.23%	0.19%
36	MALIGNANT NEOPL PLACENTA	181	6	0.02%	0.00%
37	MAL NEOPL UTERUS BODY	182	305	0.78%	0.12%
38	MAL NEOPL UTERINE ADNEXA	183	776	1.98%	0.31%
39	MAL NEOPL FE GENIT NEC	184	71	0.18%	0.03%
40	MAL NEOPL PROSTATE	185	1305	3.34%	0.53%
41	MAL NEOPL TESTIS	186	58	0.15%	0.02%
42	MAL NEOPL MALE GENIT NEC	187	16	0.04%	0.01%
43	MAL NEOPL BLADDER	188	609	1.56%	0.25%
44	MAL GU NEOPL NEC/NOS	189	482	1.23%	0.20%
45	MALIGNANT NEOPLASM EYE	190	73	0.19%	0.03%
46	MALIGNANT NEOPLASM BRAIN	191	967	2.47%	0.39%
47	MAL NEOPL NERVE NEC/NOS	192	107	0.27%	0.04%
48	MALIGNANT NEOPL THYROID	193	189	0.48%	0.08%
49	MAL NEOPL ENDOCRINE NEC	194	129	0.33%	0.05%
50	MAL NEOPL ILL-DEF SITES	195	460	1.18%	0.19%
51	SECONDARY MAL NEOPL LN	196	212	0.54%	0.09%
52	2ND MAL NEOPLASM GI/RESP	197	802	2.05%	0.33%
53	2ND MAL NEOPL OTH SITES	198	1088	2.78%	0.44%
54	MALIGNANT NEOPLASM NOS	199	877	2.24%	0.36%
55	LYMPHOSARC/RETICULOSARC	200	165	0.42%	0.07%
56	HODGKIN'S DISEASE	201	188	0.48%	0.08%
57	OTH MAL NEOPL LYMPH/HIST	202	605	1.55%	0.25%
58	MULTIPLE MYELOMA ET AL	203	196	0.50%	0.08%
59	LYMPHOID LEUKEMIA	204	380	0.97%	0.15%
60	MYELOID LEUKEMIA	205	280	0.72%	0.11%
61	MONOCYTIC LEUKEMIA	206	31	0.08%	0.01%
62	OTHER SPECIFIED LEUKEMIA	207	15	0.04%	0.01%
63	LEUKEMIA-UNSPECIF CELL	208	396	1.01%	0.16%
64	BEN NEOPL MOUTH/PHARYNX	210	169	0.43%	0.07%
65	OTH BENIGN NEOPLASM GI	211	1141	2.92%	0.46%
66	BEN INTRATHOR NEOPLASM	212	284	0.73%	0.12%
67	BEN NEOPLASM BONE/CART	213	247	0.63%	0.10%
68	LIPOMA	214	237	0.61%	0.10%
69	OTH BEN NEOPL SOFT TISS	215	211	0.54%	0.09%
70	BENIGN NEOPLASM OF SKIN	216	408	1.04%	0.17%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1992
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 246607

A10

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
71	BENIGN NEOPLASM BREAST	217	173	0.44%	0.07%
72	UTERINE LEIOMYOMA	218	3639	9.31%	1.48%
73	OTH BENIGN NEOPL UTERUS	219	157	0.40%	0.06%
74	BENIGN NEOPLASM OVARY	220	389	1.00%	0.16%
75	BEN NEOPL OTH FEM GENIT	221	127	0.32%	0.05%
76	BENIGN NEOPL MALE GENIT	222	81	0.21%	0.03%
77	BENIGN NEOPLASM URINARY	223	78	0.20%	0.03%
78	BENIGN NEOPLASM OF EYE	224	14	0.04%	0.01%
79	BENIGN NEOPL NERV SYST	225	385	0.98%	0.16%
80	BENIGN NEOPLASM THYROID	226	172	0.44%	0.07%
81	BEN NEOPL OTH ENDOCRINE	227	141	0.36%	0.06%
82	HEMANGIOMA/LYMPHANGIOMA	228	187	0.48%	0.08%
83	BENIGN NEOPLASM NEC/NOS	229	228	0.58%	0.09%
84	CA IN SITU DIGESTIVE ORG	230	233	0.60%	0.09%
85	CA IN SITU RESPIRATORY	231	186	0.48%	0.08%
86	CARCINOMA IN SITU SKIN	232	47	0.12%	0.02%
87	CA IN SITU BREAST/GU	233	763	1.95%	0.31%
88	CA IN SITU NEC/NOS	234	71	0.18%	0.03%
89	UNC BEHAV NEOPL GI/RESP	235	364	0.93%	0.15%
90	UNC BEHAV NEOPL GU	236	281	0.72%	0.11%
91	UNC NEOPL ENDOCR/NERV	237	293	0.75%	0.12%
92	UNC BEHAV NEOPL NEC/NOS	238	531	1.36%	0.22%
93	UNSPECIFIED NEOPLASM	239	3482	8.91%	1.41%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1993
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 218056

A11

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
1	MALIGNANT NEOPLASM LIP	140	17	0.04%	0.01%
2	MALIGNANT NEOPL TONGUE	141	138	0.32%	0.06%
3	MAL NEOPL MAJOR SG	142	45	0.10%	0.02%
4	MALIGNANT NEOPLASM GUM	143	14	0.03%	0.01%
5	MAL NEOPLASM FLOOR MOUTH	144	56	0.13%	0.03%
6	MAL NEOPL MOUTH NEC/NOS	145	129	0.30%	0.06%
7	MAL NEOPLASM OROPHARYNX	146	70	0.16%	0.03%
8	MAL NEOPLASM NASOPHARYNX	147	59	0.14%	0.03%
9	MAL NEOPL HYPOPHARYNX	148	61	0.14%	0.03%
10	OTH MAL NEOPL OROPHARYNX	149	85	0.20%	0.04%
11	MAL NEOPL ESOPHAGUS	150	357	0.82%	0.16%
12	MAL NEOPL STOMACH	151	300	0.69%	0.14%
13	MAL NEOPL SMALL BOWEL	152	51	0.12%	0.02%
14	MALIGNANT NEOPLASM COLON	153	1472	3.40%	0.68%
15	MAL NEOPL RECTUM/ANUS	154	997	2.30%	0.46%
16	MALIGNANT NEOPLASM LIVER	155	328	0.76%	0.15%
17	MAL NEOPL GB/BD	156	80	0.18%	0.04%
18	MAL NEOPL PANCREAS	157	389	0.90%	0.18%
19	MAL NEOPLASM PERITONEUM	158	58	0.13%	0.03%
20	OTH DIGEST MAL NEOPL	159	57	0.13%	0.03%
21	MAL NEOPL NOSE/ME/SINUS	160	49	0.11%	0.02%
22	MAL NEOPL LARYNX	161	264	0.61%	0.12%
23	MAL NEOPL TRACHEA/LUNG	162	4125	9.52%	1.89%
24	MALIGNANT NEOPL PLEURA	163	42	0.10%	0.02%
25	MAL NEOPL THYMUS/MEDIAST	164	53	0.12%	0.02%
26	MAL NEOPL RESP NEC	165	13	0.03%	0.01%
27	MAL NEOPL BONE/CART	170	329	0.76%	0.15%
28	MAL NEOPL SOFT TISSUE	171	260	0.60%	0.12%
29	MALIGNANT MELANOMA SKIN	172	298	0.69%	0.14%
30	OTHER MAL NEOPL SKIN	173	298	0.69%	0.14%
31	MAL NEOPL FEMALE BREAST	174	3326	7.68%	1.53%
32	MAL NEOPL MALE BREAST	175	12	0.03%	0.01%
33	KAPOSI'S SARCOMA	176	9	0.02%	0.00%
34	MAL NEOPL UTERUS NOS	179	96	0.22%	0.04%
35	MAL NEOPL CERVIX UTERI	180	461	1.06%	0.21%
36	MALIGNANT NEOPL PLACENTA	181	6	0.01%	0.00%
37	MAL NEOPL UTERUS BODY	182	346	0.80%	0.16%
38	MAL NEOPL UTERINE ADNEXA	183	897	2.07%	0.41%
39	MAL NEOPL FE GENIT NEC	184	69	0.16%	0.03%
40	MAL NEOPL PROSTATE	185	1676	3.87%	0.77%
41	MAL NEOPL TESTIS	186	58	0.13%	0.03%
42	MAL NEOPL MALE GENIT NEC	187	16	0.04%	0.01%
43	MAL NEOPL BLADDER	188	634	1.46%	0.29%
44	MAL GU NEOPL NEC/NOS	189	496	1.14%	0.23%
45	MALIGNANT NEOPLASM EYE	190	57	0.13%	0.03%
46	MALIGNANT NEOPLASM BRAIN	191	1030	2.38%	0.47%
47	MAL NEOPL NERVE NEC/NOS	192	118	0.27%	0.05%
48	MALIGNANT NEOPL THYROID	193	201	0.46%	0.09%
49	MAL NEOPL ENDOCRINE NEC	194	148	0.34%	0.07%
50	MAL NEOPL ILL-DEF SITES	195	419	0.97%	0.19%
51	SECONDARY MAL NEOPL LN	196	226	0.52%	0.10%
52	2ND MAL NEOPLASM GI/RESP	197	809	1.87%	0.37%
53	2ND MAL NEOPL OTH SITES	198	1299	3.00%	0.60%
54	MALIGNANT NEOPLASM NOS	199	836	1.93%	0.38%
55	LYMPHOSARC/RETICULOSARC	200	212	0.49%	0.10%
56	HODGKIN'S DISEASE	201	247	0.57%	0.11%
57	OTH MAL NEOPL LYMPH/HIST	202	780	1.80%	0.36%
58	MULTIPLE MYELOMA ET AL	203	286	0.66%	0.13%
59	LYMPHOID LEUKEMIA	204	527	1.22%	0.24%
60	MYELOID LEUKEMIA	205	406	0.94%	0.19%
61	MONOCYTIC LEUKEMIA	206	37	0.09%	0.02%
62	OTHER SPECIFIED LEUKEMIA	207	23	0.05%	0.01%
63	LEUKEMIA-UNSPECIF CELL	208	480	1.11%	0.22%
64	BEN NEOPL MOUTH/PHARYNX	210	187	0.43%	0.09%
65	OTH BENIGN NEOPLASM GI	211	1406	3.25%	0.64%
66	BEN INTRATHOR NEOPLASM	212	326	0.75%	0.15%
67	BEN NEOPLASM BONE/CART	213	276	0.64%	0.13%
68	LIPOMA	214	233	0.54%	0.11%
69	OTH BEN NEOPL SOFT TISS	215	208	0.48%	0.10%
70	BENIGN NEOPLASM OF SKIN	216	406	0.94%	0.19%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1993
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 218056

A12

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
71	BENIGN NEOPLASM BREAST	217	174	0.40%	0.08%
72	UTERINE LEIOMYOMA	218	4163	9.61%	1.91%
73	OTH BENIGN NEOPL UTERUS	219	234	0.54%	0.11%
74	BENIGN NEOPLASM OVARY	220	399	0.92%	0.18%
75	BEN NEOPL OTH FEM GENIT	221	142	0.33%	0.07%
76	BENIGN NEOPL MALE GENIT	222	86	0.20%	0.04%
77	BENIGN NEOPLASM URINARY	223	108	0.25%	0.05%
78	BENIGN NEOPLASM OF EYE	224	20	0.05%	0.01%
79	BENIGN NEOPL NERV SYST	225	465	1.07%	0.21%
80	BENIGN NEOPLASM THYROID	226	197	0.45%	0.09%
81	BEN NEOPL OTH ENDOCRINE	227	198	0.46%	0.09%
82	HEMANGIOMA/LYMPHANGIOMA	228	227	0.52%	0.10%
83	BENIGN NEOPLASM NEC/NOS	229	244	0.56%	0.11%
84	CA IN SITU DIGESTIVE ORG	230	238	0.55%	0.11%
85	CA IN SITU RESPIRATORY	231	247	0.57%	0.11%
86	CARCINOMA IN SITU SKIN	232	46	0.11%	0.02%
87	CA IN SITU BREAST/GU	233	840	1.94%	0.39%
88	CA IN SITU NEC/NOS	234	82	0.19%	0.04%
89	UNC BEHAV NEOPL GI/RESP	235	424	0.98%	0.19%
90	UNC BEHAV NEOPL GU	236	310	0.72%	0.14%
91	UNC NEOPL ENDOCR/NERV	237	364	0.84%	0.17%
92	UNC BEHAV NEOPL NEC/NOS	238	691	1.59%	0.32%
93	UNSPECIFIED NEOPLASM	239	3649	8.42%	1.67%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1994
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 200160

A13

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
1	MALIGNANT NEOPLASM LIP	140	10	0.02%	0.00%
2	MALIGNANT NEOPL TONGUE	141	151	0.37%	0.08%
3	MAL NEOPL MAJOR SG	142	37	0.09%	0.02%
4	MALIGNANT NEOPLASM GUM	143	10	0.02%	0.00%
5	MAL NEOPLASM FLOOR MOUTH	144	55	0.14%	0.03%
6	MAL NEOPL MOUTH NEC/NOS	145	106	0.26%	0.05%
7	MAL NEOPLASM OROPHARYNX	146	65	0.16%	0.03%
8	MAL NEOPLASM NASOPHARYNX	147	42	0.10%	0.02%
9	MAL NEOPL HYPOPHARYNX	148	40	0.10%	0.02%
10	OTH MAL NEOPL OROPHARYNX	149	61	0.15%	0.03%
11	MAL NEOPL ESOPHAGUS	150	327	0.80%	0.16%
12	MAL NEOPL STOMACH	151	323	0.79%	0.16%
13	MAL NEOPL SMALL BOWEL	152	50	0.12%	0.02%
14	MALIGNANT NEOPLASM COLON	153	1412	3.47%	0.71%
15	MAL NEOPL RECTUM/ANUS	154	972	2.39%	0.49%
16	MALIGNANT NEOPLASM LIVER	155	275	0.68%	0.14%
17	MAL NEOPL GB/BD	156	69	0.17%	0.03%
18	MAL NEOPL PANCREAS	157	410	1.01%	0.20%
19	MAL NEOPLASM PERITONEUM	158	57	0.14%	0.03%
20	OTH DIGEST MAL NEOPL	159	45	0.11%	0.02%
21	MAL NEOPL NOSE/ME/SINUS	160	43	0.11%	0.02%
22	MAL NEOPL LARYNX	161	254	0.62%	0.13%
23	MAL NEOPL TRACHEA/LUNG	162	3888	9.57%	1.94%
24	MALIGNANT NEOPL PLEURA	163	47	0.12%	0.02%
25	MAL NEOPL THYMUS/MEDIAST	164	47	0.12%	0.02%
26	MAL NEOPL RESP NEC	165	12	0.03%	0.01%
27	MAL NEOPL BONE/CART	170	283	0.70%	0.14%
28	MAL NEOPL SOFT TISSUE	171	272	0.67%	0.14%
29	MALIGNANT MELANOMA SKIN	172	242	0.60%	0.12%
30	OTHER MAL NEOPL SKIN	173	331	0.81%	0.17%
31	MAL NEOPL FEMALE BREAST	174	3137	7.72%	1.57%
32	MAL NEOPL MALE BREAST	175	19	0.05%	0.01%
33	KAPOSI'S SARCOMA	176	8	0.02%	0.00%
34	MAL NEOPL UTERUS NOS	179	83	0.20%	0.04%
35	MAL NEOPL CERVIX UTERI	180	450	1.11%	0.22%
36	MALIGNANT NEOPL PLACENTA	181	3	0.01%	0.00%
37	MAL NEOPL UTERUS BODY	182	335	0.82%	0.17%
38	MAL NEOPL UTERINE ADNEXA	183	815	2.01%	0.41%
39	MAL NEOPL FE GENIT NEC	184	69	0.17%	0.03%
40	MAL NEOPL PROSTATE	185	1572	3.87%	0.79%
41	MAL NEOPL TESTIS	186	45	0.11%	0.02%
42	MAL NEOPL MALE GENIT NEC	187	20	0.05%	0.01%
43	MAL NEOPL BLADDER	188	544	1.34%	0.27%
44	MAL GU NEOPL NEC/NOS	189	507	1.25%	0.25%
45	MALIGNANT NEOPLASM EYE	190	59	0.15%	0.03%
46	MALIGNANT NEOPLASM BRAIN	191	971	2.39%	0.49%
47	MAL NEOPL NERVE NEC/NOS	192	117	0.29%	0.06%
48	MALIGNANT NEOPL THYROID	193	196	0.48%	0.10%
49	MAL NEOPL ENDOCRINE NEC	194	144	0.35%	0.07%
50	MAL NEOPL ILL-DEF SITES	195	340	0.84%	0.17%
51	SECONDARY MAL NEOPL LN	196	208	0.51%	0.10%
52	2ND MAL NEOPLASM GI/RESP	197	844	2.08%	0.42%
53	2ND MAL NEOPL OTH SITES	198	1126	2.77%	0.56%
54	MALIGNANT NEOPLASM NOS	199	648	1.59%	0.32%
55	LYMPHOSARC/RETICULOSARC	200	230	0.57%	0.11%
56	HODGKIN'S DISEASE	201	219	0.54%	0.11%
57	OTH MAL NEOPL LYMPH/HIST	202	763	1.88%	0.38%
58	MULTIPLE MYELOMA ET AL	203	243	0.60%	0.12%
59	LYMPHOID LEUKEMIA	204	494	1.22%	0.25%
60	MYELOID LEUKEMIA	205	375	0.92%	0.19%
61	MONOCYTIC LEUKEMIA	206	35	0.09%	0.02%
62	OTHER SPECIFIED LEUKEMIA	207	8	0.02%	0.00%
63	LEUKEMIA-UNSPECIF CELL	208	409	1.01%	0.20%
64	BEN NEOPL MOUTH/PHARYNX	210	203	0.50%	0.10%
65	OTH BENIGN NEOPLASM GI	211	1408	3.46%	0.70%
66	BEN INTRATHOR NEOPLASM	212	351	0.86%	0.18%
67	BEN NEOPLASM BONE/CART	213	236	0.58%	0.12%
68	LIPOMA	214	213	0.52%	0.11%
69	OTH BEN NEOPL SOFT TISS	215	190	0.47%	0.09%
70	BENIGN NEOPLASM OF SKIN	216	390	0.96%	0.19%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1994
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (71)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 200160

A14

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
71	BENIGN NEOPLASM BREAST	217	172	0.42%	0.09%
72	UTERINE LEIOMYOMA	218	3775	9.29%	1.89%
73	OTH BENIGN NEOPL UTERUS	219	231	0.57%	0.12%
74	BENIGN NEOPLASM OVARY	220	350	0.86%	0.17%
75	BEN NEOPL OTH FEM GENIT	221	127	0.31%	0.06%
76	BENIGN NEOPL MALE GENIT	222	82	0.20%	0.04%
77	BENIGN NEOPLASM URINARY	223	123	0.30%	0.06%
78	BENIGN NEOPLASM OF EYE	224	17	0.04%	0.01%
79	BENIGN NEOPL NERV SYST	225	532	1.31%	0.27%
80	BENIGN NEOPLASM THYROID	226	159	0.39%	0.08%
81	BEN NEOPL OTH ENDOCRINE	227	190	0.47%	0.09%
82	HEMANGIOMA/LYMPHANGIOMA	228	195	0.48%	0.10%
83	BENIGN NEOPLASM NEC/NOS	229	261	0.64%	0.13%
84	CA IN SITU DIGESTIVE ORG	230	247	0.61%	0.12%
85	CA IN SITU RESPIRATORY	231	222	0.55%	0.11%
86	CARCINOMA IN SITU SKIN	232	44	0.11%	0.02%
87	CA IN SITU BREAST/GU	233	840	2.07%	0.42%
88	CA IN SITU NEC/NOS	234	59	0.15%	0.03%
89	UNC BEHAV NEOPL GI/RESP	235	384	0.94%	0.19%
90	UNC BEHAV NEOPL GU	236	296	0.73%	0.15%
91	UNC NEOPL ENDOCR/NERV	237	345	0.85%	0.17%
92	UNC BEHAV NEOPL NEC/NOS	238	598	1.47%	0.30%
93	UNSPECIFIED NEOPLASM	239	3432	8.44%	1.71%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1995
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 195248

A15

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
1	MALIGNANT NEOPLASM LIP	140	12	0.03%	0.01%
2	MALIGNANT NEOPL TONGUE	141	140	0.38%	0.07%
3	MAL NEOPL MAJOR SG	142	39	0.11%	0.02%
4	MALIGNANT NEOPLASM GUM	143	11	0.03%	0.01%
5	MAL NEOPLASM FLOOR MOUTH	144	57	0.15%	0.03%
6	MAL NEOPL MOUTH NEC/NOS	145	78	0.21%	0.04%
7	MAL NEOPLASM OROPHARYNX	146	79	0.21%	0.04%
8	MAL NEOPLASM NASOPHARYNX	147	39	0.11%	0.02%
9	MAL NEOPL HYPOPHARYNX	148	49	0.13%	0.03%
10	OTH MAL NEOPL OROPHARYNX	149	56	0.15%	0.03%
11	MAL NEOPL ESOPHAGUS	150	291	0.78%	0.15%
12	MAL NEOPL STOMACH	151	319	0.86%	0.16%
13	MAL NEOPL SMALL BOWEL	152	57	0.15%	0.03%
14	MALIGNANT NEOPLASM COLON	153	1402	3.78%	0.72%
15	MAL NEOPL RECTUM/ANUS	154	928	2.50%	0.48%
16	MALIGNANT NEOPLASM LIVER	155	277	0.75%	0.14%
17	MAL NEOPL GB/BD	156	79	0.21%	0.04%
18	MAL NEOPL PANCREAS	157	358	0.96%	0.18%
19	MAL NEOPLASM PERITONEUM	158	58	0.16%	0.03%
20	OTH DIGEST MAL NEOPL	159	47	0.13%	0.02%
21	MAL NEOPL NOSE/ME/SINUS	160	42	0.11%	0.02%
22	MAL NEOPL LARYNX	161	238	0.64%	0.12%
23	MAL NEOPL TRACHEA/LUNG	162	3483	9.38%	1.78%
24	MALIGNANT NEOPL PLEURA	163	50	0.13%	0.03%
25	MAL NEOPL THYMUS/MEDIAST	164	57	0.15%	0.03%
26	MAL NEOPL RESP NEC	165	5	0.01%	0.00%
27	MAL NEOPL BONE/CART	170	267	0.72%	0.14%
28	MAL NEOPL SOFT TISSUE	171	237	0.64%	0.12%
29	MALIGNANT MELANOMA SKIN	172	207	0.56%	0.11%
30	OTHER MAL NEOPL SKIN	173	231	0.62%	0.12%
31	MAL NEOPL FEMALE BREAST	174	2970	8.00%	1.52%
32	MAL NEOPL MALE BREAST	175	21	0.06%	0.01%
33	KAPOSI'S SARCOMA	176	3	0.01%	0.00%
34	MAL NEOPL UTERUS NOS	179	98	0.26%	0.05%
35	MAL NEOPL CERVIX UTERI	180	421	1.13%	0.22%
36	MALIGNANT NEOPL PLACENTA	181	2	0.01%	0.00%
37	MAL NEOPL UTERUS BODY	182	319	0.86%	0.16%
38	MAL NEOPL UTERINE ADNEXA	183	689	1.86%	0.35%
39	MAL NEOPL FE GENIT NEC	184	49	0.13%	0.03%
40	MAL NEOPL PROSTATE	185	1574	4.24%	0.81%
41	MAL NEOPL TESTIS	186	51	0.14%	0.03%
42	MAL NEOPL MALE GENIT NEC	187	14	0.04%	0.01%
43	MAL NEOPL BLADDER	188	554	1.49%	0.28%
44	MAL GU NEOPL NEC/NOS	189	488	1.31%	0.25%
45	MALIGNANT NEOPLASM EYE	190	48	0.13%	0.02%
46	MALIGNANT NEOPLASM BRAIN	191	892	2.40%	0.46%
47	MAL NEOPL NERVE NEC/NOS	192	103	0.28%	0.05%
48	MALIGNANT NEOPL THYROID	193	216	0.58%	0.11%
49	MAL NEOPL ENDOCRINE NEC	194	112	0.30%	0.06%
50	MAL NEOPL ILL-DEF SITES	195	295	0.79%	0.15%
51	SECONDARY MAL NEOPL LN	196	173	0.47%	0.09%
52	2ND MAL NEOPLASM GI/RESP	197	846	2.28%	0.43%
53	2ND MAL NEOPL OTH SITES	198	1022	2.75%	0.52%
54	MALIGNANT NEOPLASM NOS	199	597	1.61%	0.31%
55	LYMPHOSARC/RETICULOSARC	200	181	0.49%	0.09%
56	HODGKIN'S DISEASE	201	185	0.50%	0.09%
57	OTH MAL NEOPL LYMPH/HIST	202	682	1.84%	0.35%
58	MULTIPLE MYELOMA ET AL	203	227	0.61%	0.12%
59	LYMPHOID LEUKEMIA	204	405	1.09%	0.21%
60	MYELOID LEUKEMIA	205	346	0.93%	0.18%
61	MONOCYTIC LEUKEMIA	206	23	0.06%	0.01%
62	OTHER SPECIFIED LEUKEMIA	207	12	0.03%	0.01%
63	LEUKEMIA-UNSPECIF CELL	208	406	1.09%	0.21%
64	BEN NEOPL MOUTH/PHARYNX	210	150	0.40%	0.08%
65	OTH BENIGN NEOPLASM GI	211	1360	3.66%	0.70%
66	BEN INTRATHOR NEOPLASM	212	284	0.76%	0.15%
67	BEN NEOPLASM BONE/CART	213	200	0.54%	0.10%
68	LIPOMA	214	194	0.52%	0.10%
69	OTH BEN NEOPL SOFT TISS	215	151	0.41%	0.08%
70	BENIGN NEOPLASM OF SKIN	216	298	0.80%	0.15%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1995
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 195248

A16

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
71	BENIGN NEOPLASM BREAST	217	149	0.40%	0.08%
72	UTERINE LEIOMYOMA	218	3580	9.64%	1.83%
73	OTH BENIGN NEOPL UTERUS	219	239	0.64%	0.12%
74	BENIGN NEOPLASM OVARY	220	366	0.99%	0.19%
75	BEN NEOPL OTH FEM GENIT	221	130	0.35%	0.07%
76	BENIGN NEOPL MALE GENIT	222	70	0.19%	0.04%
77	BENIGN NEOPLASM URINARY	223	99	0.27%	0.05%
78	BENIGN NEOPLASM OF EYE	224	23	0.06%	0.01%
79	BENIGN NEOPL NERV SYST	225	430	1.16%	0.22%
80	BENIGN NEOPLASM THYROID	226	186	0.50%	0.10%
81	BEN NEOPL OTH ENDOCRINE	227	192	0.52%	0.10%
82	HEMANGIOMA/LYMPHANGIOMA	228	168	0.45%	0.09%
83	BENIGN NEOPLASM NEC/NOS	229	261	0.70%	0.13%
84	CA IN SITU DIGESTIVE ORG	230	207	0.56%	0.11%
85	CA IN SITU RESPIRATORY	231	176	0.47%	0.09%
86	CARCINOMA IN SITU SKIN	232	30	0.08%	0.02%
87	CA IN SITU BREAST/GU	233	670	1.80%	0.34%
88	CA IN SITU NEC/NOS	234	44	0.12%	0.02%
89	UNC BEHAV NEOPL GI/RESP	235	371	1.00%	0.19%
90	UNC BEHAV NEOPL GU	236	266	0.72%	0.14%
91	UNC NEOPL ENDOCR/NERV	237	291	0.78%	0.15%
92	UNC BEHAV NEOPL NEC/NOS	238	446	1.20%	0.23%
93	UNSPECIFIED NEOPLASM	239	2881	7.76%	1.48%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1996
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (71)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 173265

A17

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
1	MALIGNANT NEOPLASM LIP	140	15	0.04%	0.01%
2	MALIGNANT NEOPL TONGUE	141	140	0.40%	0.08%
3	MAL NEOPL MAJOR SG	142	32	0.09%	0.02%
4	MALIGNANT NEOPLASM GUM	143	8	0.02%	0.00%
5	MAL NEOPLASM FLOOR MOUTH	144	45	0.13%	0.03%
6	MAL NEOPL MOUTH NEC/NOS	145	66	0.19%	0.04%
7	MAL NEOPLASM OROPHARYNX	146	71	0.20%	0.04%
8	MAL NEOPLASM NASOPHARYNX	147	50	0.14%	0.03%
9	MAL NEOPL HYPOPHARYNX	148	39	0.11%	0.02%
10	OTH MAL NEOPL OROPHARYNX	149	50	0.14%	0.03%
11	MAL NEOPL ESOPHAGUS	150	313	0.88%	0.18%
12	MAL NEOPL STOMACH	151	313	0.88%	0.18%
13	MAL NEOPL SMALL BOWEL	152	51	0.14%	0.03%
14	MALIGNANT NEOPLASM COLON	153	1286	3.63%	0.74%
15	MAL NEOPL RECTUM/ANUS	154	820	2.31%	0.47%
16	MALIGNANT NEOPLASM LIVER	155	242	0.68%	0.14%
17	MAL NEOPL GB/BD	156	90	0.25%	0.05%
18	MAL NEOPL PANCREAS	157	350	0.99%	0.20%
19	MAL NEOPLASM PERITONEUM	158	70	0.20%	0.04%
20	OTH DIGEST MAL NEOPL	159	41	0.12%	0.02%
21	MAL NEOPL NOSE/ME/SINUS	160	44	0.12%	0.03%
22	MAL NEOPL LARYNX	161	183	0.52%	0.11%
23	MAL NEOPL TRACHEA/LUNG	162	3302	9.32%	1.91%
24	MALIGNANT NEOPL PLEURA	163	35	0.10%	0.02%
25	MAL NEOPL THYMUS/MEDIAST	164	61	0.17%	0.04%
26	MAL NEOPL RESP NEC	165	6	0.02%	0.00%
27	MAL NEOPL BONE/CART	170	236	0.67%	0.14%
28	MAL NEOPL SOFT TISSUE	171	249	0.70%	0.14%
29	MALIGNANT MELANOMA SKIN	172	200	0.56%	0.12%
30	OTHER MAL NEOPL SKIN	173	239	0.67%	0.14%
31	MAL NEOPL FEMALE BREAST	174	2722	7.68%	1.57%
32	MAL NEOPL MALE BREAST	175	14	0.04%	0.01%
33	KAPOSI'S SARCOMA	176	13	0.04%	0.01%
34	MAL NEOPL UTERUS NOS	179	103	0.29%	0.06%
35	MAL NEOPL CERVIX UTERI	180	438	1.24%	0.25%
36	MALIGNANT NEOPL PLACENTA	181	6	0.02%	0.00%
37	MAL NEOPL UTERUS BODY	182	337	0.95%	0.19%
38	MAL NEOPL UTERINE ADNEXA	183	696	1.96%	0.40%
39	MAL NEOPL FE GENIT NEC	184	56	0.16%	0.03%
40	MAL NEOPL PROSTATE	185	1424	4.02%	0.82%
41	MAL NEOPL TESTIS	186	39	0.11%	0.02%
42	MAL NEOPL MALE GENIT NEC	187	17	0.05%	0.01%
43	MAL NEOPL BLADDER	188	453	1.28%	0.26%
44	MAL GU NEOPL NEC/NOS	189	460	1.30%	0.27%
45	MALIGNANT NEOPLASM EYE	190	40	0.11%	0.02%
46	MALIGNANT NEOPLASM BRAIN	191	869	2.45%	0.50%
47	MAL NEOPL NERVE NEC/NOS	192	88	0.25%	0.05%
48	MALIGNANT NEOPL THYROID	193	205	0.58%	0.12%
49	MAL NEOPL ENDOCRINE NEC	194	125	0.35%	0.07%
50	MAL NEOPL ILL-DEF SITES	195	302	0.85%	0.17%
51	SECONDARY MAL NEOPL LN	196	202	0.57%	0.12%
52	2ND MAL NEOPLASM GI/RESP	197	810	2.29%	0.47%
53	2ND MAL NEOPL OTH SITES	198	995	2.81%	0.57%
54	MALIGNANT NEOPLASM NOS	199	554	1.56%	0.32%
55	LYMPHOSARC/RETICULOSARC	200	179	0.51%	0.10%
56	HODGKIN'S DISEASE	201	139	0.39%	0.08%
57	OTH MAL NEOPL LYMPH/HIST	202	726	2.05%	0.42%
58	MULTIPLE MYELOMA ET AL	203	222	0.63%	0.13%
59	LYMPHOID LEUKEMIA	204	385	1.09%	0.22%
60	MYELOID LEUKEMIA	205	321	0.91%	0.19%
61	MONOCYTIC LEUKEMIA	206	22	0.06%	0.01%
62	OTHER SPECIFIED LEUKEMIA	207	8	0.02%	0.00%
63	LEUKEMIA-UNSPECIF CELL	208	327	0.92%	0.19%
64	BEN NEOPL MOUTH/PHARYNX	210	111	0.31%	0.06%
65	OTH BENIGN NEOPLASM GI	211	1313	3.71%	0.76%
66	BEN INTRATHOR NEOPLASM	212	290	0.82%	0.17%
67	BEN NEOPLASM BONE/CART	213	173	0.49%	0.10%
68	LIPOMA	214	136	0.38%	0.08%
69	OTH BEN NEOPL SOFT TISS	215	165	0.47%	0.10%
70	BENIGN NEOPLASM OF SKIN	216	272	0.77%	0.16%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1996
 FOR ALL INSTITUTIONAL PROFESSIONAL SERVICES (7I)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 173265

A18

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
71	BENIGN NEOPLASM BREAST	217	155	0.44%	0.09%
72	UTERINE LEIOMYOMA	218	3797	10.72%	2.19%
73	OTH BENIGN NEOPL UTERUS	219	213	0.60%	0.12%
74	BENIGN NEOPLASM OVARY	220	394	1.11%	0.23%
75	BEN NEOPL OTH FEM GENIT	221	156	0.44%	0.09%
76	BENIGN NEOPL MALE GENIT	222	52	0.15%	0.03%
77	BENIGN NEOPLASM URINARY	223	93	0.26%	0.05%
78	BENIGN NEOPLASM OF EYE	224	16	0.05%	0.01%
79	BENIGN NEOPL NERV SYST	225	458	1.29%	0.26%
80	BENIGN NEOPLASM THYROID	226	154	0.43%	0.09%
81	BEN NEOPL OTH ENDOCRINE	227	207	0.58%	0.12%
82	HEMANGIOMA/LYMPHANGIOMA	228	141	0.40%	0.08%
83	BENIGN NEOPLASM NEC/NOS	229	183	0.52%	0.11%
84	CA IN SITU DIGESTIVE ORG	230	194	0.55%	0.11%
85	CA IN SITU RESPIRATORY	231	126	0.36%	0.07%
86	CARCINOMA IN SITU SKIN	232	26	0.07%	0.02%
87	CA IN SITU BREAST/GU	233	584	1.65%	0.34%
88	CA IN SITU NEC/NOS	234	46	0.13%	0.03%
89	UNC BEHAV NEOPL GI/RESP	235	448	1.26%	0.26%
90	UNC BEHAV NEOPL GU	236	314	0.89%	0.18%
91	UNC NEOPL ENDOCR/NERV	237	344	0.97%	0.20%
92	UNC BEHAV NEOPL NEC/NOS	238	479	1.35%	0.28%
93	UNSPECIFIED NEOPLASM	239	2443	6.90%	1.41%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1988
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 1726444

A19

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
1	MALIGNANT NEOPLASM LIP	140	56	0.09%	0.00%
2	MALIGNANT NEOPL TONGUE	141	270	0.45%	0.02%
3	MAL NEOPL MAJOR SG	142	80	0.13%	0.00%
4	MALIGNANT NEOPLASM GUM	143	24	0.04%	0.00%
5	MAL NEOPLASM FLOOR MOUTH	144	75	0.12%	0.00%
6	MAL NEOPL MOUTH NEC/NOS	145	172	0.29%	0.01%
7	MAL NEOPLASM OROPHARYNX	146	147	0.24%	0.01%
8	MAL NEOPLASM NASOPHARYNX	147	116	0.19%	0.01%
9	MAL NEOPL HYPOPHARYNX	148	67	0.11%	0.00%
10	OTH MAL NEOPL OROPHARYNX	149	156	0.26%	0.01%
11	MAL NEOPL ESOPHAGUS	150	306	0.51%	0.02%
12	MAL NEOPL STOMACH	151	347	0.58%	0.02%
13	MAL NEOPL SMALL BOWEL	152	41	0.07%	0.00%
14	MALIGNANT NEOPLASM COLON	153	1406	2.34%	0.08%
15	MAL NEOPL RECTUM/ANUS	154	1630	2.71%	0.09%
16	MALIGNANT NEOPLASM LIVER	155	412	0.69%	0.02%
17	MAL NEOPL GB/BD	156	81	0.13%	0.00%
18	MAL NEOPL PANCREAS	157	361	0.60%	0.02%
19	MAL NEOPLASM PERITONEUM	158	52	0.09%	0.00%
20	OTH DIGEST MAL NEOPL	159	146	0.24%	0.01%
21	MAL NEOPL NOSE/ME/SINUS	160	104	0.17%	0.01%
22	MAL NEOPL LARYNX	161	482	0.80%	0.03%
23	MAL NEOPL TRACHEA/LUNG	162	4342	7.22%	0.25%
24	MALIGNANT NEOPL PLEURA	163	49	0.08%	0.00%
25	MAL NEOPL THYMUS/MEDIAST	164	85	0.14%	0.00%
26	MAL NEOPL RESP NEC	165	29	0.05%	0.00%
27	MAL NEOPL BONE/CART	170	654	1.09%	0.04%
28	MAL NEOPL SOFT TISSUE	171	555	0.92%	0.03%
29	MALIGNANT MELANOMA SKIN	172	558	0.93%	0.03%
30	OTHER MAL NEOPL SKIN	173	1888	3.14%	0.11%
31	MAL NEOPL FEMALE BREAST	174	5771	9.60%	0.33%
32	MAL NEOPL MALE BREAST	175	57	0.09%	0.00%
33	MAL NEOPL UTERUS NOS	179	227	0.38%	0.01%
34	MAL NEOPL CERVIX UTERI	180	762	1.27%	0.04%
35	MALIGNANT NEOPL PLACENTA	181	9	0.01%	0.00%
36	MAL NEOPL UTERUS BODY	182	352	0.59%	0.02%
37	MAL NEOPL UTERINE ADNEXA	183	713	1.19%	0.04%
38	MAL NEOPL FE GENIT NEC	184	135	0.22%	0.01%
39	MAL NEOPL PROSTATE	185	878	1.46%	0.05%
40	MAL NEOPL TESTIS	186	71	0.12%	0.00%
41	MAL NEOPL MALE GENIT NEC	187	33	0.05%	0.00%
42	MAL NEOPL BLADDER	188	826	1.37%	0.05%
43	MAL GU NEOPL NEC/NOS	189	552	0.92%	0.03%
44	MALIGNANT NEOPLASM EYE	190	176	0.29%	0.01%
45	MALIGNANT NEOPLASM BRAIN	191	1286	2.14%	0.07%
46	MAL NEOPL NERVE NEC/NOS	192	141	0.23%	0.01%
47	MALIGNANT NEOPL THYROID	193	241	0.40%	0.01%
48	MAL NEOPL ENDOCRINE NEC	194	229	0.38%	0.01%
49	MAL NEOPL ILL-DEF SITES	195	1030	1.71%	0.06%
50	SECONDARY MAL NEOPL LN	196	224	0.37%	0.01%
51	2ND MAL NEOPLASM GI/RESP	197	612	1.02%	0.04%
52	2ND MAL NEOPL OTH SITES	198	993	1.65%	0.06%
53	MALIGNANT NEOPLASM NOS	199	3808	6.33%	0.22%
54	LYMPHOSARC/RETICULOSARC	200	252	0.42%	0.01%
55	HODGKIN'S DISEASE	201	404	0.67%	0.02%
56	OTH MAL NEOPL LYMPH/HIST	202	1073	1.78%	0.06%
57	MULTIPLE MYELOMA ET AL	203	288	0.48%	0.02%
58	LYMPHOID LEUKEMIA	204	516	0.86%	0.03%
59	MYELOID LEUKEMIA	205	319	0.53%	0.02%
60	MONOCYTIC LEUKEMIA	206	43	0.07%	0.00%
61	OTHER SPECIFIED LEUKEMIA	207	43	0.07%	0.00%
62	LEUKEMIA-UNSPECIF CELL	208	638	1.06%	0.04%
63	BEN NEOPL MOUTH/PHARYNX	210	215	0.36%	0.01%
64	OTH BENIGN NEOPLASM GI	211	2006	3.34%	0.12%
65	BEN INTRATHOR NEOPLASM	212	211	0.35%	0.01%
66	BEN NEOPLASM BONE/CART	213	661	1.10%	0.04%
67	LIPOMA	214	561	0.93%	0.03%
68	OTH BEN NEOPL SOFT TISS	215	369	0.61%	0.02%
69	BENIGN NEOPLASM OF SKIN	216	2509	4.17%	0.15%
70	BENIGN NEOPLASM BREAST	217	631	1.05%	0.04%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1988
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 1726444

A20

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
71	UTERINE LEIOMYOMA	218	2213	3.68%	0.13%
72	OTH BENIGN NEOPL UTERUS	219	167	0.28%	0.01%
73	BENIGN NEOPLASM OVARY	220	148	0.25%	0.01%
74	BEN NEOPL OTH FEM GENIT	221	94	0.16%	0.01%
75	BENIGN NEOPL MALE GENIT	222	55	0.09%	0.00%
76	BENIGN NEOPLASM URINARY	223	116	0.19%	0.01%
77	BENIGN NEOPLASM OF EYE	224	83	0.14%	0.00%
78	BENIGN NEOPL NERV SYST	225	373	0.62%	0.02%
79	BENIGN NEOPLASM THYROID	226	97	0.16%	0.01%
80	BEN NEOPL OTH ENDOCRINE	227	118	0.20%	0.01%
81	HEMANGIOMA/LYMPHANGIOMA	228	320	0.53%	0.02%
82	BENIGN NEOPLASM NEC/NOS	229	566	0.94%	0.03%
83	CA IN SITU DIGESTIVE ORG	230	263	0.44%	0.02%
84	CA IN SITU RESPIRATORY	231	281	0.47%	0.02%
85	CARCINOMA IN SITU SKIN	232	169	0.28%	0.01%
86	CA IN SITU BREAST/GU	233	862	1.43%	0.05%
87	CA IN SITU NEC/NOS	234	189	0.31%	0.01%
88	UNC BEHAV NEOPL GI/RESP	235	333	0.55%	0.02%
89	UNC BEHAV NEOPL GU	236	228	0.38%	0.01%
90	UNC NEOPL ENDOCR/NERV	237	286	0.48%	0.02%
91	UNC BEHAV NEOPL NEC/NOS	238	919	1.53%	0.05%
92	UNSPECIFIED NEOPLASM	239	7695	12.80%	0.45%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1989
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 1989784

A21

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
1	MALIGNANT NEOPLASM LIP	140	61	0.09%	0.00%
2	MALIGNANT NEOPL TONGUE	141	294	0.42%	0.01%
3	MAL NEOPL MAJOR SG	142	67	0.10%	0.00%
4	MALIGNANT NEOPLASM GUM	143	15	0.02%	0.00%
5	MAL NEOPLASM FLOOR MOUTH	144	90	0.13%	0.00%
6	MAL NEOPL MOUTH NEC/NOS	145	223	0.32%	0.01%
7	MAL NEOPLASM OROPHARYNX	146	152	0.22%	0.01%
8	MAL NEOPLASM NASOPHARYNX	147	155	0.22%	0.01%
9	MAL NEOPL HYPOPHARYNX	148	76	0.11%	0.00%
10	OTH MAL NEOPL OROPHARYNX	149	220	0.32%	0.01%
11	MAL NEOPL ESOPHAGUS	150	366	0.53%	0.02%
12	MAL NEOPL STOMACH	151	366	0.53%	0.02%
13	MAL NEOPL SMALL BOWEL	152	61	0.09%	0.00%
14	MALIGNANT NEOPLASM COLON	153	1784	2.58%	0.09%
15	MAL NEOPL RECTUM/ANUS	154	1820	2.63%	0.09%
16	MALIGNANT NEOPLASM LIVER	155	461	0.67%	0.02%
17	MAL NEOPL GB/BD	156	70	0.10%	0.00%
18	MAL NEOPL PANCREAS	157	387	0.56%	0.02%
19	MAL NEOPLASM PERITONEUM	158	56	0.08%	0.00%
20	OTH DIGEST MAL NEOPL	159	151	0.22%	0.01%
21	MAL NEOPL NOSE/ME/SINUS	160	99	0.14%	0.00%
22	MAL NEOPL LARYNX	161	599	0.86%	0.03%
23	MAL NEOPL TRACHEA/LUNG	162	5063	7.31%	0.25%
24	MALIGNANT NEOPL PLEURA	163	44	0.06%	0.00%
25	MAL NEOPL THYMUS/MEDIAST	164	90	0.13%	0.00%
26	MAL NEOPL RESP NEC	165	33	0.05%	0.00%
27	MAL NEOPL BONE/CART	170	741	1.07%	0.04%
28	MAL NEOPL SOFT TISSUE	171	583	0.84%	0.03%
29	MALIGNANT MELANOMA SKIN	172	723	1.04%	0.04%
30	OTHER MAL NEOPL SKIN	173	2155	3.11%	0.11%
31	MAL NEOPL FEMALE BREAST	174	7030	10.15%	0.35%
32	MAL NEOPL MALE BREAST	175	49	0.07%	0.00%
33	MAL NEOPL UTERUS NOS	179	246	0.36%	0.01%
34	MAL NEOPL CERVIX UTERI	180	826	1.19%	0.04%
35	MALIGNANT NEOPL PLACENTA	181	12	0.02%	0.00%
36	MAL NEOPL UTERUS BODY	182	419	0.60%	0.02%
37	MAL NEOPL UTERINE ADNEXA	183	891	1.29%	0.04%
38	MAL NEOPL FE GENIT NEC	184	174	0.25%	0.01%
39	MAL NEOPL PROSTATE	185	1170	1.69%	0.06%
40	MAL NEOPL TESTIS	186	93	0.13%	0.00%
41	MAL NEOPL MALE GENIT NEC	187	37	0.05%	0.00%
42	MAL NEOPL BLADDER	188	1103	1.59%	0.06%
43	MAL GU NEOPL NEC/NOS	189	680	0.98%	0.03%
44	MALIGNANT NEOPLASM EYE	190	196	0.28%	0.01%
45	MALIGNANT NEOPLASM BRAIN	191	1377	1.99%	0.07%
46	MAL NEOPL NERVE NEC/NOS	192	165	0.24%	0.01%
47	MALIGNANT NEOPL THYROID	193	279	0.40%	0.01%
48	MAL NEOPL ENDOCRINE NEC	194	246	0.36%	0.01%
49	MAL NEOPL ILL-DEF SITES	195	1063	1.53%	0.05%
50	SECONDARY MAL NEOPL LN	196	252	0.36%	0.01%
51	2ND MAL NEOPLASM GI/RESP	197	764	1.10%	0.04%
52	2ND MAL NEOPL OTH SITES	198	1239	1.79%	0.06%
53	MALIGNANT NEOPLASM NOS	199	4021	5.80%	0.20%
54	LYMPHOSARC/RETICULOSARC	200	331	0.48%	0.02%
55	HODGKIN'S DISEASE	201	466	0.67%	0.02%
56	OTH MAL NEOPL LYMPH/HIST	202	1225	1.77%	0.06%
57	MULTIPLE MYELOMA ET AL	203	356	0.51%	0.02%
58	LYMPHOID LEUKEMIA	204	624	0.90%	0.03%
59	MYELOID LEUKEMIA	205	331	0.48%	0.02%
60	MONOCYTIC LEUKEMIA	206	36	0.05%	0.00%
61	OTHER SPECIFIED LEUKEMIA	207	56	0.08%	0.00%
62	LEUKEMIA-UNSPECIF CELL	208	691	1.00%	0.03%
63	BEN NEOPL MOUTH/PHARYNX	210	259	0.37%	0.01%
64	OTH BENIGN NEOPLASM GI	211	2480	3.58%	0.12%
65	BEN INTRATHOR NEOPLASM	212	266	0.38%	0.01%
66	BEN NEOPLASM BONE/CART	213	647	0.93%	0.03%
67	LIPOMA	214	690	1.00%	0.03%
68	OTH BEN NEOPL SOFT TISS	215	548	0.79%	0.03%
69	BENIGN NEOPLASM OF SKIN	216	2913	4.21%	0.15%
70	BENIGN NEOPLASM BREAST	217	713	1.03%	0.04%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1989
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 1989784

A22

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
71	UTERINE LEIOMYOMA	218	2480	3.58%	0.12%
72	OTH BENIGN NEOPL UTERUS	219	160	0.23%	0.01%
73	BENIGN NEOPLASM OVARY	220	156	0.23%	0.01%
74	BEN NEOPL OTH FEM GENIT	221	99	0.14%	0.00%
75	BENIGN NEOPL MALE GENIT	222	75	0.11%	0.00%
76	BENIGN NEOPLASM URINARY	223	141	0.20%	0.01%
77	BENIGN NEOPLASM OF EYE	224	91	0.13%	0.00%
78	BENIGN NEOPL NERV SYST	225	473	0.68%	0.02%
79	BENIGN NEOPLASM THYROID	226	125	0.18%	0.01%
80	BEN NEOPL OTH ENDOCRINE	227	185	0.27%	0.01%
81	HEMANGIOMA/LYMPHANGIOMA	228	411	0.59%	0.02%
82	BENIGN NEOPLASM NEC/NOS	229	614	0.89%	0.03%
83	CA IN SITU DIGESTIVE ORG	230	332	0.48%	0.02%
84	CA IN SITU RESPIRATORY	231	344	0.50%	0.02%
85	CARCINOMA IN SITU SKIN	232	262	0.38%	0.01%
86	CA IN SITU BREAST/GU	233	1140	1.65%	0.06%
87	CA IN SITU NEC/NOS	234	288	0.42%	0.01%
88	UNC BEHAV NEOPL GI/RESP	235	392	0.57%	0.02%
89	UNC BEHAV NEOPL GU	236	260	0.38%	0.01%
90	UNC NEOPL ENDOCR/NERV	237	375	0.54%	0.02%
91	UNC BEHAV NEOPL NEC/NOS	238	1064	1.54%	0.05%
92	UNSPECIFIED NEOPLASM	239	7834	11.31%	0.39%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1990
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2303450

A23

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
1	MALIGNANT NEOPLASM LIP	140	65	0.08%	0.00%
2	MALIGNANT NEOPL TONGUE	141	353	0.45%	0.02%
3	MAL NEOPL MAJOR SG	142	96	0.12%	0.00%
4	MALIGNANT NEOPLASM GUM	143	38	0.05%	0.00%
5	MAL NEOPLASM FLOOR MOUTH	144	97	0.12%	0.00%
6	MAL NEOPL MOUTH NEC/NOS	145	249	0.32%	0.01%
7	MAL NEOPLASM OROPHARYNX	146	179	0.23%	0.01%
8	MAL NEOPLASM NASOPHARYNX	147	153	0.19%	0.01%
9	MAL NEOPL HYPOPHARYNX	148	117	0.15%	0.01%
10	OTH MAL NEOPL OROPHARYNX	149	245	0.31%	0.01%
11	MAL NEOPL ESOPHAGUS	150	446	0.57%	0.02%
12	MAL NEOPL STOMACH	151	433	0.55%	0.02%
13	MAL NEOPL SMALL BOWEL	152	86	0.11%	0.00%
14	MALIGNANT NEOPLASM COLON	153	2192	2.78%	0.10%
15	MAL NEOPL RECTUM/ANUS	154	1924	2.44%	0.08%
16	MALIGNANT NEOPLASM LIVER	155	477	0.61%	0.02%
17	MAL NEOPL GB/BD	156	96	0.12%	0.00%
18	MAL NEOPL PANCREAS	157	456	0.58%	0.02%
19	MAL NEOPLASM PERITONEUM	158	87	0.11%	0.00%
20	OTH DIGEST MAL NEOPL	159	174	0.22%	0.01%
21	MAL NEOPL NOSE/ME/SINUS	160	88	0.11%	0.00%
22	MAL NEOPL LARYNX	161	675	0.86%	0.03%
23	MAL NEOPL TRACHEA/LUNG	162	5615	7.13%	0.24%
24	MALIGNANT NEOPL PLEURA	163	52	0.07%	0.00%
25	MAL NEOPL THYMUS/MEDIAST	164	76	0.10%	0.00%
26	MAL NEOPL RESP NEC	165	21	0.03%	0.00%
27	MAL NEOPL BONE/CART	170	789	1.00%	0.03%
28	MAL NEOPL SOFT TISSUE	171	641	0.81%	0.03%
29	MALIGNANT MELANOMA SKIN	172	792	1.01%	0.03%
30	OTHER MAL NEOPL SKIN	173	2461	3.13%	0.11%
31	MAL NEOPL FEMALE BREAST	174	8092	10.28%	0.35%
32	MAL NEOPL MALE BREAST	175	49	0.06%	0.00%
33	MAL NEOPL UTERUS NOS	179	226	0.29%	0.01%
34	MAL NEOPL CERVIX UTERI	180	895	1.14%	0.04%
35	MALIGNANT NEOPL PLACENTA	181	14	0.02%	0.00%
36	MAL NEOPL UTERUS BODY	182	454	0.58%	0.02%
37	MAL NEOPL UTERINE ADNEXA	183	1093	1.39%	0.05%
38	MAL NEOPL FE GENIT NEC	184	172	0.22%	0.01%
39	MAL NEOPL PROSTATE	185	1461	1.86%	0.06%
40	MAL NEOPL TESTIS	186	119	0.15%	0.01%
41	MAL NEOPL MALE GENIT NEC	187	47	0.06%	0.00%
42	MAL NEOPL BLADDER	188	1286	1.63%	0.06%
43	MAL GU NEOPL NEC/NOS	189	830	1.05%	0.04%
44	MALIGNANT NEOPLASM EYE	190	234	0.30%	0.01%
45	MALIGNANT NEOPLASM BRAIN	191	1523	1.93%	0.07%
46	MAL NEOPL NERVE NEC/NOS	192	171	0.22%	0.01%
47	MALIGNANT NEOPL THYROID	193	319	0.41%	0.01%
48	MAL NEOPL ENDOCRINE NEC	194	272	0.35%	0.01%
49	MAL NEOPL ILL-DEF SITES	195	1118	1.42%	0.05%
50	SECONDARY MAL NEOPL LN	196	307	0.39%	0.01%
51	2ND MAL NEOPLASM GI/RESP	197	843	1.07%	0.04%
52	2ND MAL NEOPL OTH SITES	198	1517	1.93%	0.07%
53	MALIGNANT NEOPLASM NOS	199	4077	5.18%	0.18%
54	LYMPHOSARC/RETICULOSARC	200	403	0.51%	0.02%
55	HODGKIN'S DISEASE	201	541	0.69%	0.02%
56	OTH MAL NEOPL LYMPH/HIST	202	1391	1.77%	0.06%
57	MULTIPLE MYELOMA ET AL	203	366	0.46%	0.02%
58	LYMPHOID LEUKEMIA	204	744	0.94%	0.03%
59	MYELOID LEUKEMIA	205	393	0.50%	0.02%
60	MONOCYTIC LEUKEMIA	206	39	0.05%	0.00%
61	OTHER SPECIFIED LEUKEMIA	207	46	0.06%	0.00%
62	LEUKEMIA-UNSPECIF CELL	208	777	0.99%	0.03%
63	BEN NEOPL MOUTH/PHARYNX	210	296	0.38%	0.01%
64	OTH BENIGN NEOPLASM GI	211	2876	3.65%	0.12%
65	BEN INTRATHOR NEOPLASM	212	344	0.44%	0.01%
66	BEN NEOPLASM BONE/CART	213	564	0.72%	0.02%
67	LIPOMA	214	825	1.05%	0.04%
68	OTH BEN NEOPL SOFT TISS	215	569	0.72%	0.02%
69	BENIGN NEOPLASM OF SKIN	216	3627	4.61%	0.16%
70	BENIGN NEOPLASM BREAST	217	714	0.91%	0.03%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1990
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2303450

A24

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
71	UTERINE LEIOMYOMA	218	3140	3.99%	0.14%
72	OTH BENIGN NEOPL UTERUS	219	255	0.32%	0.01%
73	BENIGN NEOPLASM OVARY	220	195	0.25%	0.01%
74	BEN NEOPL OTH FEM GENIT	221	84	0.11%	0.00%
75	BENIGN NEOPL MALE GENIT	222	108	0.14%	0.00%
76	BENIGN NEOPLASM URINARY	223	158	0.20%	0.01%
77	BENIGN NEOPLASM OF EYE	224	107	0.14%	0.00%
78	BENIGN NEOPL NERV SYST	225	489	0.62%	0.02%
79	BENIGN NEOPLASM THYROID	226	162	0.21%	0.01%
80	BEN NEOPL OTH ENDOCRINE	227	191	0.24%	0.01%
81	HEMANGIOMA/LYMPHANGIOMA	228	466	0.59%	0.02%
82	BENIGN NEOPLASM NEC/NOS	229	641	0.81%	0.03%
83	CA IN SITU DIGESTIVE ORG	230	358	0.45%	0.02%
84	CA IN SITU RESPIRATORY	231	377	0.48%	0.02%
85	CARCINOMA IN SITU SKIN	232	376	0.48%	0.02%
86	CA IN SITU BREAST/GU	233	1287	1.63%	0.06%
87	CA IN SITU NEC/NOS	234	292	0.37%	0.01%
88	UNC BEHAV NEOPL GI/RESP	235	515	0.65%	0.02%
89	UNC BEHAV NEOPL GU	236	351	0.45%	0.02%
90	UNC NEOPL ENDOCR/NERV	237	424	0.54%	0.02%
91	UNC BEHAV NEOPL NEC/NOS	238	1324	1.68%	0.06%
92	UNSPECIFIED NEOPLASM	239	8642	10.97%	0.38%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1991
FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
DENOMINATOR IS 2319445

A25

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
1	MALIGNANT NEOPLASM LIP	140	74	0.08%	0.00%
2	MALIGNANT NEOPL TONGUE	141	394	0.41%	0.02%
3	MAL NEOPL MAJOR SG	142	113	0.12%	0.00%
4	MALIGNANT NEOPLASM GUM	143	48	0.05%	0.00%
5	MAL NEOPLASM FLOOR MOUTH	144	108	0.11%	0.00%
6	MAL NEOPL MOUTH NEC/NOS	145	308	0.32%	0.01%
7	MAL NEOPLASM OROPHARYNX	146	218	0.23%	0.01%
8	MAL NEOPLASM NASOPHARYNX	147	178	0.19%	0.01%
9	MAL NEOPL HYPOPHARYNX	148	142	0.15%	0.01%
10	OTH MAL NEOPL OROPHARYNX	149	244	0.25%	0.01%
11	MAL NEOPL ESOPHAGUS	150	548	0.57%	0.02%
12	MAL NEOPL STOMACH	151	495	0.52%	0.02%
13	MAL NEOPL SMALL BOWEL	152	103	0.11%	0.00%
14	MALIGNANT NEOPLASM COLON	153	2771	2.89%	0.12%
15	MAL NEOPL RECTUM/ANUS	154	2306	2.40%	0.10%
16	MALIGNANT NEOPLASM LIVER	155	527	0.55%	0.02%
17	MAL NEOPL GB/BD	156	121	0.13%	0.01%
18	MAL NEOPL PANCREAS	157	572	0.60%	0.02%
19	MAL NEOPLASM PERITONEUM	158	96	0.10%	0.00%
20	OTH DIGEST MAL NEOPL	159	163	0.17%	0.01%
21	MAL NEOPL NOSE/ME/SINUS	160	123	0.13%	0.01%
22	MAL NEOPL LARYNX	161	826	0.86%	0.04%
23	MAL NEOPL TRACHEA/LUNG	162	6713	6.99%	0.29%
24	MALIGNANT NEOPL PLEURA	163	57	0.06%	0.00%
25	MAL NEOPL THYMUS/MEDIAST	164	125	0.13%	0.01%
26	MAL NEOPL RESP NEC	165	33	0.03%	0.00%
27	MAL NEOPL BONE/CART	170	881	0.92%	0.04%
28	MAL NEOPL SOFT TISSUE	171	707	0.74%	0.03%
29	MALIGNANT MELANOMA SKIN	172	956	1.00%	0.04%
30	OTHER MAL NEOPL SKIN	173	3109	3.24%	0.13%
31	MAL NEOPL FEMALE BREAST	174	9892	10.30%	0.43%
32	MAL NEOPL MALE BREAST	175	57	0.06%	0.00%
33	MAL NEOPL UTERUS NOS	179	243	0.25%	0.01%
34	MAL NEOPL CERVIX UTERI	180	989	1.03%	0.04%
35	MALIGNANT NEOPL PLACENTA	181	12	0.01%	0.00%
36	MAL NEOPL UTERUS BODY	182	587	0.61%	0.03%
37	MAL NEOPL UTERINE ADNEXA	183	1240	1.29%	0.05%
38	MAL NEOPL FE GENIT NEC	184	215	0.22%	0.01%
39	MAL NEOPL PROSTATE	185	2047	2.13%	0.09%
40	MAL NEOPL TESTIS	186	117	0.12%	0.01%
41	MAL NEOPL MALE GENIT NEC	187	81	0.08%	0.00%
42	MAL NEOPL BLADDER	188	1699	1.77%	0.07%
43	MAL GU NEOPL NEC/NOS	189	1011	1.05%	0.04%
44	MALIGNANT NEOPLASM EYE	190	254	0.26%	0.01%
45	MALIGNANT NEOPLASM BRAIN	191	1817	1.89%	0.08%
46	MAL NEOPL NERVE NEC/NOS	192	174	0.18%	0.01%
47	MALIGNANT NEOPL THYROID	193	415	0.43%	0.02%
48	MAL NEOPL ENDOCRINE NEC	194	349	0.36%	0.02%
49	MAL NEOPL ILL-DEF SITES	195	1277	1.33%	0.06%
50	SECONDARY MAL NEOPL LN	196	441	0.46%	0.02%
51	2ND MAL NEOPLASM GI/RESP	197	1215	1.27%	0.05%
52	2ND MAL NEOPL OTH SITES	198	2140	2.23%	0.09%
53	MALIGNANT NEOPLASM NOS	199	3879	4.04%	0.17%
54	LYMPHOSARC/RETICULOSARC	200	562	0.59%	0.02%
55	HODGKIN'S DISEASE	201	807	0.84%	0.03%
56	OTH MAL NEOPL LYMPH/HIST	202	2198	2.29%	0.09%
57	MULTIPLE MYELOMA ET AL	203	394	0.41%	0.02%
58	LYMPHOID LEUKEMIA	204	870	0.91%	0.04%
59	MYELOID LEUKEMIA	205	506	0.53%	0.02%
60	MONOCYTIC LEUKEMIA	206	53	0.06%	0.00%
61	OTHER SPECIFIED LEUKEMIA	207	41	0.04%	0.00%
62	LEUKEMIA-UNSPECIF CELL	208	884	0.92%	0.04%
63	BEN NEOPL MOUTH/PHARYNX	210	328	0.34%	0.01%
64	OTH BENIGN NEOPLASM GI	211	3538	3.68%	0.15%
65	BEN INTRATHOR NEOPLASM	212	468	0.49%	0.02%
66	BEN NEOPLASM BONE/CART	213	492	0.51%	0.02%
67	LIPOMA	214	984	1.02%	0.04%
68	OTH BEN NEOPL SOFT TISS	215	573	0.60%	0.02%
69	BENIGN NEOPLASM OF SKIN	216	4420	4.60%	0.19%
70	BENIGN NEOPLASM BREAST	217	855	0.89%	0.04%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1991
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2319445

A26

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
71	UTERINE LEIOMYOMA	218	3769	3.92%	0.16%
72	OTH BENIGN NEOPL UTERUS	219	275	0.29%	0.01%
73	BENIGN NEOPLASM OVARY	220	222	0.23%	0.01%
74	BEN NEOPL OTH FEM GENIT	221	152	0.16%	0.01%
75	BENIGN NEOPL MALE GENIT	222	138	0.14%	0.01%
76	BENIGN NEOPLASM URINARY	223	168	0.17%	0.01%
77	BENIGN NEOPLASM OF EYE	224	158	0.16%	0.01%
78	BENIGN NEOPL NERV SYST	225	660	0.69%	0.03%
79	BENIGN NEOPLASM THYROID	226	159	0.17%	0.01%
80	BEN NEOPL OTH ENDOCRINE	227	268	0.28%	0.01%
81	HEMANGIOMA/LYMPHANGIOMA	228	584	0.61%	0.03%
82	BENIGN NEOPLASM NEC/NOS	229	695	0.72%	0.03%
83	CA IN SITU DIGESTIVE ORG	230	495	0.52%	0.02%
84	CA IN SITU RESPIRATORY	231	527	0.55%	0.02%
85	CARCINOMA IN SITU SKIN	232	592	0.62%	0.03%
86	CA IN SITU BREAST/GU	233	1633	1.70%	0.07%
87	CA IN SITU NEC/NOS	234	385	0.40%	0.02%
88	UNC BEHAV NEOPL GI/RESP	235	602	0.63%	0.03%
89	UNC BEHAV NEOPL GU	236	509	0.53%	0.02%
90	UNC NEOPL ENDOCR/NERV	237	569	0.59%	0.02%
91	UNC BEHAV NEOPL NEC/NOS	238	2020	2.10%	0.09%
92	UNSPECIFIED NEOPLASM	239	10275	10.70%	0.44%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1992
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2182878

A27

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
1	MALIGNANT NEOPLASM LIP	140	54	0.06%	0.00%
2	MALIGNANT NEOPL TONGUE	141	392	0.41%	0.02%
3	MAL NEOPL MAJOR SG	142	105	0.11%	0.00%
4	MALIGNANT NEOPLASM GUM	143	34	0.04%	0.00%
5	MAL NEOPLASM FLOOR MOUTH	144	125	0.13%	0.01%
6	MAL NEOPL MOUTH NEC/NOS	145	285	0.30%	0.01%
7	MAL NEOPLASM OROPHARYNX	146	240	0.25%	0.01%
8	MAL NEOPLASM NASOPHARYNX	147	178	0.19%	0.01%
9	MAL NEOPL HYPOPHARYNX	148	134	0.14%	0.01%
10	OTH MAL NEOPL OROPHARYNX	149	249	0.26%	0.01%
11	MAL NEOPL ESOPHAGUS	150	500	0.53%	0.02%
12	MAL NEOPL STOMACH	151	480	0.51%	0.02%
13	MAL NEOPL SMALL BOWEL	152	96	0.10%	0.00%
14	MALIGNANT NEOPLASM COLON	153	2799	2.95%	0.13%
15	MAL NEOPL RECTUM/ANUS	154	2228	2.35%	0.10%
16	MALIGNANT NEOPLASM LIVER	155	572	0.60%	0.03%
17	MAL NEOPL GB/BD	156	108	0.11%	0.00%
18	MAL NEOPL PANCREAS	157	579	0.61%	0.03%
19	MAL NEOPLASM PERITONEUM	158	79	0.08%	0.00%
20	OTH DIGEST MAL NEOPL	159	143	0.15%	0.01%
21	MAL NEOPL NOSE/ME/SINUS	160	122	0.13%	0.01%
22	MAL NEOPL LARYNX	161	819	0.86%	0.04%
23	MAL NEOPL TRACHEA/LUNG	162	6793	7.17%	0.31%
24	MALIGNANT NEOPL PLEURA	163	76	0.08%	0.00%
25	MAL NEOPL THYMUS/MEDIAST	164	108	0.11%	0.00%
26	MAL NEOPL RESP NEC	165	31	0.03%	0.00%
27	MAL NEOPL BONE/CART	170	853	0.90%	0.04%
28	MAL NEOPL SOFT TISSUE	171	725	0.77%	0.03%
29	MALIGNANT MELANOMA SKIN	172	955	1.01%	0.04%
30	OTHER MAL NEOPL SKIN	173	3026	3.19%	0.14%
31	MAL NEOPL FEMALE BREAST	174	10385	10.86%	0.48%
32	MAL NEOPL MALE BREAST	175	55	0.06%	0.00%
33	KAPOSI'S SARCOMA	176	12	0.01%	0.00%
34	MAL NEOPL UTERUS NOS	179	223	0.24%	0.01%
35	MAL NEOPL CERVIX UTERI	180	1013	1.07%	0.05%
36	MALIGNANT NEOPL PLACENTA	181	9	0.01%	0.00%
37	MAL NEOPL UTERUS BODY	182	594	0.63%	0.03%
38	MAL NEOPL UTERINE ADNEXA	183	1273	1.34%	0.06%
39	MAL NEOPL FE GENIT NEC	184	191	0.20%	0.01%
40	MAL NEOPL PROSTATE	185	2815	2.97%	0.13%
41	MAL NEOPL TESTIS	186	136	0.14%	0.01%
42	MAL NEOPL MALE GENIT NEC	187	54	0.06%	0.00%
43	MAL NEOPL BLADDER	188	1682	1.78%	0.08%
44	MAL GU NEOPL NEC/NOS	189	978	1.03%	0.04%
45	MALIGNANT NEOPLASM EYE	190	265	0.28%	0.01%
46	MALIGNANT NEOPLASM BRAIN	191	1722	1.82%	0.08%
47	MAL NEOPL NERVE NEC/NOS	192	192	0.20%	0.01%
48	MALIGNANT NEOPL THYROID	193	417	0.44%	0.02%
49	MAL NEOPL ENDOCRINE NEC	194	299	0.32%	0.01%
50	MAL NEOPL ILL-DEF SITES	195	1236	1.30%	0.06%
51	SECONDARY MAL NEOPL LN	196	449	0.47%	0.02%
52	2ND MAL NEOPLASM GI/RESP	197	1211	1.28%	0.06%
53	2ND MAL NEOPL OTH SITES	198	2095	2.21%	0.10%
54	MALIGNANT NEOPLASM NOS	199	3506	3.70%	0.16%
55	LYMPHOSARC/RETICULOSARC	200	430	0.45%	0.02%
56	HODGKIN'S DISEASE	201	586	0.62%	0.03%
57	OTH MAL NEOPL LYMPH/HIST	202	1771	1.87%	0.08%
58	MULTIPLE MYELOMA ET AL	203	415	0.44%	0.02%
59	LYMPHOID LEUKEMIA	204	901	0.95%	0.04%
60	MYELOID LEUKEMIA	205	488	0.52%	0.02%
61	MONOCYTIC LEUKEMIA	206	63	0.07%	0.00%
62	OTHER SPECIFIED LEUKEMIA	207	31	0.03%	0.00%
63	LEUKEMIA-UNSPECIF CELL	208	817	0.86%	0.04%
64	BEN NEOPL MOUTH/PHARYNX	210	362	0.38%	0.02%
65	OTH BENIGN NEOPLASM GI	211	3758	3.97%	0.17%
66	BEN INTRATHOR NEOPLASM	212	472	0.50%	0.02%
67	BEN NEOPLASM BONE/CART	213	521	0.55%	0.02%
68	LIPOMA	214	935	0.99%	0.04%
69	OTH BEN NEOPL SOFT TISS	215	617	0.65%	0.03%
70	BENIGN NEOPLASM OF SKIN	216	4262	4.50%	0.20%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1992
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2182878

A28

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
71	BENIGN NEOPLASM BREAST	217	773	0.82%	0.04%
72	UTERINE LEIOMYOMA	218	3753	3.96%	0.17%
73	OTH BENIGN NEOPL UTERUS	219	293	0.31%	0.01%
74	BENIGN NEOPLASM OVARY	220	195	0.21%	0.01%
75	BEN NEOPL OTH FEM GENIT	221	153	0.16%	0.01%
76	BENIGN NEOPL MALE GENIT	222	182	0.19%	0.01%
77	BENIGN NEOPLASM URINARY	223	172	0.18%	0.01%
78	BENIGN NEOPLASM OF EYE	224	120	0.13%	0.01%
79	BENIGN NEOPL NERV SYST	225	683	0.72%	0.03%
80	BENIGN NEOPLASM THYROID	226	175	0.18%	0.01%
81	BEN NEOPL OTH ENDOCRINE	227	239	0.25%	0.01%
82	HEMANGIOMA/LYMPHANGIOMA	228	570	0.60%	0.03%
83	BENIGN NEOPLASM NEC/NOS	229	635	0.67%	0.03%
84	CA IN SITU DIGESTIVE ORG	230	463	0.49%	0.02%
85	CA IN SITU RESPIRATORY	231	442	0.47%	0.02%
86	CARCINOMA IN SITU SKIN	232	502	0.53%	0.02%
87	CA IN SITU BREAST/GU	233	1713	1.81%	0.08%
88	CA IN SITU NEC/NOS	234	292	0.31%	0.01%
89	UNC BEHAV NEOPL GI/RESP	235	670	0.71%	0.03%
90	UNC BEHAV NEOPL GU	236	557	0.59%	0.03%
91	UNC NEOPL ENDOCR/NERV	237	560	0.59%	0.03%
92	UNC BEHAV NEOPL NEC/NOS	238	2242	2.37%	0.10%
93	UNSPECIFIED NEOPLASM	239	9214	9.73%	0.42%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1993
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2110066

A29

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
1	MALIGNANT NEOPLASM LIP	140	45	0.05%	0.00%
2	MALIGNANT NEOPL TONGUE	141	379	0.39%	0.02%
3	MAL NEOPL MAJOR SG	142	108	0.11%	0.01%
4	MALIGNANT NEOPLASM GUM	143	32	0.03%	0.00%
5	MAL NEOPLASM FLOOR MOUTH	144	110	0.11%	0.01%
6	MAL NEOPL MOUTH NEC/NOS	145	313	0.32%	0.01%
7	MAL NEOPLASM OROPHARYNX	146	273	0.28%	0.01%
8	MAL NEOPLASM NASOPHARYNX	147	163	0.17%	0.01%
9	MAL NEOPL HYPOPHARYNX	148	128	0.13%	0.01%
10	OTH MAL NEOPL OROPHARYNX	149	235	0.24%	0.01%
11	MAL NEOPL ESOPHAGUS	150	559	0.57%	0.03%
12	MAL NEOPL STOMACH	151	451	0.46%	0.02%
13	MAL NEOPL SMALL BOWEL	152	95	0.10%	0.00%
14	MALIGNANT NEOPLASM COLON	153	2949	3.03%	0.14%
15	MAL NEOPL RECTUM/ANUS	154	2348	2.41%	0.11%
16	MALIGNANT NEOPLASM LIVER	155	574	0.59%	0.03%
17	MAL NEOPL GB/BD	156	116	0.12%	0.01%
18	MAL NEOPL PANCREAS	157	536	0.55%	0.03%
19	MAL NEOPLASM PERITONEUM	158	78	0.08%	0.00%
20	OTH DIGEST MAL NEOPL	159	149	0.15%	0.01%
21	MAL NEOPL NOSE/ME/SINUS	160	117	0.12%	0.01%
22	MAL NEOPL LARYNX	161	779	0.80%	0.04%
23	MAL NEOPL TRACHEA/LUNG	162	6904	7.10%	0.33%
24	MALIGNANT NEOPL PLEURA	163	62	0.06%	0.00%
25	MAL NEOPL THYMUS/MEDIAST	164	102	0.10%	0.00%
26	MAL NEOPL RESP NEC	165	32	0.03%	0.00%
27	MAL NEOPL BONE/CART	170	791	0.81%	0.04%
28	MAL NEOPL SOFT TISSUE	171	667	0.69%	0.03%
29	MALIGNANT MELANOMA SKIN	172	959	0.99%	0.05%
30	OTHER MAL NEOPL SKIN	173	2934	3.02%	0.14%
31	MAL NEOPL FEMALE BREAST	174	10780	11.08%	0.51%
32	MAL NEOPL MALE BREAST	175	46	0.05%	0.00%
33	KAPOSI'S SARCOMA	176	20	0.02%	0.00%
34	MAL NEOPL UTERUS NOS	179	207	0.21%	0.01%
35	MAL NEOPL CERVIX UTERI	180	1034	1.06%	0.05%
36	MALIGNANT NEOPL PLACENTA	181	12	0.01%	0.00%
37	MAL NEOPL UTERUS BODY	182	635	0.65%	0.03%
38	MAL NEOPL UTERINE ADNEXA	183	1275	1.31%	0.06%
39	MAL NEOPL FE GENIT NEC	184	187	0.19%	0.01%
40	MAL NEOPL PROSTATE	185	3414	3.51%	0.16%
41	MAL NEOPL TESTIS	186	136	0.14%	0.01%
42	MAL NEOPL MALE GENIT NEC	187	46	0.05%	0.00%
43	MAL NEOPL BLADDER	188	1724	1.77%	0.08%
44	MAL GU NEOPL NEC/NOS	189	1031	1.06%	0.05%
45	MALIGNANT NEOPLASM EYE	190	238	0.24%	0.01%
46	MALIGNANT NEOPLASM BRAIN	191	1766	1.82%	0.08%
47	MAL NEOPL NERVE NEC/NOS	192	189	0.19%	0.01%
48	MALIGNANT NEOPL THYROID	193	437	0.45%	0.02%
49	MAL NEOPL ENDOCRINE NEC	194	306	0.31%	0.01%
50	MAL NEOPL ILL-DEF SITES	195	1090	1.12%	0.05%
51	SECONDARY MAL NEOPL LN	196	423	0.43%	0.02%
52	2ND MAL NEOPLASM GI/RESP	197	1237	1.27%	0.06%
53	2ND MAL NEOPL OTH SITES	198	2241	2.30%	0.11%
54	MALIGNANT NEOPLASM NOS	199	3244	3.33%	0.15%
55	LYMPHOSARC/RETICULOSARC	200	628	0.65%	0.03%
56	HODGKIN'S DISEASE	201	864	0.89%	0.04%
57	OTH MAL NEOPL LYMPH/HIST	202	2572	2.64%	0.12%
58	MULTIPLE MYELOMA ET AL	203	681	0.70%	0.03%
59	LYMPHOID LEUKEMIA	204	1334	1.37%	0.06%
60	MYELOID LEUKEMIA	205	688	0.71%	0.03%
61	MONOCYTIC LEUKEMIA	206	72	0.07%	0.00%
62	OTHER SPECIFIED LEUKEMIA	207	31	0.03%	0.00%
63	LEUKEMIA-UNSPECIF CELL	208	956	0.98%	0.05%
64	BEN NEOPL MOUTH/PHARYNX	210	384	0.39%	0.02%
65	OTH BENIGN NEOPLASM GI	211	4106	4.22%	0.19%
66	BEN INTRATHOR NEOPLASM	212	438	0.45%	0.02%
67	BEN NEOPLASM BONE/CART	213	486	0.50%	0.02%
68	LIPOMA	214	926	0.95%	0.04%
69	OTH BEN NEOPL SOFT TISS	215	515	0.53%	0.02%
70	BENIGN NEOPLASM OF SKIN	216	4375	4.50%	0.21%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1993
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2110066

A30

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
71	BENIGN NEOPLASM BREAST	217	663	0.68%	0.03%
72	UTERINE LEIOMYOMA	218	3469	3.57%	0.16%
73	OTH BENIGN NEOPL UTERUS	219	310	0.32%	0.01%
74	BENIGN NEOPLASM OVARY	220	199	0.20%	0.01%
75	BEN NEOPL OTH FEM GENIT	221	134	0.14%	0.01%
76	BENIGN NEOPL MALE GENIT	222	195	0.20%	0.01%
77	BENIGN NEOPLASM URINARY	223	210	0.22%	0.01%
78	BENIGN NEOPLASM OF EYE	224	130	0.13%	0.01%
79	BENIGN NEOPL NERV SYST	225	676	0.69%	0.03%
80	BENIGN NEOPLASM THYROID	226	165	0.17%	0.01%
81	BEN NEOPL OTH ENDOCRINE	227	261	0.27%	0.01%
82	HEMANGIOMA/LYMPHANGIOMA	228	606	0.62%	0.03%
83	BENIGN NEOPLASM NEC/NOS	229	551	0.57%	0.03%
84	CA IN SITU DIGESTIVE ORG	230	460	0.47%	0.02%
85	CA IN SITU RESPIRATORY	231	432	0.44%	0.02%
86	CARCINOMA IN SITU SKIN	232	351	0.36%	0.02%
87	CA IN SITU BREAST/GU	233	1739	1.79%	0.08%
88	CA IN SITU NEC/NOS	234	275	0.28%	0.01%
89	UNC BEHAV NEOPL GI/RESP	235	707	0.73%	0.03%
90	UNC BEHAV NEOPL GU	236	613	0.63%	0.03%
91	UNC NEOPL ENDOCR/NERV	237	606	0.62%	0.03%
92	UNC BEHAV NEOPL NEC/NOS	238	2331	2.40%	0.11%
93	UNSPECIFIED NEOPLASM	239	8448	8.68%	0.40%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1994
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2087951

A31

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
1	MALIGNANT NEOPLASM LIP	140	63	0.06%	0.00%
2	MALIGNANT NEOPL TONGUE	141	405	0.40%	0.02%
3	MAL NEOPL MAJOR SG	142	111	0.11%	0.01%
4	MALIGNANT NEOPLASM GUM	143	31	0.03%	0.00%
5	MAL NEOPLASM FLOOR MOUTH	144	128	0.13%	0.01%
6	MAL NEOPL MOUTH NEC/NOS	145	311	0.31%	0.01%
7	MAL NEOPLASM OROPHARYNX	146	256	0.25%	0.01%
8	MAL NEOPLASM NASOPHARYNX	147	182	0.18%	0.01%
9	MAL NEOPL HYPOPHARYNX	148	125	0.12%	0.01%
10	OTH MAL NEOPL OROPHARYNX	149	242	0.24%	0.01%
11	MAL NEOPL ESOPHAGUS	150	596	0.59%	0.03%
12	MAL NEOPL STOMACH	151	524	0.52%	0.03%
13	MAL NEOPL SMALL BOWEL	152	93	0.09%	0.00%
14	MALIGNANT NEOPLASM COLON	153	3238	3.21%	0.16%
15	MAL NEOPL RECTUM/ANUS	154	2480	2.46%	0.12%
16	MALIGNANT NEOPLASM LIVER	155	572	0.57%	0.03%
17	MAL NEOPL GB/BD	156	142	0.14%	0.01%
18	MAL NEOPL PANCREAS	157	556	0.55%	0.03%
19	MAL NEOPLASM PERITONEUM	158	116	0.12%	0.01%
20	OTH DIGEST MAL NEOPL	159	130	0.13%	0.01%
21	MAL NEOPL NOSE/ME/SINUS	160	127	0.13%	0.01%
22	MAL NEOPL LARYNX	161	765	0.76%	0.04%
23	MAL NEOPL TRACHEA/LUNG	162	7137	7.08%	0.34%
24	MALIGNANT NEOPL PLEURA	163	65	0.06%	0.00%
25	MAL NEOPL THYMUS/MEDIAST	164	99	0.10%	0.00%
26	MAL NEOPL RESP NEC	165	33	0.03%	0.00%
27	MAL NEOPL BONE/CART	170	778	0.77%	0.04%
28	MAL NEOPL SOFT TISSUE	171	721	0.71%	0.03%
29	MALIGNANT MELANOMA SKIN	172	977	0.97%	0.05%
30	OTHER MAL NEOPL SKIN	173	3199	3.17%	0.15%
31	MAL NEOPL FEMALE BREAST	174	11692	11.59%	0.56%
32	MAL NEOPL MALE BREAST	175	46	0.05%	0.00%
33	KAPOSI'S SARCOMA	176	11	0.01%	0.00%
34	MAL NEOPL UTERUS NOS	179	237	0.23%	0.01%
35	MAL NEOPL CERVIX UTERI	180	1063	1.05%	0.05%
36	MALIGNANT NEOPL PLACENTA	181	11	0.01%	0.00%
37	MAL NEOPL UTERUS BODY	182	689	0.68%	0.03%
38	MAL NEOPL UTERINE ADNEXA	183	1370	1.36%	0.07%
39	MAL NEOPL FE GENIT NEC	184	189	0.19%	0.01%
40	MAL NEOPL PROSTATE	185	3823	3.79%	0.18%
41	MAL NEOPL TESTIS	186	138	0.14%	0.01%
42	MAL NEOPL MALE GENIT NEC	187	52	0.05%	0.00%
43	MAL NEOPL BLADDER	188	1874	1.86%	0.09%
44	MAL GU NEOPL NEC/NOS	189	986	0.98%	0.05%
45	MALIGNANT NEOPLASM EYE	190	254	0.25%	0.01%
46	MALIGNANT NEOPLASM BRAIN	191	1866	1.85%	0.09%
47	MAL NEOPL NERVE NEC/NOS	192	211	0.21%	0.01%
48	MALIGNANT NEOPL THYROID	193	470	0.47%	0.02%
49	MAL NEOPL ENDOCRINE NEC	194	297	0.29%	0.01%
50	MAL NEOPL ILL-DEF SITES	195	1074	1.06%	0.05%
51	SECONDARY MAL NEOPL LN	196	460	0.46%	0.02%
52	2ND MAL NEOPLASM GI/RESP	197	1328	1.32%	0.06%
53	2ND MAL NEOPL OTH SITES	198	2196	2.18%	0.11%
54	MALIGNANT NEOPLASM NOS	199	3110	3.08%	0.15%
55	LYMPHOSARC/RETICULOSARC	200	529	0.52%	0.03%
56	HODGKIN'S DISEASE	201	746	0.74%	0.04%
57	OTH MAL NEOPL LYMPH/HIST	202	2188	2.17%	0.10%
58	MULTIPLE MYELOMA ET AL	203	541	0.54%	0.03%
59	LYMPHOID LEUKEMIA	204	1111	1.10%	0.05%
60	MYELOID LEUKEMIA	205	648	0.64%	0.03%
61	MONOCYTIC LEUKEMIA	206	58	0.06%	0.00%
62	OTHER SPECIFIED LEUKEMIA	207	22	0.02%	0.00%
63	LEUKEMIA-UNSPECIF CELL	208	870	0.86%	0.04%
64	BEN NEOPL MOUTH/PHARYNX	210	454	0.45%	0.02%
65	OTH BENIGN NEOPLASM GI	211	4451	4.41%	0.21%
66	BEN INTRATHOR NEOPLASM	212	463	0.46%	0.02%
67	BEN NEOPLASM BONE/CART	213	451	0.45%	0.02%
68	LIPOMA	214	1001	0.99%	0.05%
69	OTH BEN NEOPL SOFT TISS	215	531	0.53%	0.03%
70	BENIGN NEOPLASM OF SKIN	216	4321	4.28%	0.21%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1994
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2087951

A32

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
71	BENIGN NEOPLASM BREAST	217	613	0.61%	0.03%
72	UTERINE LEIOMYOMA	218	3600	3.57%	0.17%
73	OTH BENIGN NEOPL UTERUS	219	383	0.38%	0.02%
74	BENIGN NEOPLASM OVARY	220	183	0.18%	0.01%
75	BEN NEOPL OTH FEM GENIT	221	138	0.14%	0.01%
76	BENIGN NEOPL MALE GENIT	222	224	0.22%	0.01%
77	BENIGN NEOPLASM URINARY	223	229	0.23%	0.01%
78	BENIGN NEOPLASM OF EYE	224	142	0.14%	0.01%
79	BENIGN NEOPL NERV SYST	225	743	0.74%	0.04%
80	BENIGN NEOPLASM THYROID	226	158	0.16%	0.01%
81	BEN NEOPL OTH ENDOCRINE	227	286	0.28%	0.01%
82	HEMANGIOMA/LYMPHANGIOMA	228	635	0.63%	0.03%
83	BENIGN NEOPLASM NEC/NOS	229	533	0.53%	0.03%
84	CA IN SITU DIGESTIVE ORG	230	498	0.49%	0.02%
85	CA IN SITU RESPIRATORY	231	506	0.50%	0.02%
86	CARCINOMA IN SITU SKIN	232	376	0.37%	0.02%
87	CA IN SITU BREAST/GU	233	1887	1.87%	0.09%
88	CA IN SITU NEC/NOS	234	239	0.24%	0.01%
89	UNC BEHAV NEOPL GI/RESP	235	792	0.79%	0.04%
90	UNC BEHAV NEOPL GU	236	734	0.73%	0.04%
91	UNC NEOPL ENDOCR/NERV	237	643	0.64%	0.03%
92	UNC BEHAV NEOPL NEC/NOS	238	2649	2.63%	0.13%
93	UNSPECIFIED NEOPLASM	239	8634	8.56%	0.41%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1995
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2032367

A33

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
1	MALIGNANT NEOPLASM LIP	140	68	0.08%	0.00%
2	MALIGNANT NEOPL TONGUE	141	360	0.40%	0.02%
3	MAL NEOPL MAJOR SG	142	87	0.10%	0.00%
4	MALIGNANT NEOPLASM GUM	143	27	0.03%	0.00%
5	MAL NEOPLASM FLOOR MOUTH	144	114	0.13%	0.01%
6	MAL NEOPL MOUTH NEC/NOS	145	273	0.30%	0.01%
7	MAL NEOPLASM OROPHARYNX	146	265	0.30%	0.01%
8	MAL NEOPLASM NASOPHARYNX	147	159	0.18%	0.01%
9	MAL NEOPL HYPOPHARYNX	148	128	0.14%	0.01%
10	OTH MAL NEOPL OROPHARYNX	149	214	0.24%	0.01%
11	MAL NEOPL ESOPHAGUS	150	518	0.58%	0.03%
12	MAL NEOPL STOMACH	151	481	0.54%	0.02%
13	MAL NEOPL SMALL BOWEL	152	77	0.09%	0.00%
14	MALIGNANT NEOPLASM COLON	153	2996	3.34%	0.15%
15	MAL NEOPL RECTUM/ANUS	154	2182	2.43%	0.11%
16	MALIGNANT NEOPLASM LIVER	155	542	0.60%	0.03%
17	MAL NEOPL GB/BD	156	127	0.14%	0.01%
18	MAL NEOPL PANCREAS	157	475	0.53%	0.02%
19	MAL NEOPLASM PERITONEUM	158	88	0.10%	0.00%
20	OTH DIGEST MAL NEOPL	159	121	0.13%	0.01%
21	MAL NEOPL NOSE/ME/SINUS	160	124	0.14%	0.01%
22	MAL NEOPL LARYNX	161	725	0.81%	0.04%
23	MAL NEOPL TRACHEA/LUNG	162	6214	6.93%	0.31%
24	MALIGNANT NEOPL PLEURA	163	61	0.07%	0.00%
25	MAL NEOPL THYMUS/MEDIAST	164	94	0.10%	0.00%
26	MAL NEOPL RESP NEC	165	23	0.03%	0.00%
27	MAL NEOPL BONE/CART	170	693	0.77%	0.03%
28	MAL NEOPL SOFT TISSUE	171	647	0.72%	0.03%
29	MALIGNANT MELANOMA SKIN	172	828	0.92%	0.04%
30	OTHER MAL NEOPL SKIN	173	2797	3.12%	0.14%
31	MAL NEOPL FEMALE BREAST	174	11170	12.45%	0.55%
32	MAL NEOPL MALE BREAST	175	58	0.06%	0.00%
33	KAPOSI'S SARCOMA	176	17	0.02%	0.00%
34	MAL NEOPL UTERUS NOS	179	246	0.27%	0.01%
35	MAL NEOPL CERVIX UTERI	180	916	1.02%	0.05%
36	MALIGNANT NEOPL PLACENTA	181	5	0.01%	0.00%
37	MAL NEOPL UTERUS BODY	182	675	0.75%	0.03%
38	MAL NEOPL UTERINE ADNEXA	183	1243	1.39%	0.06%
39	MAL NEOPL FE GENIT NEC	184	166	0.19%	0.01%
40	MAL NEOPL PROSTATE	185	3848	4.29%	0.19%
41	MAL NEOPL TESTIS	186	149	0.17%	0.01%
42	MAL NEOPL MALE GENIT NEC	187	46	0.05%	0.00%
43	MAL NEOPL BLADDER	188	1666	1.86%	0.08%
44	MAL GU NEOPL NEC/NOS	189	939	1.05%	0.05%
45	MALIGNANT NEOPLASM EYE	190	238	0.27%	0.01%
46	MALIGNANT NEOPLASM BRAIN	191	1683	1.88%	0.08%
47	MAL NEOPL NERVE NEC/NOS	192	168	0.19%	0.01%
48	MALIGNANT NEOPL THYROID	193	500	0.56%	0.02%
49	MAL NEOPL ENDOCRINE NEC	194	261	0.29%	0.01%
50	MAL NEOPL ILL-DEF SITES	195	892	0.99%	0.04%
51	SECONDARY MAL NEOPL LN	196	425	0.47%	0.02%
52	2ND MAL NEOPLASM GI/RESP	197	1288	1.44%	0.06%
53	2ND MAL NEOPL OTH SITES	198	2055	2.29%	0.10%
54	MALIGNANT NEOPLASM NOS	199	2538	2.83%	0.12%
55	LYMPHOSARC/RETICULOSARC	200	517	0.58%	0.03%
56	HODGKIN'S DISEASE	201	607	0.68%	0.03%
57	OTH MAL NEOPL LYMPH/HIST	202	2016	2.25%	0.10%
58	MULTIPLE MYELOMA ET AL	203	474	0.53%	0.02%
59	LYMPHOID LEUKEMIA	204	964	1.07%	0.05%
60	MYELOID LEUKEMIA	205	549	0.61%	0.03%
61	MONOCYTIC LEUKEMIA	206	38	0.04%	0.00%
62	OTHER SPECIFIED LEUKEMIA	207	16	0.02%	0.00%
63	LEUKEMIA-UNSPECIF CELL	208	699	0.78%	0.03%
64	BEN NEOPL MOUTH/PHARYNX	210	364	0.41%	0.02%
65	OTH BENIGN NEOPLASM GI	211	3895	4.34%	0.19%
66	BEN INTRATHOR NEOPLASM	212	386	0.43%	0.02%
67	BEN NEOPLASM BONE/CART	213	375	0.42%	0.02%
68	LIPOMA	214	881	0.98%	0.04%
69	OTH BEN NEOPL SOFT TISS	215	463	0.52%	0.02%
70	BENIGN NEOPLASM OF SKIN	216	3890	4.34%	0.19%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1995
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 2032367

A34

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
71	BENIGN NEOPLASM BREAST	217	607	0.68%	0.03%
72	UTERINE LEIOMYOMA	218	2798	3.12%	0.14%
73	OTH BENIGN NEOPL UTERUS	219	319	0.36%	0.02%
74	BENIGN NEOPLASM OVARY	220	183	0.20%	0.01%
75	BEN NEOPL OTH FEM GENIT	221	123	0.14%	0.01%
76	BENIGN NEOPL MALE GENIT	222	184	0.21%	0.01%
77	BENIGN NEOPLASM URINARY	223	183	0.20%	0.01%
78	BENIGN NEOPLASM OF EYE	224	145	0.16%	0.01%
79	BENIGN NEOPL NERV SYST	225	714	0.80%	0.04%
80	BENIGN NEOPLASM THYROID	226	192	0.21%	0.01%
81	BEN NEOPL OTH ENDOCRINE	227	259	0.29%	0.01%
82	HEMANGIOMA/LYMPHANGIOMA	228	523	0.58%	0.03%
83	BENIGN NEOPLASM NEC/NOS	229	475	0.53%	0.02%
84	CA IN SITU DIGESTIVE ORG	230	446	0.50%	0.02%
85	CA IN SITU RESPIRATORY	231	419	0.47%	0.02%
86	CARCINOMA IN SITU SKIN	232	308	0.34%	0.02%
87	CA IN SITU BREAST/GU	233	1557	1.74%	0.08%
88	CA IN SITU NEC/NOS	234	157	0.17%	0.01%
89	UNC BEHAV NEOPL GI/RESP	235	690	0.77%	0.03%
90	UNC BEHAV NEOPL GU	236	611	0.68%	0.03%
91	UNC NEOPL ENDOCR/NERV	237	509	0.57%	0.03%
92	UNC BEHAV NEOPL NEC/NOS	238	2514	2.80%	0.12%
93	UNSPECIFIED NEOPLASM	239	6971	7.77%	0.34%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1996
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 1979137

A35

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
1	MALIGNANT NEOPLASM LIP	140	51	0.06%	0.00%
2	MALIGNANT NEOPL TONGUE	141	365	0.41%	0.02%
3	MAL NEOPL MAJOR SG	142	86	0.10%	0.00%
4	MALIGNANT NEOPLASM GUM	143	30	0.03%	0.00%
5	MAL NEOPLASM FLOOR MOUTH	144	115	0.13%	0.01%
6	MAL NEOPL MOUTH NEC/NOS	145	244	0.27%	0.01%
7	MAL NEOPLASM OROPHARYNX	146	222	0.25%	0.01%
8	MAL NEOPLASM NASOPHARYNX	147	158	0.18%	0.01%
9	MAL NEOPL HYPOPHARYNX	148	118	0.13%	0.01%
10	OTH MAL NEOPL OROPHARYNX	149	193	0.21%	0.01%
11	MAL NEOPL ESOPHAGUS	150	541	0.60%	0.03%
12	MAL NEOPL STOMACH	151	509	0.57%	0.03%
13	MAL NEOPL SMALL BOWEL	152	86	0.10%	0.00%
14	MALIGNANT NEOPLASM COLON	153	2935	3.26%	0.15%
15	MAL NEOPL RECTUM/ANUS	154	2145	2.38%	0.11%
16	MALIGNANT NEOPLASM LIVER	155	528	0.59%	0.03%
17	MAL NEOPL GB/BD	156	120	0.13%	0.01%
18	MAL NEOPL PANCREAS	157	539	0.60%	0.03%
19	MAL NEOPLASM PERITONEUM	158	102	0.11%	0.01%
20	OTH DIGEST MAL NEOPL	159	112	0.12%	0.01%
21	MAL NEOPL NOSE/ME/SINUS	160	132	0.15%	0.01%
22	MAL NEOPL LARYNX	161	647	0.72%	0.03%
23	MAL NEOPL TRACHEA/LUNG	162	6281	6.98%	0.32%
24	MALIGNANT NEOPL PLEURA	163	80	0.09%	0.00%
25	MAL NEOPL THYMUS/MEDIAST	164	108	0.12%	0.01%
26	MAL NEOPL RESP NEC	165	28	0.03%	0.00%
27	MAL NEOPL BONE/CART	170	670	0.74%	0.03%
28	MAL NEOPL SOFT TISSUE	171	729	0.81%	0.04%
29	MALIGNANT MELANOMA SKIN	172	879	0.98%	0.04%
30	OTHER MAL NEOPL SKIN	173	2925	3.25%	0.15%
31	MAL NEOPL FEMALE BREAST	174	11500	12.78%	0.58%
32	MAL NEOPL MALE BREAST	175	42	0.05%	0.00%
33	KAPOSI'S SARCOMA	176	24	0.03%	0.00%
34	MAL NEOPL UTERUS NOS	179	252	0.28%	0.01%
35	MAL NEOPL CERVIX UTERI	180	934	1.04%	0.05%
36	MALIGNANT NEOPL PLACENTA	181	6	0.01%	0.00%
37	MAL NEOPL UTERUS BODY	182	675	0.75%	0.03%
38	MAL NEOPL UTERINE ADNEXA	183	1263	1.40%	0.06%
39	MAL NEOPL FE GENIT NEC	184	170	0.19%	0.01%
40	MAL NEOPL PROSTATE	185	3888	4.32%	0.20%
41	MAL NEOPL TESTIS	186	121	0.13%	0.01%
42	MAL NEOPL MALE GENIT NEC	187	48	0.05%	0.00%
43	MAL NEOPL BLADDER	188	1618	1.80%	0.08%
44	MAL GU NEOPL NEC/NOS	189	983	1.09%	0.05%
45	MALIGNANT NEOPLASM EYE	190	210	0.23%	0.01%
46	MALIGNANT NEOPLASM BRAIN	191	1627	1.81%	0.08%
47	MAL NEOPL NERVE NEC/NOS	192	178	0.20%	0.01%
48	MALIGNANT NEOPL THYROID	193	497	0.55%	0.03%
49	MAL NEOPL ENDOCRINE NEC	194	245	0.27%	0.01%
50	MAL NEOPL ILL-DEF SITES	195	921	1.02%	0.05%
51	SECONDARY MAL NEOPL LN	196	463	0.51%	0.02%
52	2ND MAL NEOPLASM GI/RESP	197	1279	1.42%	0.06%
53	2ND MAL NEOPL OTH SITES	198	2095	2.33%	0.11%
54	MALIGNANT NEOPLASM NOS	199	2321	2.58%	0.12%
55	LYMPHOSARC/RETICULOSARC	200	538	0.60%	0.03%
56	HODGKIN'S DISEASE	201	621	0.69%	0.03%
57	OTH MAL NEOPL LYMPH/HIST	202	2136	2.37%	0.11%
58	MULTIPLE MYELOMA ET AL	203	463	0.51%	0.02%
59	LYMPHOID LEUKEMIA	204	1005	1.12%	0.05%
60	MYELOID LEUKEMIA	205	569	0.63%	0.03%
61	MONOCYTIC LEUKEMIA	206	46	0.05%	0.00%
62	OTHER SPECIFIED LEUKEMIA	207	18	0.02%	0.00%
63	LEUKEMIA-UNSPECIF CELL	208	640	0.71%	0.03%
64	BEN NEOPL MOUTH/PHARYNX	210	330	0.37%	0.02%
65	OTH BENIGN NEOPLASM GI	211	4208	4.68%	0.21%
66	BEN INTRATHOR NEOPLASM	212	427	0.47%	0.02%
67	BEN NEOPLASM BONE/CART	213	321	0.36%	0.02%
68	LIPOMA	214	792	0.88%	0.04%
69	OTH BEN NEOPL SOFT TISS	215	414	0.46%	0.02%
70	BENIGN NEOPLASM OF SKIN	216	3828	4.25%	0.19%

PATIENTS BY ICD-9 CANCER DIAGNOSES. FISCAL YEAR 1996
 FOR ALL AMBULATORY PROFESSIONAL SERVICES (7A)
 IN THE SUMMARY DATA SETS (ARMY, AIR FORCE, NAVY)
 DENOMINATOR IS 1979137

A36

OBS	ICD9DX Name	ICD9DX	Frequency	Percent	Prevalence
71	BENIGN NEOPLASM BREAST	217	631	0.70%	0.03%
72	UTERINE LEIOMYOMA	218	2957	3.29%	0.15%
73	OTH BENIGN NEOPL UTERUS	219	285	0.32%	0.01%
74	BENIGN NEOPLASM OVARY	220	164	0.18%	0.01%
75	BEN NEOPL OTH FEM GENIT	221	135	0.15%	0.01%
76	BENIGN NEOPL MALE GENIT	222	196	0.22%	0.01%
77	BENIGN NEOPLASM URINARY	223	190	0.21%	0.01%
78	BENIGN NEOPLASM OF EYE	224	141	0.16%	0.01%
79	BENIGN NEOPL NERV SYST	225	752	0.84%	0.04%
80	BENIGN NEOPLASM THYROID	226	178	0.20%	0.01%
81	BEN NEOPL OTH ENDOCRINE	227	289	0.32%	0.01%
82	HEMANGIOMA/LYMPHANGIOMA	228	546	0.61%	0.03%
83	BENIGN NEOPLASM NEC/NOS	229	445	0.49%	0.02%
84	CA IN SITU DIGESTIVE ORG	230	408	0.45%	0.02%
85	CA IN SITU RESPIRATORY	231	375	0.42%	0.02%
86	CARCINOMA IN SITU SKIN	232	308	0.34%	0.02%
87	CA IN SITU BREAST/GU	233	1544	1.72%	0.08%
88	CA IN SITU NEC/NOS	234	151	0.17%	0.01%
89	UNC BEHAV NEOPL GI/RESP	235	793	0.88%	0.04%
90	UNC BEHAV NEOPL GU	236	613	0.68%	0.03%
91	UNC NEOPL ENDOCR/NERV	237	583	0.65%	0.03%
92	UNC BEHAV NEOPL NEC/NOS	238	2543	2.83%	0.13%
93	UNSPECIFIED NEOPLASM	239	6352	7.06%	0.32%